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Background: Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR, resistance to rifampicin
and isoniazid) disease, is associated with a worse patient outcome. Drug resistance diagnosed using
microbiological culture takes days to weeks, as TB bacteria grow slowly. Rapid molecular tests for
drug resistance detection (1 day) are commercially available and may promote faster initiation of
appropriate treatment.
Objectives: To (1) conduct a systematic review of evidence regarding diagnostic accuracy of molecular
genetic tests for drug resistance, (2) conduct a health-economic evaluation of screening and diagnostic
strategies, including comparison of alternative models of service provision and assessment of the value of
targeting rapid testing at high-risk subgroups, and (3) construct a transmission-dynamic mathematical
model that translates the estimates of diagnostic accuracy into estimates of clinical impact.
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Review methods and data sources: A standardised search strategy identified relevant studies from
EMBASE, PubMed, MEDLINE, Bioscience Information Service (BIOSIS), System for Information on Grey
Literature in Europe Social Policy & Practice (SIGLE) and Web of Science, published between 1 January
2000 and 15 August 2013. Additional ‘grey’ sources were included. Quality was assessed using quality
assessment of diagnostic accuracy studies version 2 (QUADAS-2). For each diagnostic strategy and
population subgroup, a care pathway was constructed to specify which medical treatments and health
services that individuals would receive from presentation to the point where they either did or did not
complete TB treatment successfully. A total cost was estimated from a health service perspective for each
care pathway, and the health impact was estimated in terms of the mean discounted quality-adjusted
life-years (QALYs) lost as a result of disease and treatment. Costs and QALYs were both discounted at
3.5% per year. An integrated transmission-dynamic and economic model was used to evaluate the
cost-effectiveness of introducing rapid molecular testing (in addition to culture and drug sensitivity testing).
Probabilistic sensitivity analysis was performed to evaluate the impact on cost-effectiveness of diagnostic
and treatment time delays, diagnosis and treatment costs, and associated QALYs.
Results: A total of 8922 titles and abstracts were identified, with 557 papers being potentially eligible.
Of these, 56 studies contained sufficient test information for analysis. All three commercial tests performed
well when detecting drug resistance in clinical samples, although with evidence of heterogeneity between
studies. Pooled sensitivity for GenoType® MTBDRplus (Hain Lifescience, Nehren, Germany) (isoniazid and
rifampicin resistance), INNO-LiPA Rif.TB® (Fujirebio Europe, Ghent, Belgium) (rifampicin resistance)
and Xpert® MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) (rifampicin resistance) was 83.4%, 94.6%,
95.4% and 96.8%, respectively; equivalent pooled specificity was 99.6%, 98.2%, 99.7% and 98.4%,
respectively. Results of the transmission model suggest that all of the rapid assays considered here, if
added to the current diagnostic pathway, would be cost-saving and achieve a reduction in expected
QALY loss compared with current practice. GenoType MTBDRplus appeared to be the most cost-effective
of the rapid tests in the South Asian population, although results were similar for GeneXpert. In all other
scenarios GeneXpert appeared to be the most cost-effective strategy.
Conclusions: Rapid molecular tests for rifampicin and isoniazid resistance were sensitive and specific.
They may also be cost-effective when added to culture drug susceptibility testing in the UK. There is global
interest in point-of-care testing and further work is needed to review the performance of emerging tests
and the wider health-economic impact of decentralised testing in clinics and primary care, as well as
non-health-care settings, such as shelters and prisons.
Study registration: This study is registered as PROSPERO CRD42011001537.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Worldwide, there are almost 9 million cases of tuberculosis (TB) every year. The disease mainly affectsthe lungs and is spread person to person by breathing in droplets that contain the TB bacteria
coughed up by someone else. TB can be cured but, if the bacteria have become resistant to the most
effective drugs (isoniazid and rifampicin), the treatment can take up to 2 years, requires more toxic drugs
and is less likely to be successful.
Although seeing bacteria in a person’s phlegm under a microscope is a quick way of making a diagnosis,
often the bacteria cannot be seen. Growing the bacteria requires special materials and, although less likely
to miss a case of disease, this can take weeks. Scientists have developed new tests that give results within
a day and can identify cases almost as well as growing the bacteria.
This report describes the performance, cost and likely benefit of rapid tests for drug-resistant TB. It brings
together all that is currently known on the subject from the world’s scientific literature and uses a
computer model to explore what the impact of the tests could be (including the cost to the NHS). All of
the new tests were good at telling when people had lung TB and when a case was likely to be cured by
treatment with isoniazid and rifampicin. Faster diagnosis benefits patients by improving treatment results,
including survival, can reduce costs of keeping patients in isolation until their diagnosis and may reduce
spread of the disease between people.
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Scientific summary
Background
Tuberculosis (TB) is a major global health problem, killing 1.3 million people annually. Around 9000 cases
of TB are currently reported each year in the UK, and London has the highest rate of TB of any Western
European capital. The increasing prevalence of drug resistance threatens TB control programmes
worldwide. Multidrug-resistant (MDR) TB is defined as resistance to, at least, rifampicin and isoniazid – the
two most powerful first-line anti-TB drugs. MDR-TB has a worse patient outcome than drug-sensitive
(DS) disease.
The conventional diagnostic work-up for patients with suspected respiratory TB disease includes sputum
smear microscopy to provide an early indication of infectivity, followed by culture to confirm diagnosis and
for drug susceptibility testing (DST). Culture is considered the gold standard but takes up to 42 days,
and sometimes longer, for a definitive result. Rapid molecular assays can return a result in as little as
1–3 days. This may be beneficial for patients, the community and the UK NHS. People incorrectly considered
to have TB may benefit from an early rule out: avoiding or shortening unnecessary isolation and treatment
with its associated high costs (for the patient as drug-related adverse events and for the NHS in terms of
hospital admission and negative pressure isolation). For patients with disease, early accurate diagnosis
will ensure that they commence effective treatment promptly and that, when necessary, they are
isolated earlier.
However, rapid assays are less accurate than culture, raising the possibility of false-positive (FP) and
false-negative (FN) results. Both types of error can be costly and harmful. FN results provide inappropriate
reassurance and may harm the patient by delaying time to effective treatment and placing contacts at risk
if infection control measures are relaxed. FP results may unnecessarily expose patients to the inconvenience
of isolation and adverse effects of medication. These costs and harms are likely to be particularly acute for
patients with, or at high perceived risk of, MDR-TB. Current guidance, therefore, recommends that rapid
molecular tests may have a role alongside culture but that they should not replace culture. This limits, but
may not eliminate, potential costs and harms of misdiagnosis, as clinicians can take corrective action when
culture results arrive. The additional cost of the molecular test also cannot be offset by savings from
reduced need for culture. There is, therefore, a trade-off between the costs and health impacts of adding a
rapid molecular test to the current diagnostic pathway.
Objectives
1. To conduct a systematic review of evidence, in the available published and ‘grey’ literature in medical,
scientific and economic databases, on the diagnostic accuracy of genetic tests for detecting TB drug
resistance compared with culture-based methods.
2. To utilise this information to conduct a health-economic evaluation of various screening and diagnostic
strategies, including comparison of alternative models of service provision (centralised vs. disseminated)
and assessment of the value of targeting rapid testing at various high-risk subgroups.
3. To construct a transmission-dynamic mathematical model to explore the extent to which the use of
more rapid diagnostic tests may interrupt the transmission of drug-resistant TB, including MDR-TB, and
produce public health benefit.
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Methods
Systematic review
A standardised search strategy was used to generate a comprehensive list of relevant studies from six
electronic literature databases: EMBASE, PubMed, MEDLINE, Bioscience Information Service (BIOSIS),
System for Information on Grey Literature in Europe Social Policy & Practice (SIGLE) and Web of Science
(PROSPERO CRD42011001537). The search strategy was confined to any paper published on 1 January
2000 to 15 August 2013. Additional sources included Cumulative Index to Nursing and Allied Health
Literature (CINAHL), NHS Economic Evaluation Database (NHS EED), diagnostic equipment manufacturer
websites, published diagnostic accuracy reviews and experts within the field. All articles that could
potentially meet defined eligibility criteria were selected for initial review. Two reviewers independently
evaluated eligible full-text papers. Key data variables extracted included patient characteristics, drug
resistance(s) investigated, test used and test characteristics. Publication details, sensitivity and specificity
were recorded. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies
tool version 2 (QUADAS-2). Each group of tests, with sufficient studies available, was analysed separately.
For each test comparison, the sensitivity, specificity and their exact 95% confidence intervals (CIs) were
calculated using Stata version 13.1 (StataCorp LP, College Station, TX, USA). Diagnostic accuracy across
studies was summarised using a summary receiver operating characteristic curve. Variability across studies
was assessed and modelled using this approach.
Health economics
For each diagnostic strategy and population subgroup, a care pathway was defined. This specified which
medical treatments and health services individuals would receive, from presentation to the point where
they either did or did not complete TB treatment successfully. The pathways were defined by perceived risk
of MDR-TB, smear status, the result of the molecular test, and the culture and DST results. These factors
gave 12 unique pathways for which only culture testing was used, and a further 32 for which rapid
molecular assays were added, alongside confirmatory culture testing. A total cost was estimated for each
care pathway, including the cost of consultations and investigations prior to referral to TB services, TB
diagnosis, medication, inpatient care and isolation, outpatient care, and contact tracing and associated
treatment of any latent TB cases. Costs were taken from the Personal Social Services Research Unit, NHS
reference costs or published literature and uprated if necessary to 2011–12 prices. All costs were estimated
from a NHS perspective. For each care pathway the health impact was estimated in terms of the mean
discounted quality-adjusted life-years (QALYs) lost as a result of TB disease and treatment. Costs and QALY
outcomes were discounted at an annual rate of 3.5%.
Transmission modelling
An integrated transmission-dynamic and economic model was used to evaluate the cost-effectiveness of
introducing rapid molecular testing into the diagnostic pathway, alongside culture and DST. The model
used is a compartmental (state transition) model. This approach divides the population up according to
infection status, each contained in a separate compartment. There are flows between compartments
as individuals become infected, progress to disease, are diagnosed and placed on treatment, etc. The
compartmental model is used to describe the infection and treatment dynamics for both non-MDR-TB and
MDR-TB strains. Economic parameters were derived as described above and epidemiological parameter
estimates were obtained from the Office for National Statistics, Enhanced Tuberculosis Surveillance
data and the literature. Probabilistic sensitivity analysis (PSA) was performed to evaluate the impact on
cost-effectiveness of diagnostic and treatment time delays, diagnosis costs and treatment costs, and
associated QALYs. Parameters relating to diagnostic test performance were subject to deterministic
sensitivity analysis, in which each parameter was varied individually across its range.
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Results
Systematic review
A total of 8922 titles and abstracts were identified through database searches and hand-searching. After
the first phase of screening, 557 papers were identified as potentially eligible for the review. A total of
56 studies contained sufficient information on the performance of the rapid diagnostic tests to be included in
the review. The findings of the systematic review suggest that all three commercial tests, INNO-LiPA Rif.TB®
(Fujirebio Europe, Ghent, Belgium), Xpert® MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) and GenoType®
MTBDRplus (Hain Lifescience, Nehren, Germany) demonstrate promising levels of diagnostic discrimination
when detecting rifampicin and/or isoniazid susceptibility in clinical samples. The pooled sensitivity and specificity
estimates for detecting isoniazid resistance by MTBDR plus were 83.4% (95% CI 66.3% to 100.0%) and
99.6% (95% CI 99.0% to 100.0%), respectively. The pooled specificity for detecting rifampicin resistance was
98.2% (95% CI 97.2% to 99.3%) and pooled sensitivity was 94.6% (95% CI 91.6% to 97.6%). The pooled
estimates of sensitivity for INNO-LiPA (95.4%, 95% CI 92.2% to 98.3%) and specificity (99.7%, 95% CI
99.5% to 100.0%) suggested good levels of diagnostic accuracy when used to detect rifampicin resistance in
clinical samples. For the detection of rifampicin resistance by GeneXpert, the pooled sensitivity was 96.8%
(95% CI 94.2% to 99.4%) and pooled specificity was 98.4% (95% CI 97.8% to 99.0%). Although there was
evidence of heterogeneity between included studies, the findings of these analyses are consistent with
previous estimates.
Health economics
Costs and QALYs were estimated for 44 unique care pathways. With a culture-only strategy, the total
estimated cost ranged from £2252 per patient (smear-negative patient correctly identified as free from TB)
to £130,214 (smear-positive patients with MDR-TB not identified as high risk and, therefore, not treated
presumptively). The range was similarly wide with molecular testing: from a minimum of £2334 (correctly
diagnosed smear-negative patients without TB) to a maximum of £131,771 (smear-positive patients with
MDR-TB thought to be at high risk and with an inaccurate molecular test result indicating DS disease).
It should be noted that the incidence of the very-high-cost pathways is likely to be low (as both MDR-TB
and misdiagnoses are rare). The expected cost for a patient with smear-positive DS disease (deemed low
risk of MDR-TB, correctly diagnosed by molecular test and treated appropriately) is £9392. The cost for a
similar patient, correctly diagnosed and treated under the culture strategy is slightly lower, at £8670.
Estimated mean QALY losses ranged from 0 (for patients without TB who are correctly diagnosed and
treated) to about 1.205 QALYs lost (for patients with smear-positive MDR-TB with a FN molecular test
result for MDR-TB, who are not treated presumptively but are subsequently correctly diagnosed by
confirmatory culture and DST). A large proportion of the estimated QALY losses were attributable to
adverse events related to MDR-TB treatment.
Transmission modelling
An integrated transmission-dynamic and economic model was used to evaluate the cost-effectiveness of
introducing rapid molecular testing for TB infection and DST in England and Wales, including accounting
for effects of more rapid diagnosis and treatment in averting transmission of infection. The evaluation
considered three ethnic groups: Black African, South Asian and Eastern European. The first two groups
represent a large proportion (61%) of the TB cases in England and Wales, and the available data allow us
to estimate numbers of transmission events expected to be averted by faster diagnosis and treatment of TB
and MDR-TB. The Eastern European group is of interest because of its high proportion of TB cases that
are MDR (≈27%). Three different molecular test combinations were considered (GeneXpert only, and
GeneXpert combined with INNO-LiPA or MTBDRplus), in two locations (either local to the hospital or in a
regional laboratory).
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The introduction of molecular testing had a small impact on transmission, as current practice is effective in
limiting transmission from patients with TB while they are undergoing clinical examination. There is benefit
for smear-negative patients, most of whom test positive by molecular methods and therefore can be
diagnosed promptly and start treatment earlier than if they were to wait for culture confirmation. The
major benefit of molecular testing is faster diagnosis of MDR-TB, which produces cost savings as patients
with smear-positive disease and suspected MDR-TB are isolated until their MDR status is known and then
appropriate treatment commenced. The cost saving resulted from the high daily cost of isolation. The
imperfect specificity of molecular tests increases annual numbers of TB diagnoses attributable to FP results
and the consequent inappropriate treatment of some patients incurs a QALY loss as well as a financial cost.
The results of the transmission modelling suggest that all assays are cost saving and achieved a reduction
in the QALY loss from TB compared with that expected under current practice. Across the Black African
and Eastern European populations the GeneXpert scenario was the most cost-effective rapid test, at both
10- and 20-year time horizons, and £20,000 or £30,000 willingness-to-pay threshold per QALY. For the
South Asian population, using a 10-year time horizon, the MDRTBplus scenario was the most cost-effective
rapid test, with the highest estimated incremental net benefit compared with current practice, although
the difference with GeneXpert was very small. At a 20-year time horizon, the MTBDRplus scenario was
also the most cost-effective test.
Differences in the cost-effectiveness of local compared with regional testing were small and subject to
considerable uncertainty.
Discussion and conclusions
Rapid molecular tests such as the manual line probe assays (LPAs) and automated GeneXpert are able to
identify rifampicin resistance (and isoniazid resistance for some LPAs) with promising levels of specificity
and are almost as sensitive as microbiological culture, but produce results more quickly (within 1 day of the
sample being obtained). Their sensitivity approaches that of microbiological culture but provides results
much faster.
The positive predictive value (PPV) for resistance is dependent on the prevalence of drug resistance in the
background population. This is low in the UK, and hence a proportion of rifampicin resistance results will
be FPs if used in a general screen, although the corresponding negative predictive value (NPV) will be
high. PPV will be > 90% only when the underlying prevalence is > 15%. This is seen within populations in
countries such as the Baltic States, Russia and Ukraine and from where active migration to the UK occurs.
This low PPV associated with low prevalence is linked to the earlier World Health Organization advice to
perform a confirmatory test (either a second molecular or culture-based test). Further caution is also urged
because of the heterogeneity observed between studies. Realising the benefit of molecular testing will rely
on the effectiveness of the means by which suspected MDR-TB is established.
Overall, the results suggested that adding any of the rapid assays assessed here to the current diagnostic
pathway was likely to be cost-effective in the UK context, in which patient samples are routinely cultured.
The GeneXpert and MTBDRplus scenarios appear to be more cost-effective than INNO-LiPA in most
scenarios. These results are subject to uncertainty, as some key assumptions and parameters were based
on expert judgement or literature published some time ago. However, results were informed by detailed
estimates of diagnostic assay costs based on a time-and-motion study and bed-stay durations from audit
data. They also incorporated estimated impacts of transmission based on dynamic modelling.
The performance of these tests is less clear-cut for non-pulmonary material and other low-bacillary
specimens, such as from children or human immunodeficiency virus (HIV)-positive patients.
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Recommendations for research
There is a need to assess the performance of these tests in specific patient populations, such as children
and those infected with HIV. Pilots need to be developed, which can provide detailed information
regarding real test performance and associated cost-effectiveness when rapid tests are delivered as a near
‘point of care’ (POC) test within and outside a traditional hospital environment (e.g. in a clinic within a
hospital, a mobile unit, a prison, a homeless shelter, migrant accommodation). These can be used to
determine the cost-effectiveness for future POC tests compared with laboratory-based assays, particularly
in the context of capital-intensive laboratory-based microbiological reference analyses and next-generation
sequencing-based approaches.
Study registration
This study is registered as PROSPERO CRD42011001537.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Introduction
Tuberculosis (TB) remains a major global health problem and ranks as the second leading cause of death
from an infectious disease worldwide, after the human immunodeficiency virus (HIV). TB is an airborne
disease caused by bacteria belonging to the Mycobacterium tuberculosis complex (MTBC). It typically
affects the lungs (pulmonary TB) and is spread through the air by coughing. Most infections in humans
result in an asymptomatic, latent TB infection, and about 1 in 10 latent infections eventually progresses to
active disease (30–50% in patients co-infected with HIV).
Without treatment, TB mortality rates are high. Among HIV-negative patients of smear-positive pulmonary
TB, around 70% die within 10 years. For culture-positive (but smear-negative) patients, 20% die within
10 years. Combination drug therapy has been the mainstay of TB treatment for decades and short-course,
rifampicin-based regimens will cure almost all cases. The currently recommended treatment for new
cases of drug-susceptible TB is a 6-month regimen of four drugs: isoniazid, rifampicin, ethambutol and
pyrazinamide. Interrupted and incomplete therapy selects for drug-resistant strains which are more difficult
to treat successfully. TB drug resistance is a growing international problem, which, with HIV co-infection,
threatens the success of national TB programmes.
Multidrug-resistant (MDR) TB (MDR-TB) is defined as resistance to at least rifampicin and isoniazid – the
two most powerful first-line anti-TB drugs. Treatment for MDR-TB is longer and requires more expensive,
more toxic drugs. The World Health Organization (WHO) recommends treatment regimens last 20 months,
and success rates are much lower. Further resistance can develop to form extensively drug-resistant
TB (XDR-TB), defined as MDR plus additional resistance to any fluoroquinolone and at least one of the
injectable agents (amikacin, capreomycin or kanamycin). Infection with XDR-TB further decreases chances
of treatment success and survival.1–4 So far, co-infection with HIV and XDR-TB has been largely fatal.5,6
Recent years have seen an ominous accumulation of reports of ‘totally’ drug-resistant strains, which do not
exhibit susceptibility to any tested drugs.7
Global burden of tuberculosis
In 2012, 8.6 million people developed active TB and 1.3 million died from the disease.8 Over 95% of
deaths occurred in low- and middle-income countries. TB is also a major killer of those co-infected with
HIV, causing one-quarter of all deaths.
Tuberculosis continues to be a significant public health and clinical problem in the industrialised world.
Within countries of the WHO European Region, those in the east have much higher notification rates
than in the west. The Region reported 309,648 new episodes of TB (34.0 per 100,000 population), with
> 60,000 deaths estimated as being due to TB, or 6.7 cases per 100,000 population.9 Notification rates for
newly detected and relapsed TB cases in the WHO 18 High Priority Countries (all from the central and
eastern part of the Region), remained almost eight times higher (68.5 per 100,000 population) than in the
rest of the Region (8.4 per 100,000).9
Globally, in 2012, 3.6% of new TB cases and 20.2% of previously treated cases were estimated to have
MDR-TB. The highest rates of MDR-TB are found in Eastern Europe and Central Asia, where, in some
countries, > 20% of new TB patients and > 50% of those previously treated for TB have MDR-TB.8
On average, an estimated 9.6% of MDR-TB patients have XDR-TB. By the end of 2012, 92 countries had
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reported at least one case of XDR-TB. In May 2009, the 62nd World Health Assembly urged member states
to take action to achieve universal access to diagnosis and treatment of MDR-TB and XDR-TB by 2015.10
Epidemiology of tuberculosis in the UK
Around 9000 cases of TB are currently reported each year in the UK.11 Most cases occur in major cities;
London has the highest rate of TB of any Western European capital. The incidence of MDR-TB in the UK is
low (approximately 1–1.5%) and has remained relatively constant over recent years. However, in some
areas of the country, such as London, and in certain population groups, the incidence is much higher.
Institutional outbreaks of MDR-TB have occurred in the UK, notably in London hospitals,12 and wider
pan-institutional outbreaks, such as one involving isoniazid-resistant strains, have been reported.13
Molecular basis of drug resistance
For M. tuberculosis, drug resistance is primarily acquired through mutation of chromosomal genes.
Recognised mechanisms include mutations that (1) block the drug target (e.g. mutations in rpoB prevent
binding of rifampicin to RNA polymerase14), (2) block activation of a prodrug (e.g. mutations in katG lead to
loss of the ability of catalase to activate isoniazid to its active form15), or (3) produce an activity that binds or
inactivates the drug (e.g. mutations in the inhA promoter increase the amount of InhA product that binds
sufficient isoniazid to reduce its effective intracellular concentration to below an inhibitory level16).
Although many of the mutations leading to resistance are recognised, further work is required to elucidate
fully the mutations that are responsible for resistance against some drugs, and to determine the predictive
value of finding a particular mutation in a strain of M. tuberculosis (MTB).17,18
Approximately 95% of rifampicin-resistant M. tuberculosis isolates are additionally resistant to isoniazid,
enabling the detection of resistance to rifampicin to be used as a marker for MDR-TB with a high level
of accuracy. Assays to detect mutations associated with other key resistances, including for XDR-TB,
have been developed, although the scientific understanding of the mechanisms of resistance is less
well understood.
Diagnosis of drug resistance
Conventional culture methods
Conventional culture and drug susceptibility testing (DST) is a slow process, requiring isolation of mycobacteria
from clinical specimens, identification of MTBC, and testing of the susceptibility pattern of strains in the
presence of anti-TB drugs. Depending on the methodology, culture-based methods can take several months
to be completed; however, they remain the ‘gold standard’ for M. tuberculosis DST.
A TB strain is classified as resistant to a drug if ≥ 1% of the bacterial population is able to grow at a
‘critical’ concentration of drug, which inhibits 95% of wild-type strains.19 DST using agar- or egg-based
Löwenstein–Jensen (LJ) solid media is the most commonly utilised method. Standard methods using LJ
medium include the absolute concentration method, the resistance ratio method and the proportion
method.19 In the absolute concentration method, a standardised bacterial suspension is inoculated on to
drug-free media and media containing graded concentrations of the drug to be tested. The minimum
inhibitory concentration (MIC) is the lowest concentration of the drug that inhibits growth. In the
resistance ratio method, the growth of the test strain is compared with that of a control susceptible strain.
Resistance is expressed as the ratio of the MIC of the test strain to the MIC of the control strain. The
proportion method determines the percentage of growth (number of colonies) of a defined inoculum on a
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drug-free control medium compared with growth on culture media containing the critical concentration (or
range of concentrations) of the test drug.
Automated commercial liquid culture systems use the proportion method and are designed to detect
growth inhibition in drug-containing media as early as possible. One of the first systems was the BACTEC
460 TB system (Becton Dickinson Diagnostic Instrument Systems, Towson, MD, USA), which uses a
radiometric method to measure carbon dioxide production. Subsequently, non-radiometric methods, such
as the BACTEC MGIT (Mycobacteria Growth Indicator Tube) 960 system (Becton Dickinson Diagnostic
Instrument Systems) have become widely adopted.20 The BACTEC MGIT 960 system uses fluorimetric
detection to monitor oxygen consumption resulting from bacterial growth. Growth in media containing
the drug of interest is compared with growth in a drug-free control tube, which is inoculated with a
1 : 100 dilution of the M. tuberculosis strain. Every 60 minutes, the BACTEC MGIT 960 measures the
fluorescence emitted from the tube. Once the fluorescence indicates that there are 105–106 colony-forming
units (CFUs) per millilitre of medium, the tube is flagged as positive. If there is at least equal growth in a
drug-containing tube and the control tube, this indicates that at least 1% of the bacteria present in the
sample are resistant to that drug and the sample is classified as resistant. If the tube does not become
positive within 6 weeks, the machine marks it as negative. The BACTEC MGIT 960 can reduce the mean
time taken to detection of M. tuberculosis to 14.4 days compared with 24.1 days on solid medium.21
Non-commercial culture systems based on the growth of microcolonies can also facilitate more rapid
diagnosis than conventional methods.22 Microscopic observation of drug susceptibility (MODS) is a liquid
culture-based method in which early growth in drug-free and drug-containing media is detected by
microscopic examination.23 Similarly, thin-layer agar (TLA) methods rely on the microscopic detection of
growth on solid media.24
Rapid molecular tests
A significant reduction in the time for diagnosis of clinically significant drug resistance depends on
genotypic methods that identify mutations in genes responsible for resistance. Specific nucleotide
sequences in processed specimens (crude extracts or treated sputum) can be detected within a few hours,
so the total time for the TB detection can be reduced to < 1 day. Improved biosafety is another advantage
of molecular assays, as they require high containment only initially. However, molecular methods lack the
sensitivity of phenotypic methods, as the genetic basis of resistance is not completely understood for any
anti-TB drug. For example, although 95% of rifampicin-resistant M. tuberculosis strains have mutations in
the 81 base pair (bp) rifampicin resistance determining region (RRDR) of the gene encoding the RNA
polymerase-subunit, rpoB, 5% of strains have no known resistance mutations.25 Up to 10–25% of
low-level isoniazid-resistant M. tuberculosis strains do not have mutations in either katG or the inhA
promoter.26
Molecular tools for the detection of M. tuberculosis and determination of drug resistance that have been
developed over the past decade are largely nucleic acid amplification tests (NAATs) to increase sensitivity,
combined with highly specific detection systems. The polymerase chain reaction (PCR) is the most common
methodology utilised in NAAT; alternatives include real-time PCR, isothermal strand displacement
amplification or transcription-mediated amplification, and the ligase chain reaction.27–30 Although NAAT
can theoretically detect a single copy of nucleic acid in a specimen, sensitivity can be significantly
compromised by the presence of PCR inhibitors in clinical specimens and loss of nucleic acids during
specimen processing, and therefore tends to vary.
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Line probe assays
In 2008, the WHO formally endorsed the use of line probe assays (LPAs) for rapid screening of patients
at risk of MDR-TB31 and they are now in routine use in many TB laboratories in high- and
middle-income countries.
To perform LPAs, first deoxyribonucleic acid (DNA) is extracted from M. tuberculosis cultures or directly
from clinical specimens. Regions of interest in resistance-determining genes are amplified by PCR using
biotinylated primers. Following amplification, labelled PCR products are hybridised with oligonucleotide
probes that are immobilised on nitrocellulose membrane strips. Captured PCR products are detected by
binding to streptavidin-conjugated alkaline phosphatase and colorimetric development, which can be
observed visually. If a mutation is present in one of the target regions, the amplicon will not hybridise with
the relevant probe. Mutations are therefore detected by lack of binding to wild-type probes, as well as by
binding to specific probes for the most commonly occurring mutations.
Currently, the main commercial LPAs for the rapid diagnosis of TB and rifampicin resistance in clinical
specimens are the INNO-LiPA Rif.TB® (Fujirebio Europe, Ghent, Belgium) and the GenoType®
Mycobacterium tuberculosis drug resistance plus assay (MTBDRplus) (Hain Lifescience, Nehren, Germany),
which additionally detects isoniazid resistance.32–35 The GenoType® Mycobacterium tuberculosis drug
resistance second-line assay (MTBDRsl) (Hain Lifescience) is the only available rapid assay for detection of
resistance to fluoroquinolones and injectable second-line drugs, as well as ethambutol, offering rapid
detection of XDR-TB in mycobacterial cultures.36,37
GeneXpert MTB/RIF
The Xpert® MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) is a fully automated real-time PCR-based assay
for the detection of M. tuberculosis and resistance to rifampicin in clinical specimens.29,38 GeneXpert is a
cartridge-based system that fully integrates all the steps from sample preparation to detection on the
GeneXpert multidisease platform. The test was developed as a point-of-care (POC) technology, which
could be performed with minimal biohazard and little technical training.
The specimen is initially treated with a reagent that liquefies sputum and inactivates the bacilli. The sample
is transferred to the GeneXpert cartridge, loaded on to the GeneXpert machine and the entire assay
is then conducted automatically within the cartridge. The M. tuberculosis bacilli are purified and
concentrated from the liquefied sputum; subsequently, DNA is isolated from the captured bacilli by
sonication. The rpoB gene is then amplified by hemi-nested real-time PCR. Molecular beacons – using
novel fluorophores and quenchers – hybridise to each of the five amplified target regions of the gene and
are detected in real-time using a six-colour laser detection device.
The initial multicentre validation study indicated that a single GeneXpert test directly from sputum could
detect 98.2% of smear-positive patients and 72.5% of patients with smear-negative disease.29 This was
a substantial improvement over alternative molecular tests. In December 2010, the WHO endorsed
GeneXpert for use in TB-endemic countries and led a global roll-out of the test.39
The test co-evaluator, the Foundation for Innovative and New Diagnostics (FIND), negotiated a 75% price
reduction for low- and middle-income countries most affected by TB, with an additional reduction in
price once there was a significant volume of demand. By the end of September 2013, 1843 GeneXpert
instruments and 4.2 million test cartridges had been procured by 88 of the 145 countries that were
eligible for concessional prices.40 The introduction of GeneXpert-based diagnosis increased TB case finding
in India, South Africa and Uganda compared with the use of simple microscopy and clinical diagnosis from
72–85% to 95–99% of the cohort of individuals with suspected TB.41
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Future directions
Whole genome sequencing (WGS) offers a powerful new approach for the diagnosis of M. tuberculosis
drug resistance, promising rapid, unambiguous determination of all existing, clinically significant mutations.
In the authors’ opinion, the continuing cost reductions of this technology may eventually neutralise
arguments over the value of targeted sequencing compared with WGS. Recent studies using WGS to
research novel determinants of resistance have revealed that drug resistance may be more multifactorial
than previously appreciated which, in some cases, may explain discordance between phenotypes and
genotypes.42–44 As more resistance loci are identified, and the phenotypic effects of multiple mutations and
strain background are elucidated, the public health value of routine WGS for diagnosis of drug resistance
will increase. In addition, WGS reveals the genetic relatedness of strains, allowing transmission networks to
be traced with unparalleled resolution and obviates the need for separate molecular fingerprinting analysis.
DOI: 10.3310/hta19340 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 34
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Drobniewski et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5

Chapter 2 Objectives
A lthough the incidence of MDR-TB and XDR-TB in the UK is relatively low, its impact on the individual,his/her close contacts, and the health-care economy is disproportionably large. Tests that can rapidly
detect drug resistance have the potential to reduce this impact. The aim of this study was to investigate
the clinical impact and cost-effectiveness of the use of genetic markers for identifying MDR-TB and XDR-TB
in the UK compared with conventional culture-based DST.
The key research objectives were to:
1. conduct a systematic review of evidence on the diagnostic accuracy of genetic tests for detecting
drug-resistant TB, including MDR-TB, in comparison with the reference standard of culture-based DST,
in the available published and ‘grey’ literature in medical, scientific and economic databases
2. utilise this information to conduct a health-economic evaluation of adding a rapid molecular test for
detecting drug-resistant TB to the current diagnostic pathway in the UK (including culture-based DST)
3. construct a transmission-dynamic mathematical model to explore the extent to which the addition of
rapid diagnostic tests for drug resistance may interrupt the transmission of drug-resistant TB, including
MDR-TB, and produce public health benefit.
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Chapter 3 Systematic review
Objectives
Primary objectives
As outlined in Chapter 2, the primary purpose of this review was to produce a critical assessment of
studies that report data on the diagnostic accuracy of molecular tests used to detect drug resistance in
M. tuberculosis.
Types of studies
All diagnostic studies that compared a molecular (index) test with a gold standard (reference) test were
considered in this review. No restrictions on study setting were applied, and studies from all countries were
eligible for inclusion. When clearly stated in the paper, the study design was recorded for subgroup analysis.
Types of participants and clinical specimens
Studies of adults or children with suspected MDR-TB or XDR-TB were considered to be eligible for
inclusion. This review also considered those studies for which the participant’s details were not clearly
stated, and work was carried out on anonymised samples. When categorising the participant population,
individuals aged ≥ 16 years were classed as adult participants.
When cited, studies that reported comorbidity with HIV infection or a previous history of TB within the
participant population were considered for inclusion. These data were also recorded during the data
extraction process for subgroup analysis.
Only studies that were carried out on clinical samples, including pulmonary or extrapulmonary samples,
were considered for inclusion. Those studies that used clinical specimens ‘spiked’ with mycobacteria or
cultured isolates were excluded from the review. Studies where the test was carried out on both cultured
and clinical samples were considered for inclusion only if the diagnostic accuracy data were reported by
the type of sample tested. Studies that pooled data from clinical and cultured specimens were excluded.
Index tests
Studies that used a genetic rapid diagnostic method to test for either first- or second-line drug
susceptibility were considered for inclusion. Although studies using commercial assays are more commonly
present in the literature, data on in-house tests were also considered for inclusion when there was
sufficient information to assess their diagnostic accuracy in detecting MDR-TB or XDR-TB.
Reference tests
Studies that compared an appropriate index test against an appropriate reference standard test were
potentially eligible for inclusion. This review accepted any TB phenotypic drug susceptibility test that has
been endorsed by the WHO. These include culture on solid or liquid media and use of rapid liquid culture
systems. If a study compared a rapid culture test against a NAAT with the ability to detect mutations
associated with drug susceptibility, it was included in the review.
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Methods
Search strategy
A standardised search strategy (PROSPERO registration CRD42011001537, see Appendix 1), was designed
to generate a comprehensive list of relevant studies from five electronic literature databases: EMBASE,
PUBMED, MEDLINE, Bioscience Information Service (BIOSIS) and Web of Science. The strategy design was
based upon a previously successful model used by the European Centre for Disease Prevention and
Control (ECDC). It was further validated by comparing the citation output against the bibliography of
two published diagnostic reviews of rapid diagnostic tests for TB and drug susceptibility.45,46
The electronic databases were initially searched on 29 October 2012, and the search was repeated in
August 2013 to update the review. The search strategy was confined to any paper published between
1 January 2000 to the date of the last search, 15 August 2013. These limits were imposed so that early
diagnostic studies of older commercially available tests, such as INNO-LiPA, would not be missed.
Additional sources were checked to ensure that the review included studies that were not missed. These
included Cumulative Index to Nursing and Allied Health Literature (CINAHL), NHS Economic Evaluation
Database (NHS EED), System for Information on Grey Literature in Europe Social Policy & Practice (SIGLE),
diagnostic equipment manufacturer websites and experts within the field. Additional hand-searching
was carried out to identify papers using the citation lists of published diagnostic accuracy reviews.45,46
In addition, when study authors were contacted to confirm details within their papers they were also
requested to suggest studies that could be potentially missing from the review. A systematic review
database was developed in Microsoft® Office 2010 (Microsoft Corporation, Redmond, WA, USA)
to manage and record the review process.
Study selection
Studies were included in the review if they met the inclusion criteria listed below. Studies that met these
criteria were included irrespective of the published language, the country of origin or their current
publication status (i.e. grey literature, published or ‘in press’).
The eligibility criteria were as follows:
l Studies that:
¢ assessed rapid genetic diagnostic methods to detect drug susceptibility of M. tuberculosis
¢ used human clinical samples
¢ compared the results of the rapid (index) test with sequencing or a culture-based sequencing DST
as a reference standard
¢ reported sufficient data to calculate the true positive (TP), true negative (TN), false positive (FP) and
false negative (FN) of the rapid diagnostic test
¢ reported at least 10 samples susceptible to the drug of interest and 10 samples that were resistant
to the drug of interest, identified by the reference standard.
All articles that could potentially meet the eligibility criteria outlined above were selected for initial review.
The assessment of study eligibility was not blinded to publication details, such as journal or author names.
Data extraction
Two reviewers independently evaluated titles, abstracts and full-text papers (see Appendix 2). Each
reviewer had an independent copy of the review database.
In order to identify valid studies, the initial data extraction from the electronic databases were reviewed by
one of the study reviewers (MC). The second reviewer (CT) validated a randomised subset (50%) of the
titles for eligibility. The subsequent potentially eligible studies were randomly sorted and abstracts were
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divided between reviewers (MC, CT, AS), with each reviewer assessing a randomised subset (60%) of the
abstracts, with a 10% overlap to check consistency.
The full-text papers of eligible papers were independently reviewed and data were extracted by the first
reviewer MC (100%) and by the second reviewers AS (69%) and AB (31%).
Key variables – including patient characteristics, drug resistance(s) investigated, test used, characteristics of
the tests (i.e. nature of assay used, method of drug resistance, detection and location) – were recorded.
Other characteristics to be recorded – including study quality, publication details, time for analysis,
sensitivity and specificity – were extracted for the data set. A sample data collection form is shown in
Appendix 3 and the full list of extracted variables is given in Appendix 4.
These data were matched and, when the extracted data did not match, they were re-extracted by both the
first and second reviewers MC and AB, respectively. In the event that the TN, FP, FN, TN did not match
the reported sensitivity and specificity, the data were re-extracted a third time by the primary reviewer (MC),
and the study author was contacted for clarification.
Quality assessment
The quality of each study deemed eligible – either through bias or concerns regarding applicability – was
assessed using the Quality Assessment of Diagnostic Accuracy Studies tool version 2 (QUADAS-2).47 The
QUADAS-2 tool was tailored to this study by selecting relevant key questions in each QUADAS-2 domain.
It was considered that, although the questions regarding bias when conducting the reference test were
applicable, the questions regarding reference test applicability were not, as these were part of the study
eligibility criteria.
During data extraction, each study was independently evaluated using QUADAS-2, and disagreement
between reviewers’ opinions was resolved by discussion, with reference back to the original article. As
recommended by Whiting et al.,47 if a domain contained one or more question answered as ‘not clear’ or
‘high-bias’ then it was considered an area of potential bias or a concern regarding the applicability of the
test. As recommended by Whiting et al.,47 further quantitative sensitivity analysis was not performed.
Data synthesis
The study extraction data set from each reviewer was cleaned using Microsoft Excel version 2010, Microsoft
Access version 2010 and Stata version 13.1 (StataCorp LP, College Station, TX, USA: www.statacorp.com).
Each group of tests, with sufficient studies available, was analysed separately. For each test comparison,
the sensitivity, specificity and their exact 95% confidence intervals (CIs) were calculated using Stata.
If meta-analysis was not found to be appropriate, because of a small number of studies or clinical
heterogeneity, a qualitative narrative synthesis was used.
Statistical heterogeneity of sensitivities and specificities were investigated in any group of studies that had
more than four studies with apparent clinical heterogeneity. Statistical analysis of the review data reflects
that suggested by Lijmer et al.48,49 and Higgins and Thompson.50 Heterogeneity between studies was
assessed using the I2-statistic.50
Accuracy is usually presented in individual studies in terms of sensitivity and specificity, that is, dichotomous
data rather than differences in distributions. Standard meta-analytic techniques, which are a simple pooled
estimate of sensitivity and another of specificity, may be inappropriate, as these two statistics are likely to be
correlated. Therefore, diagnostic accuracy across studies were summarised using a summary receiver operating
characteristic (SROC) curve. This figure is a graphical summary of a hierarchical logistic regression model used to
explain variability in study diagnostic odds ratios (DORs). In particular, variability across studies as a result of
blinding or the use of different thresholds to define positivity were assessed and modelled using this approach.
Hierarchical summary receiver operating characteristic (HSROC) curve models were used because they account
for both between- and within-study variation in TP and FP rates.
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Results
Details of included and excluded studies
A total of 8922 titles and abstracts were identified through database searches and hand-searching.
After the first phase of screening, 557 papers were identified as being potentially eligible for the
review (Figure 1).
A total of 56 studies contained sufficient information on the performance of the rapid diagnostic tests
to be included in the review. These studies were divided into five categories, depending on the rapid
test investigated: INNO-LiPA studies (n= 9),33,35,51–57 GeneXpert studies (n= 6),29,38,58–61 MTBDRplus
Full-text papers included and data
extracted
(n = 56)
INNO-LiPA
studies
(n = 9)
GeneXpert
studies
(n = 6)
MTBDRplus
studies
(n = 18)
MTBDRsl
studies
(n = 6)
Other studies
(n = 17)
Studies excluded (n = 501)
• Review, n = 35
• Editorial, n = 5
• Not M. tuberculosis study, n = 1
• Drug trial/development study, n = 2
• Inappropriate study type, n = 105
• Samples isolated from culture, n = 186
• Samples ‘spiked’, n = 3
• Reference standard not appropriate, n = 13
• Sample size below minimum
   requirement, n = 48
• Rapid test for MTB not MDR or
   XDR-TB, n = 35
• Abstract (poster/talk), no data, n = 30
• Duplicate, n = 38
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Citations identified through database
searching
1 January 2000–29 October 2012 (n = 13,711)
29 October 2012–15 August 2013 (n = 1373)
Total (n = 15,084)
Additional citations
identified through
other sources
(n = 2)
Full-text papers screened for eligibility
(n = 557)
Records screened after
duplicates removed
(n = 8922)
Records excluded based
on title and abstract
(n = 8365)
FIGURE 1 Flow diagram showing study selection process.
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studies (n= 18),34,62–75,98–100 MTBDRsl studies (n= 6)37,76–80 and other rapid diagnostic studies (n= 17);81–97
the last category comprised any report with insufficient information about the type and manufacture
of the assay tested, or assays that had been designed in-house.
Subgroup analysis was limited by the dearth of information reported on participant age, HIV status and
other identified risk factors for heterogeneity in diagnostic studies (Table 1). Among the 56 studies, only
one study37 was conducted on samples from HIV-positive patients and two studies58,97 on patients that
were not HIV positive. The remaining studies were conducted on samples with either mixed or undisclosed
HIV status. The majority of studies did not report any data on participant age (n= 44), and the remaining
studies were carried out on adults (n= 8) or a mix of adults and children (n= 4).
TABLE 1 Breakdown of studies by subcategory for the three key commercial tests reviewed for diagnostic accuracy
Category Subcategory GeneXpert INNO-LiPA MTBDRplus
HIV status HIV-positive patients 0 0 0
HIV-negative patients 1 0 0
HIV-negative and HIV-positive patients 3 2 2
Not specified 2 7 16
Participant age Adults (≥ 16 years) 4 1 2
Children (< 16 years) 0 0 0
Adults and children 0 1 1
Not specified 2 7 15
Reference standard Solid culture 1 1 5
Liquid culture 2 7 8
Solid and liquid culture 3 1 5
Not specified 0 0 0
Smear status of samples Smear positive 1 6 10
Smear negative 0 2 0
Not specified 5 4 8
Study methodology Blinded 1 2 5
Not blinded 0 0 0
Not specified 5 7 13
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GeneXpert
Findings of the review
A total of six29,38,58–61 studies reporting the use of GeneXpert were eligible for inclusion and subsequently
analysed (Table 2). The reported sensitivity and specificity of the GeneXpert test varied between
81.3–100.0% and 97.4–100.0%, respectively (see Table 2). The pooled estimates of sensitivity (96.8%,
95% CI 94.2% to 99.4%) and specificity (98.4%, 95% CI 97.8% to 99.0%) suggested a high level of
diagnostic accuracy when this test was used to detect rifampicin resistance in clinical samples (Figure 2).
The calculation and analysis of the DOR for each study also suggested a high level of diagnostic accuracy
when the study data were pooled (DOR= 1209.2, 95% CI 446.3 to 3276.4; p< 0.05) (Figure 3). However,
there was marked heterogeneity between studies, indicated by both the wide 95% CI of the DOR, and
both tests for heterogeneity using both the chi-squared distribution [11.46, degrees of freedom (df)= 5;
p= 0.04] and the I2 method (56.4%), which is more robust when evaluating meta-analyses containing
a small number of studies.
Subsequent analysis and the construction of a HSROC curve indicated similarly high levels of predicted
sensitivity (96.5%, 95% CI 91.4% to 98.5%) and specificity (98.2%, 95% CI 97.6% to 98.8%), with the
majority of the studies and the summary point clustered in the top left-hand corner of the plot (Figure 4).
However, again there was evidence of heterogeneity between the study estimates in the distended
predicted 95% confidence ellipse.
Further investigation into the potential causes of heterogeneity could not be carried out as the small
number of studies included in the analysis could not be reasonably broken down into subcategories for
subgroup analysis (see Table 1).
Secondary analyses
In order to investigate possible sources of heterogeneity between studies, a qualitative assessment of the
studies was carried out using the QUADAS-2 framework. Each study was evaluated using a predefined set
of indicator questions to evaluate factors that may bias the study findings or raise concerns about the
applicability of the study. The summarised results of this assessment are outlined in Table 3 and Figure 5.
In the ‘Flow and timing’ domain, used to assess possible biases introduced by the use of patient samples,
there was a marked lack of clarity surrounding the timing and the thresholds of the index test and
reference test and the exclusion of samples from the assay.
TABLE 2 GeneXpert sensitivity and specificity for the detection of rifampicin resistance in clinical samples
Study (first author
and year) TP FP FN TN Sensitivity (%) 95% CI (%) Specificity (%) 95% CI (%)
Boehme (2010)29 200 10 5 505 97.6 94.4 to 99.2 98.1 96.5 to 99.1
Boehme (2011)38 236 14 14 796 94.4 90.8 to 96.9 98.3 97.1 to 99.1
Naidoo (2010)60 157 8 1 635 99.4 96.5 to 100 98.8 97.6 to 99.5
Kim (2012)58 21 0 0 41 100.0 83.9 to 100 100.0 91.4 to 100
Kurbatova (2013)59 57 1 5 38 91.9 82.2 to 97.3 97.4 86.5 to 99.9
O’Grady (2012)61 13 2 3 78 81.3 54.4 to 96.0 97.5 91.3 to 99.7
SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Note: weights are from random-effects analysis
D + L overall (I 2 = 61.4%, p = 0.024)
Boehme (2010)29
Kim (2012)58
Naidoo (2010)63
O’Grady (2012)61
I – V overall
Kurbatova (2013)59
Study
Boehme (2011)38
0.97 (0.94 to 0.99)
0.98 (0.94 to 0.99)
1.00 (0.84 to 1.00)
0.99 (0.97 to 1.00)
0.81 (0.54 to 0.96)
0.98 (0.97 to 0.99)
0.92 (0.82 to 0.97)
ES (95% CI)
0.94 (0.91 to 0.97)
100.00
27.19
% weight (D + L)
(a)
8.09
30.58
1.51
8.87
23.77
0 0.2 0.4 0.6 0.8 1
(b)
Study ES (95% CI) % weight (D + L)
0 0.2 0.4 0.6 0.8 1
Note: weights are from random-effects analysis
D + L overall (I 2 = 0.0%, p = 0.895)
O’Grady (2012)61
I – V overall
Boehme (2011)38
Kurbatova (2013)59
Naidoo (2010)63
Kim (2012)58
Boehme (2010)29
0.98 (0.98 to 0.99)
0.98 (0.91 to 1.00)
0.98 (0.98 to 0.99)
0.98 (0.97 to 0.99)
0.97 (0.87 to 1.00)
0.99 (0.98 to 0.99)
1.00 (0.91 to 1.00)
0.98 (0.96 to 0.99)
100.00
1.94
36.85
0.77
38.29
1.86
20.30
FIGURE 2 Detection of rifampicin resistance by GeneXpert: forest plot of (a) sensitivities and (b) specificities.
D+ L, DerSimonian and Laird; ES, effect size; I–V, instrumental variables.
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TABLE 3 Quality Assessment of Diagnostic Accuracy Studies version 2: risk of bias and applicability concerns
summary of GeneXpert diagnostic accuracy for the detection of rifampicin resistance in clinical samples, by study
Study (first author and year)
Risk of bias Applicability concerns
Patient
selection
Index
text
Reference
standard
Flow and
timing
Patient
selection
Index
text
Boehme (2010)29 ☺ ☺ ☺ ? ☺ ☺
Boehme (2011)38 ☺ ? ? ? ☺ ?
Naidoo (2010)60 ? ? ? ? ? ☺
Kim (2012)58 ☹ ☹ ☹ ? ☺ ☺
Kurbatova (2013)59 ☺ ☹ ☹ ? ☺ ☺
O’Grady (2012)61 ? ? ? ☺ ☺ ?
☺, low risk of bias;☹, high risk of bias; ?, unclear risk of bias.
O’Grady (2012)61
0.0
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0.8
1.0
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0.00.20.40.60.81.0
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HSROC curve
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FIGURE 4 Summary receiver operating characteristic plots of GeneXpert diagnostic accuracy for the detection of
rifampicin resistance in clinical samples.
0
Patient selection
Index test
Reference standard
Q
U
A
D
A
S-
2 
d
o
m
ai
n
Flow and timing
20 40 60
Proportion of studies
with low, high or unclear
risk of bias (%)
80 100 0 20 40 60
Proportion of studies with low,
high or unclear concerns
regarding applicability (%)
80 100
Low
High
Unclear
FIGURE 5 Risk of bias and applicability concerns summary of GeneXpert diagnostic accuracy for the detection of
rifampicin resistance in clinical samples.
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Concerns regarding a high risk of bias in both the ‘Reference test’ and ‘Index test’ domains were
associated with the absence of, or a lack of clarity associated with, blinding within the study. The study
identified as high risk in the ‘Patient selection’ domain did not enrol patients either consecutively or
randomly, and there was a strong indication that convenience sampling had been used.
When assessing the applicability of the methodology to the research question, the research setting and
patient population did not raise concerns regarding the applicability of the assay.
There was no statistically significant evidence of publication bias based on both Egger’s test and Begg’s
test (p> 0.05), based on rifampicin resistance.
INNO-LiPA
Findings of the review
A total of nine studies33,35,51–57 reporting the use of INNO-LiPA were eligible for inclusion (Table 4). It was
possible to extract data broken down by smear status from only two studies35,52 (see Table 1).
The reported sensitivity and specificity of the INNO-LiPA test varied between 86.7–100.0% and
82.4–100.0%, respectively (see Table 4). The pooled estimates of sensitivity (95.4%, 95% CI 92.2% to
TABLE 4 INNO-LiPA sensitivity and specificity for the detection of rifampicin resistance in clinical samples
Study (first author
and year) TP FP FN TN Sensitivity (%) 95% CI (%) Specificity (%) 95% CI (%)
Pulmonary specimens
Costeira (2007)51 11 2 1 99 91.7 61.5 to 99.8 98.0 93.0 to 99.8
Drobniewski (2000)52 55 3 9 14 85.9 75.0 to 93.4 82.4 56.6 to 96.2
Higuchi (2004)53 22 1 0 19 100.0 84.6 to 100.0 95.0 75.1 to 99.9
Johansen (2003)54 26 0 0 21 100.0 86.8 to 100.0 100.0 83.9 to 100.0
Ogwang (2009)55 13 2 2 13 86.7 59.5 to 98.3 86.7 59.5 to 98.3
Sam (2006)56 31 2 1 623 96.9 83.8 to 99.9 99.7 98.8 to 100.0
Skenders (2005)57 31 2 3 52 91.2 76.3 to 98.1 96.3 87.3 to 99.5
Viveiros (2005)33 31 0 1 310 96.9 83.8 to 99.9 100.0 98.8 to 100.0
Sputum specimens
Smear positive
Drobniewski (2000)52 11 0 4 11 73.3 44.9 to 92.2 100.0 71.5 to 100.0
Seoudi (2012)35 52 5 4 1554 92.9 82.7 to 98.0 99.7 99.3 to 99.9
Smear negative
Seoudi (2012)35 20 0 1 100 95.2 76.2 to 99.9 100.0 96.4 to 100.0
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98.3%) and specificity (99.7%, 95% CI 99.5% to 100.0%) suggested a high level of diagnostic accuracy
when this test was used to detect rifampicin resistance in clinical samples (Figure 6).
The calculation and analysis of the DOR for each study suggested a high level of diagnostic accuracy when
the study data were pooled (DOR= 770.2, 95% CI 159.6 to 3717.2; p< 0.05) (Figure 7). However, there
was some evidence of heterogeneity between the estimates reported by the studies, indicated by both a
wide 95% CI of the DOR, and both tests for heterogeneity using both the chi-squared distribution
(43.9, df= 9; p< 0.05) and the I2 method (79.5%).
Subsequent analysis and the construction of a HSROC curve indicated similarly high levels of predicted
sensitivity (94.1%, 95% CI 89.5% to 96.7%) and specificity (99.1%, 95% CI 96.5% to 99.8%), with the
majority of the studies and the summary point clustered in the top left-hand corner of the plot (Figure 8).
However, there was a strong indication of heterogeneity, particularly with regard to specificity of the test,
as demonstrated by the shape and orientation of the 95% confidence ellipse.
Further investigation into the potential causes of heterogeneity could not be carried out, as the small
number of studies included in the analysis could not be broken down into large enough subcategories for
subgroup analysis (see Table 1).
Note: weights are from random-effects analysis
D + L overall (I 2 = 5.0%, p = 0.395)
aSeoudi (2012)35
I – V overall
Sam (2006)56
Drobniewski (2000)52
Study
bSeoudi (2012)35
Johansen (2003)54
Higuchi (2004)53
Viveiros (2005)53
Skenders (2005)57
Costeira (2007)51
Ogwang (2009)55
0.95 (0.92 to 0.98)
0.93 (0.83 to 0.98)
0.95 (0.93 to 0.98)
0.97 (0.84 to 1.00)
0.86 (0.75 to 0.93)
ES (95% CI)
0.95 (0.76 to 1.00)
1.00 (0.87 to 1.00)
1.00 (0.85 to 1.00)
0.97 (0.84 to 1.00)
0.91 (0.76 to 0.98)
0.92 (0.62 to 1.00)
0.87 (0.60 to 0.98)
100.00
14.09
12.77
9.99
6.14
18.43
% weight (D + L)
(a)
13.88
12.77
7.20
2.40
2.33
0 0.2 0.4 0.6 0.8 1
FIGURE 6 Detection rifampicin resistance by INNO-LiPA: forest plots of (a) sensitivities and (b) specificities.
D+ L, DerSimonian and Laird; ES, effect size; I–V, instrumental variables. a, All specimens; b, smear-positive
specimens. (continued )
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(b)
Note: weights are from random-effects analysis
D + L overall (I 2 = 0.0%, p = 0.489)
Ogwang (2009)55
Johansen (2003)54
Skenders (2005)57
I – V overall
Drobniewski (2000)52
Higuchi (2004)53
Sam (2006)56
Viveiros (2005)33
bSeoudi (2012)35
aSeoudi (2012)35
Study
Costeira (2007)51
1.00 (0.99 to 1.00)
0.87 (0.60 to 0.98)
1.00 (0.84 to 1.00)
0.96 (0.87 to 1.00)
1.00 (0.99 to 1.00)
0.82 (0.57 to 0.96)
0.95 (0.75 to 1.00)
1.00 (0.99 to 1.00)
1.00 (0.99 to 1.00)
1.00 (0.96 to 1.00)
1.00 (0.99 to 1.00)
ES (95% CI)
0.98 (0.93 to 1.00)
100.00
0.02
0.09
0.16
0.02
0.04
19.93
17.62
1.88
59.70
0.54
% weight (D + L)
0 0.2 0.4 0.6 0.8 1
FIGURE 6 Detection rifampicin resistance by INNO-LiPA: forest plots of (a) sensitivities and (b) specificities.
D+ L, DerSimonian and Laird; ES, effect size; I–V, instrumental variables. a, All specimens; b, smear-positive
specimens.
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Secondary analyses
In order to investigate possible sources of heterogeneity between studies, a qualitative assessment of the
studies was carried out using the QUADAS-2 framework. The summarised results of this assessment are
outlined in Table 5 and Figure 9.
As with the GeneXpert studies, there was a marked lack of clarity surrounding the timing and thresholds
of the index reference tests. This, combined with a lack of clarity surrounding the exclusion of samples
from the assays, contributes to the high proportion of studies designated to have an unclear risk of bias in
the ‘Flow and timing’ domain.
Concerns regarding a high risk of bias in both the ‘Reference test’ and ‘Index test’ domains were
associated with the absence of, or a lack of clarity associated with, blinding within the study.
0.0
0.2
0.4
0.6
0.8
1.0
Se
n
si
ti
vi
ty
0.00.20.40.60.81.0
Specificity
Drobniewski (2000)52Ogwang (2009)
55
Study estimate
Summary point
HSROC curve
95% confidence region
95% prediction region
FIGURE 8 Summary receiver operating characteristic plot of INNO-LiPA diagnostic accuracy for the detection of
rifampicin resistance in clinical samples.
TABLE 5 Quality Assessment of Diagnostic Accuracy Studies version 2: risk of bias and applicability concerns
summary of INNO-LiPA diagnostic accuracy for the detection of rifampicin resistance in clinical samples, by study
Study (first author and year)
Risk of bias Applicability concerns
Patient
selection Index text
Reference
standard
Flow and
timing
Patient
selection
Index
text
Costeira (2007)51 ? ? ? ? ☺ ☺
Drobniewski (2000)52 ☹ ? ? ? ☺ ☺
Higuchi (2004)53 ? ☹ ☺ ☹ ☺ ☺
Johansen (2003)54 ☺ ? ? ? ☺ ☺
Ogwang (2009)55 ☺ ? ? ? ☺ ☺
Sam (2006)56 ☺ ☺ ☺ ☺ ☺ ☺
Seoudi (2012)35 ☺ ? ? ☺ ☺ ☺
Skenders (2005)57 ☺ ☹ ☹ ? ? ?
Viveiros (2005)33 ☺ ? ? ? ☺ ☺
☺, low risk of bias;☹, high risk of bias; ?, unclear risk of bias.
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When assessing the applicability of the methodology to the research question the studies were categorised
as either low or unclear concern.
There was no statistically significant evidence of publication bias based on both Egger’s test and Begg’s
test (p> 0.05), based on rifampicin resistance.
GenoType MTBDRplus
Findings of the review
A total of 18 studies34,62–75,98–100 reporting the use of GenoType MTBDRplus® (Hain Lifescience, Nehren,
Germany) were eligible for inclusion into the meta-analysis (Table 6).
The reported sensitivity and specificity of the MTBDRplus to detect resistance to rifampicin ranged between
82.1–100.0% and 89.9–100.0%, respectively (see Table 6). The pooled estimates of sensitivity (94.6%,
95% CI 91.6% to 97.6%) and specificity (98.2%, 95% CI 97.2% to 99.3%) suggested a high level of
diagnostic accuracy when this test was used to detect rifampicin resistance in clinical samples (Figure 10).
The calculation and analysis of the DOR for each study suggested a high level of diagnostic accuracy when
the study data were pooled (DOR= 666.0, 95% CI 339.3 to 1307.2; p< 0.05) (Figure 11). However, there
was some evidence of heterogeneity between the estimates reported by the studies, indicated by both a
wide 95% CI of the DOR and both tests for heterogeneity using both the chi-squared distribution (35.1,
df= 17; p< 0.05) and the I2 method (51.5%).
Subsequent analysis and the construction of a HSROC plot indicated similarly high levels of predicted
sensitivity (96.1%, 95% CI 91.9% to 98.1%) and specificity (98.1%, 95% CI 96.7% to 98.1%), with the
majority of the studies and the summary point clustered in the top left-hand corner of the plot (Figure 12).
However, there was a strong indication of heterogeneity, particularly with regard to the sensitivity of the
test, as demonstrated by the length and orientation of the 95% confidence ellipse.
The reported sensitivity and specificity of the MTBDRplus to detect resistance to isoniazid in clinical samples
ranged between 29.4–100.0% and 95.7–100.0%, respectively (see Table 6). The pooled estimates of
sensitivity (83.4%, 95% CI 66.3% to 100.0%) and specificity (99.6%, 95% CI 99.0% to 100.0%)
suggested a high level of diagnostic accuracy when this test was used to detect isoniazid resistance in
clinical samples (see Figure 10).
0
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FIGURE 9 Risk of bias and applicability concerns summary of INNO-LiPA diagnostic accuracy for the detection of
rifampicin resistance in clinical samples, by study.
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TABLE 6 GenoType Mycobacterium tuberculosis drug resistance plus assay sensitivity and specificity for the
detection of isoniazid and rifampicin resistance in clinical samples
Study (first author
and year) TP FP FN TN Sensitivity (%) 95% CI (%) Specificity (%) 95% CI (%)
Rifampicin
Macedo (2009)98 23 0 0 43 100.0 85.2 to 100.0 100.0 91.8 to 100.0
Nikolayevskyy (2009)99 103 4 4 38 96.3 90.7 to 99.0 90.5 77.4 to 97.3
Somoskovi (2006)74 51 0 41 51 55.4 44.7 to 65.8 100.0 93.0 to 100.0
Albert (2010)73 15 4 0 73 100.0 78.2 to 100.0 94.8 87.2 to 98.6
Dorman (2012)68 12 2 2 200 85.7 57.2 to 98.2 99.0 96.5 to 99.9
Mironova (2012)34 323 35 16 311 95.3 92.4 to 97.3 89.9 86.2 to 92.9
Eliseev (2013)66 69 2 0 31 100.0 94.8 to 100.0 93.9 79.8 to 99.3
Barnard (2008)70 94 2 1 357 98.9 94.3 to 100.0 99.4 98.0 to 99.9
Farooqi (2012)65 51 1 4 54 92.7 82.4 to 98.0 98.2 90.3 to 100.0
Asencios (2012)71 22 1 2 75 91.7 73.0 to 99.0 98.7 92.9 to 100
Tukvadze (2012)62 112 4 13 329 89.6 82.9 to 94.3 98.8 97.0 to 99.7
Maschmann (2013)100 23 2 5 32 82.1 63.1 to 93.9 94.1 80.3 to 99.3
Anek-Vorapong (2010)72 19 0 0 145 100.0 82.4 to 100.0 100.0 97.5 to 100.0
Crudu (2012)69 100 2 6 48 94.3 88.1 to 97.9 96.0 86.3 to 99.5
Hillemann (2006)64 15 0 0 27 100.0 78.2 to 100.0 100.0 87.2 to 100
Cauwelaert (2011)67 47 4 1 202 97.9 88.9 to 99.9 98.1 95.1 to 99.5
Lacoma (2008)75 29 1 0 20 100.0 88.1 to 100.0 95.2 76.2 to 99.9
Lyu (2013)63 57 4 2 365 96.6 88.3 to 99.6 98.9 97.2 to 99.7
Isoniazid
Macedo (2009)98 24 0 0 43 100.0 85.8 to 100.0 100.0 91.8 to 100.0
Albert (2010)73 21 0 5 66 80.8 60.6 to 93.4 100.0 94.6 to 100.0
Barnard (2008)70 114 1 7 330 94.2 88.4 to 97.6 99.7 98.3 to 100.0
Farooqi (2012)65 45 0 14 49 76.3 63.4 to 86.4 100.0 92.7 to 100.0
Asencios (2012)71 30 3 1 66 96.8 83.3 to 99.9 95.7 87.8 to 99.1
Tukvadze (2012)62 52 2 125 281 29.4 22.8 to 36.7 99.3 97.5 to 99.9
Anek-Vorapong (2010)72 27 0 2 135 93.1 77.2 to 99.2 100.0 97.3 to 100.0
Hillemann (2006)64 17 0 0 25 100.0 80.5 to 100.0 100.0 86.30 to 100.0
Cauwelaert (2011)67 55 4 14 181 79.7 68.3 to 88.4 97.8 94.6 to 99.4
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FIGURE 12 Summary receiver operating characteristic plots of MTBDRplus diagnostic accuracy for the detection of
(a) isoniazid and (b) rifampicin resistance in clinical samples.
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The calculation and analysis of the DOR for each study suggested a high level of diagnostic accuracy when
the study data were pooled (DOR= 565.2, 95% CI 175.3 to 1823.0; p< 0.05) (see Figure 11). However,
there was some evidence of heterogeneity between the estimates reported by the studies, indicated by
both a wide 95% CI of the DOR, and both tests for heterogeneity using both the chi-squared distribution
(18.4, df= 8; p< 0.05) and the I2 method (56.5%).
Subsequent analysis and the construction of a HSROC plot indicated similarly high levels of predicted
sensitivity (90.0%, 95% CI 73.6 to 96.7) and specificity (99.4%, 95% CI 97.9% to 99.8%), with the majority
of the studies and the summary point clustered in the top left-hand corner of the plot (see Figure 12).
However, there was at least one extreme outlier, Tukvadze et al.,62 which, potentially, contributed to the
substantial heterogeneity apparent in the sensitivity estimate. The authors of this study62 had been
unsuccessfully contacted regarding a discrepancy between the diagnostic accuracy data reported and the
published calculation of sensitivities and specificities. When the study62 was excluded from the analysis,
the heterogeneity within the sample was reduced I2 method (36.1%). However, there was only a small
change in the predicted estimates of sensitivity (91.8%, 95% CI 82.8% to 96.2%) and specificity (99.4%,
95% CI 97.3% to 99.9%).
Further investigation into the potential causes of heterogeneity could not be carried out, as the small
number of studies included in the analysis could not be broken down into large enough subcategories for
subgroup analysis (see Table 1).
Secondary analyses
In order to investigate possible sources of heterogeneity between studies, a qualitative assessment of the
studies was carried out using the QUADAS-2 framework. The summarised results of this assessment are
outlined in Table 7 and Figure 13.
When compared with the studies included in the INNO-LiPA and GeneXpert analyses, there appeared to
be a marked reduction in the quality of methodological reporting with studies using the MTBDRplus.
The lack of detail regarding timing, thresholds, patient selection and blinding resulted in the majority of
studies classified as either ‘high bias’ or ‘unclear bias’ in the four key Quality Assessment of Diagnostic
Accuracy Studies (QUADAS) domains. This is particularly marked in the ‘Flow and timing’ domain, for
which all studies performed poorly.
There was no statistically significant evidence of publication bias based on both Egger’s test and Begg’s
test (p> 0.05) based on rifampicin resistance, although there was strong evidence of publication bias using
isoniazid (Egger’s test, p= 0.001).
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TABLE 7 Quality Assessment of Diagnostic Accuracy Studies version 2: risk of bias and applicability concerns
summary of MTBDRplus for the detection drug susceptibility in clinical samples, by study
Study (first author
and year)
Risk of bias Applicability concerns
Patient
selection
Index
text
Reference
standard
Flow and
timing
Patient
selection
Index
text
Macedo (2009)98 ☹ ☺ ☺ ☹ ☺ ☺
Nikolayevskyy (2009)99 ? ? ? ? ? ☺
Somoskovi (2006)74 ☹ ? ? ? ☺ ?
Albert (2010)73 ☺ ☺ ☺ ? ☺ ☺
Dorman (2012)68 ☺ ? ☺ ? ☺ ☺
Mironowa (2012)34 ☺ ? ? ? ☺ ?
Eliseev (2013)66 ☺ ? ? ? ☹ ☺
Barnard (2008)70 ? ? ? ? ☹ ☺
Farooqi (2012)65 ? ? ? ? ? ?
Asencios (2012)71 ☺ ? ? ? ? ☺
Tukvadze (2012)62 ☺ ? ? ? ☺ ☺
Maschmann (2013)100 ☹ ☹ ☹ ? ☺ ☺
Anek-Vorapong (2010)72 ? ? ☺ ? ☺ ☺
Crudu (2012)69 ? ☺ ? ? ☺ ?
Hillemann (2006)64 ? ? ? ? ? ?
Cauwelaert (2011)67 ? ? ? ? ? ☺
Lacoma (2008)75 ☹ ? ? ? ☹ ☺
Lyu (2013)63 ☹ ? ? ? ☹ ☹
☺, low risk of bias;☹, high risk of bias; ?, unclear risk of bias.
0
Patient selection
Index test
Reference standard
Q
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Flow and timing
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Proportion of studies
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FIGURE 13 Quality Assessment of Diagnostic Accuracy Studies version 2: risk of bias and applicability concerns
summary of MTBDRplus for the detection drug susceptibility in clinical samples.
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GenoType MTBDRsl
Findings of the review
A total of six studies37,76–80 reporting the use of GenoType MTBDRsl® (Hain Lifescience) met the inclusion
criteria for the review (Table 8). These studies reported the diagnostic accuracy of MTBDRsl to detect
resistance to a range of injectable drugs and fluoroquinolones resistance in clinical samples. However, the
sample size for each drug category of interest was limited, and only the groups of studies reporting
diagnostic accuracy for specific drugs were not sufficiently large for meta-analysis.
Other studies
In addition to the studies that reported diagnostic data from the widely used commercial tests, 17 studies81–97
reporting data on other genetic rapid diagnostic tests were identified using the inclusion criteria. These tests
were broadly broken into those studies that utilised a variety of TB biochip assays (n= 7, 41.2%) and those
that used in-house PCR assays (n= 10, 59.8%).
The majority of studies (n= 13) reported the diagnostic accuracy of these test to detect rifampicin
resistance in clinical samples (Table 9). The reported sensitivities and specificities of these studies were
high, ranging between 79.8% and 100.0% and 92.2% and 100%, respectively. However, as the
manufacture and design of these assays were not consistent it was not possible to conduct a meta-analysis
on this data set.
TABLE 8 GenoType Mycobacterium tuberculosis drug resistance second-line assay sensitivity and specificity for the
detection of injectable drugs, fluoroquinolones and ethambutol resistance in clinical samples
Study (first author
and year) TP FP FN TN Sensitivity (%) 95% CI (%) Specificity (%) 95% CI (%)
Amikacin
Barnard (2012)80 43 3 0 470 100.0 91.7 to 100 99.4 98.2 to 99.9
Capreomycin
Lacoma (2012)77 23 4 0 25 100.0 85.2 to 100.0 86.2 68.3 to 96.1
Kanamycin
Kontsevaya (2013)37 6 0 58 12 9.38 3.52 to 19.3 100.00 73.5 to 100.0
Ajbani (2012)76 22 0 0 128 100.0 84.6 to 100.0 100.00 97.2 to 100.0
Fluoroquinolones
Lacoma (2012)77 3 2 5 42 37.5 8.52 to 75.5 95.5 84.5 to 99.4
Ofloxacin
Hilleman (2009)78 8 0 1 51 88.90 51.7 to 99.7 100.0 93.0–100.0
Ethambutol
Kontsevaya (2013)37 18 5 32 32 36.0 22.9 to 50.8 86.5 71.2 to 95.4
Miotto (2012)79 13 17 5 21 72.2 46.5 to 90.3 55.3 38.2 to 71.4
Hilleman (2009)78 10 34 15 0 38.5 20.2 to 59.4 0.0 0.0 to 10.3
Ajbani (2012)76 60 8 46 36 56.6 46.6 to 66.2 81.8 67.2 to 91.8
Lacoma (2012)77 22 4 18 6 55.0 38.4 to 70.7 60.0 26.2 to 87.8
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Discussion
The findings of this review suggest that all three commercial tests – INNO-LiPA, GeneXpert and MTBDRplus –
demonstrate promising levels of diagnostic discrimination when detecting rifampicin and isoniazid
susceptibility in clinical samples.
This study used a broad set of inclusion criteria, with respect to the type of rapid diagnostic tests evaluated,
research settings and the lack of restrictions applied to the language of publication. However, the restriction
on the minimum number of samples tested resulted in a discrepancy between the number of studies
included in this review and those published in other published systematic reviews on this subject.45,46
Despite these resections, the findings of this study are consistent with previous estimates that indicated
that both MTBDRplus and GeneXpert can demonstrate high levels (> 90%) of sensitivity and specificity
when detecting drug susceptibility.45,46
It has been suggested that heterogeneity will always be present in any systematic review.102–104 However,
the level of heterogeneity observed in these analyses suggests that the predicted and pooled estimates of
diagnostic accuracy for all three commercial tests should be interpreted with caution. A key limitation
of this work is the lack of subcategory analysis to explore potential sources of heterogeneity between
the studies. This has been hampered by the lack of clear methodological detail reported in the majority of
the papers, as demonstrated by the small number of studies that report details on study blinding and study
design. In addition to this, the small sample sizes used to evaluate diagnostic drug susceptibility tests have
resulted in the exclusion of studies that would otherwise supplement the data set and allow subcategory
analysis to be performed.
TABLE 9 Non-commercial studies investigating sensitivity and specificity for the detection of rifampicin resistance
in clinical samples
Study TP FP FN TN Sensitivity (%) 95% CI (%) Specificity (%) 95% CI (%)
Antonova (2008)81 – – – – – – – –
Calderón-Espinoza (2006)82 107 7 7 83 93.9 87.8 to 97.5 92.2 84.6 to 96.8
Cho (2009)83 11 0 1 34 91.7 61.5 to 99.8 100.0 89.7 to 100.0
Choi (2010)84 25 4 1 62 96.2 80.4 to 99.9 93.9 85.2 to 98.3
García-Sierra (2011)85 27 0 2 16 93.1 77.2 to 99.2 100.0 79.4 to 100.0
Gryadunov (2005)86 17 0 1 95 94.4 72.7 to 99.8 100.0 96.2 to 100.0
Guo (2009)87 72 3 4 50 94.7 87.1 to 98.5 94.3 84.3 to 98.8
Kim (2001)89 23 0 0 33 100.0 85.2 to 100.0 100.0 89.4 to 100.0
Lu (2012)90 67 21 17 585 79.8 69.6 to 87.7 96.5 94.8 to 97.8
Mikhailovich (2001)91 11 0 2 18 84.6 54.6 to 98.1 100.0 81.5 to 100.0
Mokrousov (2003)92 72 0 15 23 82.8 73.2 to 90.0 100.0 85.2 to 100.0
Nosova (2013)93 – – – – – – – –
Pang (2013)88 176 33 25 1580 87.6 82.2 to 91.8 98.0 97.1 to 98.6
Sheen (2009)94 – – – – – – – –
Siu (2011)95 – – – – – – – –
Vadwai (2012)96 187 11 10 73 94.9 90.9 to 97.5 86.9 77.8 to 93.3
Zhang (2012)97 16 7 2 68 88.9 65.3 to 98.6 90.7 81.7 to 96.2
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Chapter 4 Time-and-motion analysis
Introduction
A time-and-motion study was undertaken at the National Mycobacterium Reference Laboratory (NMRL) to
compare the working time for DST using two culture-based methods to three rapid molecular assays.
Culture is the ‘gold standard’ for MTB, DST and can be performed in solid or liquid medium. The resistance
ratio method is used at the NMRL for DST of first-line drugs on LJ egg-based medium, which is prepared
in-house. The resistance ratio is determined by dividing the MIC of the test strain by the MIC of a control
(susceptible) strain.19 For each batch of test strains, four control strains are inoculated on to five different
concentrations of each first-line drug. The test strains are then measured against the modal MIC of the
control strains. At the NMRL, each slope is checked weekly, up to 12 weeks post inoculation.
The proportion method determines the proportion of bacteria in the sample that are resistant to a drug.
If the proportion of resistant bacteria is ≥ 1% of the total bacterial population, the sample is classified as
resistant. Automated liquid culture systems, such as the BACTEC MGIT 960 system, use the proportion
method for DST. Tubes for the BACTEC MGIT 960 system contain an oxygen-quenched fluorochrome. As
bacteria grow and consume oxygen, fluorescence increases and is detected by the machine. The BACTEC
MGIT 960 system is used at the NMRL for second-line DST. Tubes containing the critical concentration
of each drug to be tested are inoculated with the test sample.105 The bacterial suspension is diluted 100-fold
before inoculation into the control drug-free tube. If there is at least equal growth in a drug-containing tube
and the control tube, this indicates that at least 1% of the bacteria present in the sample are resistant to
that drug and therefore the sample can be classified as resistant.20 The BACTEC MGIT 960 system monitors
fluorescence every 60 minutes up to a maximum of 6 weeks. At the NMRL, the machine output is
checked daily.
Molecular tests on primary specimens are performed at the NMRL to enable rapid identification of MTB
and possible drug resistance. In order to isolate live pure mycobacteria for downstream phenotypic tests
and archiving, samples from non-sterile sites are first decontaminated using the same procedures used for
processing specimens arriving for culture only. Thus these steps are necessarily included in the timings for
these assays, although they are not strictly required for performing the molecular assay.
Two different commercial LPAs are used at the NMRL for the detection of MDR genotypes: INNO-LiPA
and MTBDRplus. The INNO-LiPA test identifies rifampicin-resistance mutations in the rpoB gene.
The MTBDRplus assay identifies these mutations, and, additionally, mutations associated with isoniazid-
resistance in katG and the inhA promoter. At the NMRL, the LPAs are used to test a broad range of
samples including sputum, bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), bone marrow, tissues
fixed in wax blocks and purulent material. To perform LPAs, first DNA is extracted from MTB cultures or
directly from clinical specimens, and regions of interest are amplified. Labelled amplicons are hybridised to
probes immobilised on membrane strips and detected by a colourimetric reaction.
For the INNO-LiPA assay the amplification stage is a two-step nested PCR. At the NMRL, for each
sample six PCR reactions are set up, three containing neat sample and three with a 1 : 10 dilution of the
sample. In each set of three reactions, one PCR tube is spiked with MTB, DNA as an inhibition control.
A negative result for this reaction indicates the presence of contaminants inhibiting the Taq polymerase.
Dilution of the sample 1 : 10 is frequently sufficient to dilute contaminants to a level at which they are
no longer inhibitory. For each PCR run, five negative controls are made to identify contamination, and a
low positive control (10 copies of MTB, DNA) is included. All of the PCR products are visualised after
electrophoresis on agarose gels, and one positive amplicon per sample is used in the 1 INNO-LiPA assay.
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The MTBDRplus assay involves a single amplification step. At the NMRL, one PCR reaction is set up per
sample, and each run includes one positive and one negative control. All samples, including controls, are
run on the MTBDRplus assay. The hybridisation and subsequent wash steps of the MTBDRplus assay
are semi-automated on a BeeBlot processor (Bee Robotics, Caernarfon, UK). At the NMRL, the MTBDRplus
assay is often run alongside other GenoType tests, such as the Mycobacterium CM or AS assays (Hain
Lifescience, Nehren, Germany), which use the same BeeBlot programme.
The GeneXpert assay is an automated assay that detects the presence of MTB in clinical samples and tests
for rifampicin resistance.29 The specimen is incubated in sample reagent for 15 minutes then transferred
into a cartridge, which is loaded into the GeneXpert machine, and the entire assay is conducted
automatically within the cartridge. At the NMRL, the GeneXpert assay is used to analyse respiratory and
CSF samples. Respiratory samples are decontaminated to remove non-MTB organisms before they are
processed in the GeneXpert. CSF samples should be sterile (unless infection is present), therefore, they do
not require decontamination and are processed directly.
At the NMRL, the workflow for the identification of MTB and determination of its drug-resistance profile
comprises an integrated series of culture-based and molecular tests designed to provide the most reliable
clinically informative data as rapidly as possible (Figure 14). In this study we have timed individual stages
independently, allowing an estimation of the time taken to process a sample through a theoretical
exclusively phenotypic compared with molecular diagnostic pathway. Samples are almost always processed
in batches, with the procedure-dependent batch size selected to optimise both efficiency and timely
reporting. By recording the number of samples processed at each stage of every procedure,
we can calculate the theoretical time spent per sample.
Methods
Observation
Selection of days on which to observe the diagnostic tests was made based on convenience. Several
biomedical scientists (BMSs) perform each diagnostic test at the NMRL and the observations were not
restricted to any particular members of staff. The observer followed the BMS continuously while they were
carrying out the diagnostic test.
Data collection
Based on the NMRL standard operating procedures (SOPs) for each diagnostic test, paper forms were
created on which the working time involved in each significant task was recorded (see Appendix 7). The
wall clocks present in each laboratory were used to time each task and the start and end time of each
task was recorded on the form. Timings were rounded to the nearest minute or, if the time taken was
significantly < 1 minute, rounded to the nearest 10 seconds. Any relevant additional information (such as
tasks carried out while waiting for a sample in the centrifuge) was recorded in the ‘notes section’ next to
the relevant task. The data were recorded in a spreadsheet, and the start and end times for each task were
used to determine the working time for each task. The sum of the working times for each task equals the
total working time. Every task involved in conducting the diagnostic test (such as paperwork, setting up,
cleaning up, recording results, etc.) was included in the working time.
If a waiting time (e.g. waiting for a centrifuge to finish a spin) was ≤ 15 minutes, the waiting time was
included in the working time, as the BMS could not realistically undertake separate tasks in that time.
If the waiting time was > 15 minutes, unless the BMS remained unoccupied, the time was not recorded
as working time, as the BMS had enough time to complete other unrelated tasks. If the BMS used the
waiting time to complete tasks that were relevant to the test being timed, those tasks were timed and it
was noted that they took place while waiting. The time taken for automated machines to conduct stages
of an assay (> 15 minutes) or the time cultures spent in incubators was not recorded because no labour on
the part of the BMS was involved.
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FIGURE 14 Standard work flow for specimens and cultures received at the NMRL. Mycobacterium CM/AS,
GenoType Mycobacterium CM/AS assay (Hain Lifescience).
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The number of samples being processed during each observation was recorded. In addition, the number
of each type of sample was recorded, because some sample types require slightly different methods of
preparation. Reference cultures arrive on either solid or liquid medium and the number of each was
also recorded.
Data analysis
At the NMRL, samples are processed in batches and, with the exception of the GeneXpert, individual
samples are almost never assayed. For many tasks, the time taken to perform it is independent of the
number of samples involved, for example preparation of PCR master mixes. The theoretical time taken for
one sample was calculated by dividing the time taken by the number of samples. Thus, this is the mean
time taken for a sample in an average batch size at the NMRL and does not represent the actual time that
would be taken if a single sample was processed individually.
Results
GeneXpert assay
At the NMRL, the GeneXpert system is used to assay respiratory and CSF specimens. As all samples
received are subsequently cultured to permit further phenotypic testing, respiratory specimens undergo a
preliminary decontamination step before following the manufacturer’s recommendations for sample
processing. Occasionally, a large volume (> 2ml) of CSF is received and it is concentrated by centrifugation
prior to processing.
At the NMRL, the GeneXpert assay is performed on demand, on a daily basis, on up to four samples
simultaneously. This assay was observed between November 2012 and April 2013: 10 times for respiratory
specimens (Table 10) and seven times for CSF specimens (Table 11). The mean theoretical hands-on time
taken to process a single CSF specimen was 24 minutes. For respiratory specimens, the equivalent
calculated time for a single specimen was 44 minutes.
Line probe assays
The INNO-LiPA assay is run on primary samples received for molecular testing, other than respiratory
specimens and CSF (which are run on the GeneXpert). The MTBDRplus assay, which is less sensitive, is
subsequently run on isolates determined to be rifampicin resistant by either the INNO-LiPA or GeneXpert,
in order to identify isoniazid-resistance mutations. The MTBDRplus assay is also run on cultures received by
the reference laboratory.
At the NMRL, the INNO-LiPA and the MTBDRplus assays are conducted on a weekly basis. Typically, there
are samples requiring INNO-LiPA testing every week, but the MTBDRplus assay is not always needed.
The initial stages for each assay, resulting in amplification-ready DNA, are performed together. Set-up of
the first-round PCR is also carried out for both assays together. Typically, the subsequent steps are carried
out the following day. These are performed separately for each assay. The INNO-LiPA assay requires a
second-round PCR and electrophoresis step to identify reactions containing amplicon. If no tubes contain
sample amplicon then the hybridisation stage is not performed. Thus, for this assay, the time taken to
identify negative samples is less than that to identify positive samples. For the MTBDRplus assay, all
samples and controls are hybridised to strips, and there is no difference between the processing time for
positive and negative samples.
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Between November 2012 and April 2013, the INNO-LiPA assay performed in isolation was observed seven
times and the two LPAs performed together observed a further five times (Table 12). The theoretical time
per sample for each stage was calculated and the stages required for each assay summed to estimate the
theoretical time for a single sample for each assay performed independently, if processed in a batch of
2–15 samples. The calculated per sample hands-on time for a PCR-positive INNO-LiPA assay was 45 minutes
and for the MTBDRplus assay was 50 minutes.
Culture-based drug susceptibility testing
Phenotypic testing is considered the gold standard for determining MTB drug resistance, and samples
received at the NMRL for molecular testing are subsequently assayed using culture-based methods.
The observations of the culture-based methods took place between April 2013 and June 2013.
Prior to DST, primary specimens are cultured in drug-free media (LJ and MGIT) to provide sufficient
replicating bacilli for testing. LJ slopes are examined weekly for growth, and MGIT growth is monitored
daily. Purity of the culture is assessed by plating on Columbia Blood Agar plates and acid-fast staining. The
theoretical mean time taken to complete all tasks for the culture of one primary specimen was 20 minutes
(Table 13).
Testing for resistance to first-line drugs (rifampicin, isoniazid, ethambutol, pyrazinamide and streptomycin)
is conducted using solid egg-based LJ medium that is prepared in-house. The resistance ratio method
utilised requires three slopes per drug. In addition, four control slants (positive, p-nitrobenzoic acid,
thiophene 2-carboxylic acid hydrazide and low temperature) are included for each sample to identify
positivelyMTB complex isolates. Thus, a total of 19 slopes are inoculated per sample. The LJ slopes are
prepared on demand, in batches corresponding to 30 eggs-worth of medium, which fills approximately
780 bijou bottles. In each batch, slopes containing a single drug are prepared; these are stored for up to
2 months. The theoretical time taken to prepare LJ slopes for testing one sample was estimated at 4 minutes
(Table 14). In total, the theoretical hands-on time required to set up the first-line sensitivities for one
specimen was 21 minutes (see Table 14). Including the time required for the initial culture in drug-free
media, the total hands-on time for one specimen was 41 minutes.
Testing for second-line drugs [aminoglycosides, capreomycin, fluoroquinolones, thioamides and linezolid
(Zyvox®, Pfizer)] is conducted in the BACTEC MGIT 960 system at the NMRL and requires 11 tubes per
sample. Media-containing MGITs are purchased commercially and prepared by the addition of supplied
supplements plus drugs when required. The theoretical time to prepare tubes sufficient to test one sample
was 9 minutes. In total, the hands-on time required for one specimen (for 10 drugs) was 28 minutes
(Table 15). Including the time required for initial specimen culture, the total theoretical per-sample time
was 49 minutes.
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Discussion
This time-and-motion study was carried out in order to estimate the total working time required for
conducting molecular and culture-based diagnostic tests on specimens received at the NMRL. The results
are summarised in Table 16. The BMS staff were aware both that they were being timed and of the aims
of the study. Although it was not the purpose of the time-and-motion study to assess the efficiency of the
BMSs, the knowledge that they were being timed may have affected the rate at which they worked. The
timings were recorded by a junior member of staff, new to the laboratory, in order to minimise this effect.
In this study, convenience sampling was the only practical method of sampling but it inevitably led to more
timings being taken on certain days of the week and when the workload in the laboratory was not
too heavy.
A broad range of sample types is received at the NMRL and each requires a unique series of preparation
steps designed to optimise the outcome of downstream tests. For example, although respiratory specimens
must be decontaminated to kill non-mycobacterial species, specimens from sterile sites, such as CSF, which
typically have a low mycobacterial load, are not preprocessed. Specific procedures for the isolation of
mycobacteria from specimens such as tissues or bone marrow are also utilised. This variation results in
differences in the working time taken for each batch.
The GeneXpert assay is designed to be performed directly on specimens, and the in-cartridge procedure
includes steps for killing the bacilli and releasing DNA. At the NMRL, all specimens are cultured in order
that, subsequent to molecular tests, gold-standard phenotypic DST can be performed. This means that
sputum must be liquefied and decontaminated before an aliquot can be used for the GeneXpert assay.
In other laboratories, the sputum may be loaded directly into the cartridge. Thus, when used as a POC
device, hands-on time will be equivalent for all specimens and approximate that of CSF specimens at
the NMRL.
The theoretical time taken to process a single specimen is calculated based on the actual batch size
used at the NMRL. The length of time taken for many of the tasks involved in a procedure will not be
dependent on the number of samples. For example, tasks such as PCR master mix preparation and LPA
hybridisation are essentially independent of batch size (see Table 12). The timings presented here may,
therefore, be substantially different from those at other laboratories with different levels of
specimen throughput.
TABLE 16 Summary of working time for culture and molecular tests at the NMRL
Test
Theoretical time per specimen
(hours:minutes:seconds)
Mean number of samples
per batch
Number of
drugs tested
DST BACTEC MGIT 960 00:48:24 4 10
DST LJ slopes 00:41:00 20 5
GeneXpert (CSF) 00:23:42 1 1
GeneXpert (respiratory) 00:44:20 2 1
INNO-LiPA 00:45:25 7 1
MTBDRplus 00:50:29 1 2
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Comparison of the time taken to perform the two LPAs illustrates the substantial effect that batch size has
on the theoretical working time per sample. The INNO-LiPA requires two PCR stages, and hybridisation
washes are performed manually. The calculated time spent per sample – 45 minutes – was based on
timings when the mean batch size was seven samples. The MTBDRplus assay utilises a single PCR step and
the hybridisation stage is semiautomated, however, the calculated time spent per sample was 50 minutes,
as only one or two samples were processed together.
It is important to reiterate that the information obtained from each of the tests described is not the same.
The GeneXpert and INNO-LiPA assays identify MTBC complex and diagnose rifampicin resistance.
The MTBDRplus assay provides these results plus isoniazid resistance. As conducted at the NMRL, the method
for DST on LJ slopes includes controls that identify MTBC complex and diagnoses resistance to five first-line
drugs. The timings for the BACTEC MGIT 960 DSTs are for the diagnosis of resistance to 10 drugs.
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Chapter 5 Health-care costs and utilities
Introduction
The economic value of diagnostic tests is a function of the cost, timing and accuracy of the tests and of
the resultant impact on clinical decisions, and hence on health outcomes and expenditure. Tests cannot be
evaluated in isolation but have to be considered within a pathway of care, specifying how patients are
treated while waiting for test results, what treatments they are offered when the results arrive, how and
when diagnostic errors (FPs and FNs) are detected and then what corrective action is taken. The health
and monetary consequences of alternative diagnostic/treatment pathways can be weighed up using
a cost–utility framework, in which the value of health effects is quantified using the metric of the
quality-adjusted life-year (QALY).106 QALY estimates should take account of mortality and impacts on
quality of life, caused both by the disease and by adverse effects of treatment. Similarly, cost estimates
should incorporate the cost of diagnostic tests, costs for treating the disease and caring for the patient,
and costs associated with adverse effects. From a broader ‘societal’ perspective, costs borne by patients and
their families and the value of lost productivity would also be included alongside direct costs to health-care
payers. For an infectious disease, the analysis should also account for impacts related to transmission,
including QALY loss and costs for secondary cases.107 The overall expected costs and QALYs associated with
alternative pathways can then be compared to identify which offers the most cost-effective use of scarce
health-care resources.
The conventional diagnostic work-up for patients with suspected respiratory TB disease includes sputum
smear microscopy to give an early indication of infectivity, followed by culture to diagnose active TB and to
test for drug sensitivity.108 Culture is diagnostic but can take from 14 to 42 days to provide a definitive
result: usually around 14 days to identify MTB and a further 14 days for DST, but it can take longer for
slow-growing cultures. Rapid molecular assays can return a result in as little as 1–3 days, which might have
a variety of benefits for individual patients, the community and the UK NHS. Patients wrongly suspected of
having TB may benefit from an early rule-out, avoiding or shortening unnecessary isolation and treatment.
This would be particularly valuable for people who are thought to be at high risk of MDR-TB, who are
more likely to be admitted to very expensive negative pressure isolation, and who may be exposed to
presumptive treatment with second-line drugs that have a relatively poor adverse effect profile. For
patients with the disease, early accurate diagnosis will ensure that they commence effective treatment
and that, where necessary, they are isolated earlier, minimising the impact on their own health while
diminishing the risk of transmission. Early diagnosis of drug-resistant disease is particularly important to
protect the health of the individual and the community.
However, as shown in Chapter 3, rapid assays are less accurate than culture, raising the possibility of FP and
FN results. Both types of error can be costly and harmful. FN results give inappropriate reassurance and may
harm the patient by delaying time to effective treatment and place contacts at risk if infection control
measures are relaxed. FP results may unnecessarily expose patients to the inconvenience of isolation and
adverse effects of medication. These cost and harms are likely to be particularly acute for patients with, or
at high perceived risk of, MDR-TB. Current guidance therefore recommends that rapid molecular tests may
have a role alongside culture but that they should not replace culture.109,110 This limits potential costs and
harms of misdiagnosis, as clinicians can take corrective action when the culture results arrive, but it does not
entirely eliminate these risks. The additional cost of the molecular test also cannot be offset by savings from
reduced need for culture. There is, therefore, a trade-off between the costs and health impacts of adding a
rapid molecular test to the current diagnostic pathway, as the benefits of a faster diagnosis may be partly or
wholly offset by the additional cost of the test and by costs and health consequences of errors.
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We conducted a cost–utility analysis to evaluate the addition of a rapid molecular test for TB disease and
drug sensitivity alongside the culture testing, compared with culture testing alone, in patients with
suspected respiratory disease. It should be noted that, although the aim of this study was to assess the role
of rapid molecular assays in testing for drug susceptibility, the assays’ ability to diagnose MTB accurately
was also relevant to the economic analysis. Identifying drug-sensitive (DS) TB as well as resistant TB reduces
both unnecessary treatment and isolation and the risk of onward transmission. Therefore, in order to
capture all aspects of the cost and effects related to the diagnostic accuracy of rapid molecular assays, the
economic analysis had to focus on the population of patients with suspected TB across the whole care
pathway, not just from the point of DST and onward. The analysis followed the National Institute for
Health and Care Excellence (NICE) public health reference case, including the adoption of a public sector
perspective and the use of a 3.5% annual discount rate for both costs and QALYs.111 A dynamic model
was used to estimate the impact of the alternative diagnostic strategies on transmission of TB within
defined communities, and to estimate related costs and QALY effects. Probabilistic sensitivity analysis (PSA)
was used to reflect the impact of uncertainty over the input parameters for the transmission model.
However, some aspects of structural uncertainty, relating to modelling assumptions, could not be
integrated in the PSA. In this chapter we present estimates (means and PSA distributions) for the cost and
QALY parameters that, alongside the estimates of diagnostic accuracy presented in Chapter 3, provided
key inputs for the transmission model. The structure, assumptions and parameterisation of the transmission
model, and the cost-effectiveness results are presented in Chapter 6.
Overview of methods
Key aspects of the decision problem and assumptions adopted for our analysis are described below.
Diagnostic strategies
l The baseline for comparison was the current diagnostic strategy, including smear microscopy, culture
for identification of MTB and DST for culture-positive cases. It was assumed that smear microscopy
results are available within 1 day of collection of the sputum sample. Culture testing was assumed to
be 100% accurate for both TB diagnosis and drug susceptibility and was treated as the reference
standard for other tests. The results of culture tests were assumed to take 14 days for diagnosis of MTB
and an additional 14 days for DST. Note that times to test results will differ between patients, and that
the figures used here are intended as an average across the population.
l The intervention evaluated was the addition of a rapid molecular assay for the detection of TB disease
and drug resistance, alongside the current diagnostic strategy. We assumed that molecular test results
would be available for both TB status and drug sensitivity 3 days from collection of the sputum sample,
on average.
l The currently available molecular assays test for MTB and rifampicin resistance (GeneXpert and
INNO-LiPA) and MTBDRplus also tests for isoniazid resistance. In practice, the results of culture-based
DST are used to identify sensitivity to other drugs and to derive individualised drug regimens. However,
for the modelling we did not distinguish between different patterns of drug resistance. This is a
simplification and relies on the assumptions that patients with resistance to a single drug would not
incur significant additional risks or costs for isolation or drug treatment compared with patients with DS
disease, and that patients with different patterns of multiple drug resistance would face similar risks
and costs to one another (this is unlikely to be true for XDR-TB, but this is still a rare phenomenon in
the UK). Furthermore, we assumed that the diagnostic accuracy of the molecular assays for detecting
‘true’ MDR-TB is the same as for detecting rifampicin resistance (as reported in Chapter 3). This is
justified by the observation that a large majority of MDR patients are resistant to rifampicin.38
l The analysis focused on the GeneXpert system, the INNO-LiPA and MTBDRplus assay as exemplars for
the rapid molecular assays.
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l At present, microscopy and mycobacterial culture are most usually performed in local hospital laboratories,
but DST for MTB-positive cases is performed at specialist mycobacterial reference laboratories.112
We assumed that these arrangements would not change with the wider adoption of molecular testing.
However, we did investigate alternative scenarios for the location of rapid molecular assays: centralised,
with molecular testing conducted only at TB specialist reference laboratories, and localised, with molecular
testing distributed at local TB laboratories. It was assumed that centralised testing would reduce the mean
cost per test (owing to economies of scale in the laboratory arising from more intensive use of capital) but
at the expense of possible delay and an additional cost for transport of samples.
Population and subgroups
l The transmission model adopted a population approach, modelling incidence of TB and the process of
diagnosis and treatment in three sections of the community with high incidence of MDR-TB: Black
African, South Asian and Eastern European individuals.
l The population subject to intervention was individuals being tested for suspected TB disease. This
includes individuals who present symptomatically or as a result of active case finding. Individuals may
have been referred to TB services from general practice, emergency departments or other specialties.
l Individuals undergoing diagnosis are categorised into subgroups which are defined by their true disease
status, prior risk status perceived by clinicians and test results (see Diagnostic subgroups, below).
Care pathways
l For each diagnostic strategy and subgroup, we defined a care pathway that specified what medical
treatments and health services individuals would receive between presentation to the point when they
either complete TB treatment successfully, or fail to complete treatment (are lost to follow-up). See
Care pathways, below.
l We estimated a total cost for each care pathway, including the cost of consultations and investigations
prior to referral to TB services, TB diagnosis, medication, inpatient care and isolation, outpatient care,
and contact tracing and associated treatment of any latent TB cases.
l In addition, for each care pathway the health impact is estimated in terms of the mean discounted
QALYs lost as a result of TB disease and treatment.
Diagnostic subgroups
Various factors define the unique care pathways that patients can follow after referral for suspected TB.
Under the current diagnostic strategy (the baseline comparator), the key factors are as follows.
True clinical status (no tuberculosis, DS tuberculosis, MDR-TB): a patient starting the process of
diagnosis for pulmonary TB can be in one of three clinical states: no active TB disease, DS TB, or MDR-TB.
As noted above, for simplicity, we did not differentiate between resistance to single or multiple drugs, or
between different patterns of drug resistance.
Smear status (positive, negative): the smear status is identified by microscopy, within 1 day of
collection of the sputum sample. Smear status indicates infectivity and so determines if the clinician
decides to isolate the patient or provides presumptive medication prior to diagnosis.
MDR risk status (high risk, low risk): risk status is determined a priori by the clinician, with patients who
are deemed to be at ‘high risk’ of MDR-TB invoking more conservative action. The main risk factors for
MDR-TB are history of prior TB drug treatment, birth in a high-incidence country, HIV infection, residence
in London, age between 25 and 44 years, and male gender.108 However, these features are non-specific,
and presumptive treatment of every patient with one or more of these risk factors would be unrealistic.
DOI: 10.3310/hta19340 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 34
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Drobniewski et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
For the purposes of calculation, we defined risk status simply as a percentage of suspected TB cases that
a clinician deems to be at sufficiently high risk of MDR-TB to warrant admission to a negative pressure
isolation room and presumptive treatment with MDR medications if the person is smear positive. However,
the decision to prescribe MDR medication presumptively would also depend on the expected delay in
diagnosis. We assumed that presumptive treatment would not be used with molecular testing, as the
results are available in a few days compared with 2–4 weeks for culture and DST alone. In the absence
of better information, we assumed that clinicians would be relatively ‘well-calibrated’ in their judgement,
and that the proportion of patients identified as high risk would be similar to the ratio of MDR cases to
all TB cases in the relevant population: 1.6% (13 cases) of Black African patients, 1.4% (31 cases) of
South Asian patients, and 24% (13 cases) of Eastern European patients.113 Based on these figures,
we assumed that 2% of patients would be treated as high risk in the Black African and South Asian
populations, and 25% in the Eastern European population.
These three factors define the 12 diagnostic subgroups that have distinctive care pathways under the
current diagnostic strategy (Table 17).
The introduction of a rapid assay increases the number of possible care pathways, because errors in
molecular test results can impact on treatment decisions prior to day 28, when the correct culture results
are available. There are 32 permutations of true disease status, smear status, risk status and molecular
assay results that lead to distinct care pathways (Table 18).
One final factor that leads to variation in the care pathway, and hence in the cost and QALYs attached to
the diagnostic subgroups, is whether or not the individual completes their course of medication. This
affects the duration of care the patient receives and therefore the total duration over which they accrue
costs and QALYs from treatment, and whether they are cured or re-enter the population as a transmission
risk. We assumed that, on average, individuals who fail to complete treatment default half-way through
the course of treatment: uncertainty over this proportion was reflected in the PSA by sampling from a beta
distribution with a mean of 0.5 and standard error of 0.1.
TABLE 17 Diagnostic subgroups with culture testing only
Code True disease status Smear status Risk status
7_C No TB Positive High
21_C Low
14_C Negative High
28_C Low
1_C DS TB Positive High
15_C Low
8_C Negative High
22_C Low
4_C MDR-TB Positive High
18_C Low
11_C Negative High
25_C Low
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TABLE 18 Diagnostic subgroups with rapid molecular test and culture
ID True disease status Smear status Risk status Molecular test result
7_R No TB Positive High No TB
33_R DS TB
34_R MDR-TB
21_R Low No TB
35_R DS TB
36_R MDR-TB
14_R Negative High No TB
29_R DS TB
30_R MDR-TB
28_R Low No TB
31_R DS TB
32_R MDR-TB
1_R DS TB Positive High DS TB
3_R MDR-TB
15_R Low DS TB
17_R MDR-TB
8_R Negative High DS TB
10_R MDR-TB
12_R No TB
22_R Low DS TB
24_R MDR-TB
26_R No TB
2_R MDR-TB Positive High DS TB
4_R MDR-TB
16_R Low DS TB
18_R MDR-TB
9_R Negative High DS TB
11_R MDR-TB
13_R No TB
23_R Low DS TB
25_R MDR-TB
27_R No TB
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Care pathways
Each of the above diagnostic subgroups was assumed to follow a distinct care pathway. We considered
the care pathway to be broken down into the following stages:
Pre referral This is the period of time from when a patient becomes symptomatic or is first suspected of
having TB, to the time when they are referred to a TB or respiratory specialist for investigation. We
assumed that the referral can come from one of three channels: from primary care, from an emergency
department, or from another hospital specialty.
Diagnosis The duration of the diagnostic period is from the first collection of sputum samples until the
definitive diagnosis for TB and drug sensitivity is received. The diagnostic period can overlap with treatment
as an inpatient or outpatient.
Inpatient treatment From the point the patient is admitted until they are discharged. For smear-positive
patients, inpatient care will include isolation until the patient is no longer considered a transmission risk.
If the patient is smear positive and at high risk of MDR-TB, or if they are diagnosed with MDR-TB, we
assumed isolation in a negative pressure room.
Outpatient treatment Once a patient is deemed well enough, and is no longer a transmission risk, they
will be discharged and continue treatment as an outpatient.
The addition of a rapid molecular test is assumed to impact on the care pathways in two main ways during
the diagnostic period: first, it may influence clinical decisions about what presumptive drug treatment is
offered, if any, and, second, it may influence decisions about whether or not a patient is admitted and, if
so, to what level of isolation. These decisions may also have implications for the total duration of drug
treatment and the time spent as an outpatient, which depend on when effective treatment is initiated.
Drug treatment
The standard drug treatment for TB consists of 6 months of isoniazid and rifampicin, supplemented in the
first 2 months with pyrazinamide and ethambutol, generally in a fixed-dose combination tablet form.108
Treatment for MDR-TB is less standardised. For the modelling exercise, we assumed a full course to consist
of seven drugs: an injectable drug (either amikacin or capreomycin) for 4 months, and oral medications
[moxifloxacin (Avelox®, Bayer) or levofloxacin, prothionamide, cycloserine, ethambutol, pyrazinamide, and
pyridoxine – vitamin B6] for 20 months.114 We assumed that MDR treatment is effective for DS disease, but
that standard treatment is not effective for MDR-TB, and that, to be effective, MDR treatment must last for
the full 20 months. The mean duration of treatment for patients who failed to complete was assumed to
be 3 months for standard treatment and 10 months for MDR treatment.
Our assumptions about what treatments would be offered to the 12 diagnostic subgroups under the
current practice (culture only) strategy are set out in Table 19. We assumed that patients perceived to be
at low risk of drug-resistant disease with a smear-positive microscopy result would commence the
standard course of treatment presumptively (at day 1). This treatment continues if the patient has a
culture-confirmed TB diagnosis at day 14 but is assumed to stop if they receive a negative diagnosis at that
time. If culture indicates the presence of drug-resistant disease at day 28, it is assumed that the patient
then switches to a MDR treatment regimen. Smear-negative patients who are at low risk of MDR-TB are
assumed not to receive treatment presumptively but to start standard treatment if they have a positive TB
diagnosis at day 14 and to switch to a MDR regimen if MDR-TB is confirmed by culture at day 28.
Assumptions are similar for patients perceived to be at high risk of MDR-TB, except that presumptive
treatment (where applicable) is with a MDR regimen rather than a standard regimen.
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The drug treatment pathways in the presence of rapid molecular testing are shown in Table 20. We
assumed that clinicians would not treat presumptively in advance of a molecular test result (at day 3),
regardless of the patient’s smear status and perceived MDR risk status. Treatment between days 4 and 14
is based entirely on the molecular test result. Any treatment is stopped if culture indicates no TB at day 14,
and, if necessary, is switched to an appropriate regimen when culture drug sensitivity results are available
at day 28. The only role for risk assessment in this case is in determining what regimen patients receive
between days 15 and 28 if the molecular test (falsely) indicates no TB but culture at day 14 confirms a
diagnosis of TB. We assume that smear-positive patients cannot have a FN molecular test for MTB.
Location of care and isolation
Our assumptions regarding the durations of hospital stay, isolation and outpatient care are summarised in
Tables 21 and 22. Some patients may be admitted to hospital for treatment of acute symptoms and/or for
isolation, and the remainder of the treatment period is spent under outpatient care. Clinical practice in this
area is likely to vary and is probably influenced by practical constraints such as the availability of isolation
beds, as well as by different interpretations of guidelines and judgement over the risks for individual
patients. We have not been able to obtain nationally representative data on length of stay and duration of
isolation broken down by the different diagnostic groups required for the model. The assumptions are
therefore based on local audit data and expert opinion from members of the research team. It should also
be emphasised that the figures quoted below are all means for the relevant population, and that lengths
of stay and isolation are highly variable between individuals. As for other model parameters, uncertainty
over these means is modelled in the PSA.
The mean duration of infectivity (time to smear conversion) has been reported as 14 days from the start of
effective therapy,108 and we assumed that patients with DS disease who have been admitted for isolation
will be fit for discharge at this time. Patients with MDR-TB are likely to require longer isolation and inpatient
care. Estimates of length of stay for patients with pulmonary MDR-TB were derived from an audit at a
London hospital, with an estimated mean of 89 days [standard deviation (SD) 74 days] for 13 smear-positive
cases and 46 days (SD 33 days) for seven smear-negative cases admitted between 2009 and 2013 (M Lipman,
Royal Free Hospital, 2014, personal communication). The mean length of stay for these 20 patients (74 days)
was similar to that reported for nine patients with MDR-TB treated at another London hospital between 1996
and 1999 (78 days).115 Guidelines108 recommend that patients with or thought to be at high risk of MDR-TB
TABLE 19 Drug treatments with culture testing only
Code Risk status Smear status True disease status
Drug treatment regimen
Days 1–14 Days 15–28 Day 29 . . .
21_C Low Positive No TB Standard None None
15_C DS TB Standard Standard Standard
18_C MDR-TB Standard Standard MDR
28_C Negative No TB None None None
22_C DS TB None Standard Standard
25_C MDR-TB None Standard MDR
7_C High Positive No TB MDR None None
1_C DS TB MDR MDR Standard
4_C MDR-TB MDR MDR MDR
14_C Negative No TB None None None
8_C DS TB None MDR Standard
11_C MDR-TB None MDR MDR
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TABLE 20 Drug treatments with rapid molecular testing and culture
ID
Risk
status
Smear
status
Rapid
test result
True
disease status
Drug treatment regimen
Days
1–3
Days
4–14
Days
15–28
Day
29 . . .
21_R Low Positive No TB No TB None None None None
35_R DS TB No TB None Standard None None
15_R DS TB None Standard Standard Standard
16_R MDR-TB None Standard Standard MDR
36_R MDR-TB No TB None MDR None None
17_R DS TB None MDR MDR Standard
18_R MDR-TB None MDR MDR MDR
28_R Negative No TB No TB None None None None
26_R DS TB None None Standard Standard
27_R MDR-TB None None Standard MDR
31_R DS TB No TB None Standard None None
22_R DS TB None Standard Standard Standard
23_R MDR-TB None Standard Standard MDR
32_R MDR-TB No TB None MDR None None
24_R DS TB None MDR MDR Standard
25_R MDR-TB None MDR MDR MDR
7_R High Positive No TB No TB None None None None
33_R DS TB No TB None Standard None None
1_R DS TB None Standard Standard Standard
2_R MDR-TB None Standard Standard MDR
34_R MDR-TB No TB None MDR None None
3_R DS TB None MDR MDR Standard
4_R MDR-TB None MDR MDR MDR
14_R Negative No TB No TB None None None None
12_R DS TB None None MDR Standard
13_R MDR-TB None None MDR MDR
29_R DS TB No TB None Standard None None
8_R DS TB None Standard Standard Standard
9_R MDR-TB None Standard Standard MDR
30_R MDR-TB No TB None MDR None None
10_R DS TB None MDR MDR Standard
11_R MDR-TB None MDR MDR MDR
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are admitted to negative pressure isolation, and not released from isolation until confirmation that they are
not infectious, based on two consecutive negative smear tests (with samples taken at least 1 week apart) and
a negative culture test. For the model, we assumed that patients with smear-positive MDR-TB remain in a
negative pressure room until discharge after 89 days, but that smear-negative MDR patients are transferred to
a non-isolation bed (on average) half way through their 46-day stay. These assumptions are broadly consistent
with data reported from an earlier audit: 449 negative pressure isolation days for 15 episodes (mean stay
30 days), of which 96 ‘correct’ days of negative pressure isolation were for the two true MDR-TB cases
(mean 48 days).52
The total duration of treatment is governed by the time to correct diagnosis, when patients start the
correct treatment (if any), and the duration of that treatment. Tables 21 and 22 present timings for
patients who complete treatment, but the transmission model also allowed for a proportion of patients to
default from treatment during the outpatient period.
First, to consider the timings under the usual care (culture) strategy, see Table 21. Patients with
smear-positive microscopy results are admitted because of the risk of transmission; as a precaution, those
deemed to be at high risk of MDR-TB are admitted to a negative pressure isolation room, and those at low
risk to a standard isolation room (a single room without negative pressure but vented to the outside of the
building).108 At day 14, admitted patients with a negative culture result for MTB (FPs) are discharged. The
smear-positive patients with DS disease (who will have started an effective presumptive treatment regimen
on day 1) remain in hospital for 14 days until they are no longer infectious. High-risk patients with
smear-positive MDR-TB (who will also have started effective presumptive treatment on day 1) remain in
negative pressure isolation until they are discharged after 89 days. However, low-risk, smear-positive
MDR-TB patients (who will have been initially treated with an ineffective standard regimen) spend 27 days
in standard isolation, until drug resistance is detected by culture. They then commence an effective MDR
drug regimen and transfer to a negative pressure room, where they stay for a further 89 days until they
are discharged.
TABLE 21 Location of care and isolation with culture testing only
Code
Risk
status
Smear
status
True
disease
status
Duration of treatment by location (days)
Standard
inpatient
Inpatient
isolation
Negative
pressure Outpatient
Pathway
duration
21_C Low Positive No TB 0 13 0 0 14
15_C DS TB 0 14 0 169 184
18_C MDR-TB 0 27 89 521 638
28_C Negative No TB 0 0 0 0 14
22_C DS TB 0 0 0 183 197
25_C MDR-TB 23 0 23 578 638
7_C High Positive No TB 0 0 13 0 14
1_C DS TB 0 0 27 156 184
4_C MDR-TB 0 0 89 521 611
14_C Negative No TB 0 0 13 0 14
8_C DS TB 4 0 23 156 197
11_C MDR-TB 23 0 23 564 624
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TABLE 22 Location of care and isolation with rapid molecular testing and culture
ID
Risk
status
Smear
status
Rapid
test
result
True
disease
status
Duration of treatment by location (days)
Standard
inpatient
Inpatient
isolation
Negative
pressure Outpatient
Pathway
duration
21_R Low Positive No TB No TB 0 2 0 0 14
35_R DS TB No TB 0 13 0 0 14
15_R DS TB 0 16 0 167 186
16_R MDR-TB 0 27 89 519 638
36_R MDR-TB No TB 0 2 11 0 14
17_R DS TB 0 2 25 156 186
18_R MDR-TB 0 2 89 519 613
28_R Negative No TB No TB 0 0 0 0 14
26_R DS TB 0 0 0 183 197
27_R MDR-TB 23 0 23 578 638
31_R DS TB No TB 0 0 0 11 14
22_R DS TB 0 0 0 183 186
23_R MDR-TB 23 0 23 589 638
32_R MDR-TB No TB 0 0 11 0 14
24_R DS TB 2 0 23 158 186
25_R MDR-TB 23 0 23 564 613
7_R High Positive No TB No TB 0 0 2 0 14
33_R DS TB No TB 0 11 2 0 14
1_R DS TB 0 14 2 167 186
2_R MDR-TB 0 25 91 519 638
34_R MDR-TB No TB 0 0 13 0 14
3_R DS TB 0 0 27 156 186
4_R MDR-TB 0 0 91 519 613
14_R Negative No TB No TB 0 0 0 0 14
12_R DS TB 0 0 14 169 197
13_R MDR-TB 23 0 23 564 624
29_R DS TB No TB 0 0 0 11 14
8_R DS TB 0 0 0 183 186
9_R MDR-TB 23 0 23 589 638
30_R MDR-TB No TB 0 0 11 0 14
10_R DS TB 2 0 23 158 186
11_R MDR-TB 23 0 23 564 613
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Patients with smear-negative disease are a much lower transmission risk, and we assume that they are not
initially admitted. Further, we assume that smear-negative patients with a positive culture test at 14 days
remain at home, unless they are thought to be at high risk of MDR-TB. The smear-negative patients at
high risk of MDR-TB with a positive culture are admitted to negative pressure isolation, discharged after
14 days if DST confirms that they have DS disease, but remain in hospital for a total of 46 days if MDR-TB
is confirmed (23 further days in a negative pressure room and 23 in a non-isolation bed).
During outpatient follow-up, all patients were assumed to have one appointment per month at a
consultant-led hospital clinic. Patients on a MDR drug regimen were assumed to have an additional
face-to-face contact with a TB specialist nurse each month. This is an assumed average; some patients
will not need both appointments each month, but other patients may require more frequent contact for
monitoring of treatment adherence or of adverse reactions to medication.
Assumptions about the duration and location of treatment with rapid molecular testing are summarised in
Table 22. Patients with a positive smear result were assumed to be admitted: those regarded as high risk
of MDR to negative pressure isolation and those at low risk to a standard isolation room. If the molecular
test at day 3 is negative, any admitted patients are discharged. Smear-positive patients for whom the
molecular test indicates DS disease remain in hospital in a standard isolation room until those with a
negative culture for TB are discharged at day 14, those with DS TB are discharged when no longer
infectious after 14 days of treatment, and those with culture-confirmed MDR-TB transfer to a negative
pressure room on day 28 and stay there for 89 days. Smear-positive patients with a molecular test
indicating MDR-TB are transferred (if necessary) to a negative pressure room on day 3 and stay there until
culture confirmation that they do not have MTB or that they do not have drug-resistant disease, or they
remain in isolation until discharge after 89 days for true MDR cases. We assumed that patients with
smear-negative microscopy would not be admitted for isolation but that they might be admitted for
observation, insertion of a peripherally inserted central catheter or equivalent for treatment with injectable
drugs, and/or for treatment of acute symptoms following a molecular test result indicating MDR-TB, and
would remain in hospital until culture confirmation of their true status.
Examples of care pathways
The care pathways described above define the utilisation of health services (tests, medications, inpatient
care and outpatient follow-up) and hence the costs incurred for the NHS. They also define the duration of
patients’ exposure to TB symptoms and to adverse events of treatment, and hence to their QALY loss over
the treatment period. Figures 15 and 16 illustrate how the costs and QALYs are incurred over the care
pathway for a patient with smear-positive DS TB, but who is perceived in advance to be at high risk of
MDR disease.
Figure 15 shows the expected results under the current diagnostic strategy (culture only). Owing to the
perceived transmission risk, the patient is admitted to negative pressure isolation on presentation and
remains there until DST results become available at day 28, after which he/she is discharged to outpatient
follow-up. MDR medication is started on admission as a pre-emptive measure, but the patient is
transferred to a standard regimen when culture confirms DS disease at day 28. The overall course of
treatment lasts for 6 months (183 days), if completed. The patient has impaired quality of life (utility) as a
result of developing symptoms during the prereferral period, more severe symptoms while in hospital, and
then some continuing loss of quality of life after discharge while recovering. While on MDR treatment,
the patient is at risk of additional side effects (particularly ototoxicity attributable to injectable agents).
Figure 16 shows how the treatment pathway, and associated costs and QALY loss, would be expected to
change for this patient with a (correct) molecular test result on day 3. At this time, the patient would be
released from negative pressure isolation to a normal isolation room and start a standard drug regimen.
Both of these changes would save money for the NHS, and the patient would not be exposed to the
risks of the MDR regimen, reducing the risks of toxicity. In this case, the length of hospital stay and total
duration of the pathway would not change.
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Method for estimating costs
Costs were estimated for each care pathway, including costs (1) of tests and consultations prior to referral
for a TB diagnosis, (2) for tracing, testing and treating latent infection in contacts of each index case,
(3) of tests during the diagnostic period, (4) of medication, (5) and for inpatient care and outpatient
follow-up. The first two of these items (prereferral and public health control costs) were treated as a
fixed (deterministic) cost per index case. The other costs differed between the pathways. All costs were
estimated from a NHS perspective and were discounted to a present value at an annual rate of 3.5%.
An example of a cost calculation for one of the care pathways is shown in Table 23. This is for a
smear-positive patient considered to be at high risk of MDR disease, but who in fact has DS disease and
is treated under the current culture-based diagnostic strategy (as in Figure 15). The high cost for this
pathway is driven by the (unnecessary) expense of negative pressure isolation, and MDR medications.
In reality, only a small proportion of patients presenting with TB symptoms will be considered at such high
risk of MDR-TB and incur this high cost.
Method for estimating quality-adjusted life-year loss
The QALY loss associated with each pathway was also estimated. This was estimated relative to expected
survival and quality of life (utility) for individuals of the same age but without TB and not undergoing
diagnosis or treatment for TB. QALYs were discounted to present values using an annual rate of 3.5% per
year. Three potential health impacts were considered: impairments to utility attributable to TB per se, utility
impairments attributable to adverse effects of treatment, and the case fatality risk.
TABLE 23 Example of cost calculation: person with DS smear-positive disease at high risk of MDR disease
(group 1_C)
Item Costs (£)
Prereferral
Weighted average of GP, A&E and inpatient care costs prior to referral 195
Diagnostic
Cost of culture and DST 42
Medication
Presumptive treatment with MDR regimen: 27 days 572
Treatment on standard regimen once diagnosed with DS TB: 156 days 140
Permanent adverse effects of MDR treatment 218
Health care
Time spent as inpatient in negative pressure isolation: 27 days 30,400
Time spent as inpatient in normal isolation room: 0 days 0
Time spent as inpatient not isolated: 0 days 0
Time spent as outpatient (includes follow-up visits, tests): 156 days 675
Contact tracing and treatment of latent TB infection (per index case) 2035
Total 34,277
A&E, accident and emergency; GP, general practitioner.
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Tuberculosis status
Three stages of disease were distinguished for the purpose of estimating the QALY loss as a result of, TB
symptoms: the pretreatment stage (between onset of symptoms and the start of the diagnostic period),
the acute treatment stage (during hospital stay), and the postacute treatment stage (during outpatient
treatment). The impact of TB morbidity was estimated, based on utility decrements for each period of time,
subtracted from an age-weighted average utility level for a healthy individual. Each utility decrement was
integrated over an appropriate time period to provide a total discounted QALY loss attributable to TB
morbidity. The duration of the three periods differed between the various care pathways described
(see Care pathways, above). Pathways with quicker, more accurate diagnosis are associated with lower
QALY losses, as they have a shorter time to start (and hence to finish) effective treatment. Utility
decrements for the three disease stages were sourced from Kruijshaar et al.116
Adverse effects of treatment
Tuberculosis medications can have significant, and in some cases permanent, adverse effects that may
also impact on quality of life. Isoniazid, rifampicin and pyrazinamide – part of the standard treatment
regimen for drug-sensitive TB – are associated with various adverse effects, most notably that of
hepatoxicity.117 However, this is rare, so, for the purposes of this analysis, we assumed that first-line
medication does not carry a risk of long-term permanent harm. Penalties for adverse effects of standard
drug treatment are implicitly incorporated in the analysis in three ways. First, empirical estimates of the
utility loss during TB treatment inevitably include some element attributable to (tolerated) side effects of
treatment. Second, some patients who default from treatment are likely to do so because of (intolerable)
side effects, and the transmission model incorporates health and cost penalties for patients who do not
complete treatment. Third, costs of care while in hospital, and during follow-up, include costs for
monitoring adverse effects.
Given the focus of this analysis on the accurate identification and treatment of patients with MDR-TB,
it was important to reflect the additional risks of MDR medications. In particular, the aminoglycosides
that make up part of the MDR treatment regimen carry a risk of ototoxicity and of long-term hearing
damage.118,119 We included an estimate of the lifetime QALY loss associated with permanent hearing loss,
as a proxy to reflect the overall utility impact of permanent serious adverse effects of MDR treatment.
The method that we used was based on an economic analysis by Veenstra et al.120 to evaluate
pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in patients with cystic fibrosis.
We updated their analysis, using recent estimates of adverse events rates associated with aminoglycosides
in patients with TB and updated estimates of utility loss associated with hearing impairment. (Refer to
Table 35 for further details.)
Mortality risk
In addition to the morbidity impacts described above, TB can still be a fatal disease and one might expect
MDR-TB to carry a higher risk of fatality than DS disease. QALYs lost per TB case fatality were calculated
from UK life tables, utility by age, and the age distribution of TB case fatalities.112,121,122 The estimated
QALY loss for TB mortality – approximately 20 QALYs per case fatality – was applied within the
transmission model.
Table 24 shows an example of the QALY calculations. This relates to the same example illustrated in
Figure 15 and Table 23. This individual spends 73 days prior to the start of the diagnostic period with
active TB (0.01 QALYs lost), 27 days in the acute stage in hospital (0.015 QALYs lost) and 156 days under
treatment as an outpatient (0.03 QALYs lost). In addition, they incur an expected loss of 0.228 QALYs as a
result of side effects associated with 27 days of MDR treatment.
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Sources of parameter estimates
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was used to examine the impact of uncertainty over the input parameters to
the transmission model. For each parameter subject to uncertainty, a probability distribution was defined
and a set of 10,000 parameter values were generated by random (Monte Carlo) sampling in Excel. Separate
streams of random numbers were set for each parameter to ‘seed’ them in such a way that when the
distributions of some parameters were changed for alternative decision scenarios (described below), the
values of other parameters would not change. This reduces unnecessary variation between scenarios.
Matrices of PSA sample values were saved as text CSV (comma-separated values) files and provided to the
mathematical modellers as inputs for the transmission model. Alongside the ‘economic data’ (cost and
utility estimates) described in this chapter, samples of some other key input parameters were included in
the PSA file, including the estimates of diagnostic accuracy obtained from the systematic review presented
in Chapter 3.
Distributions were chosen to reflect the appropriate ranges for the parameters of interest. For example,
beta distributions were used for probabilities and utility multipliers, as these can take on values of only
between zero and one. Costs were sampled from a gamma distribution, as they must be > 1 and usually
have a positive skew. Some parameters not subject to significant uncertainty were treated as fixed. For
example, the unit costs of most medications are defined nationally, and, although there is some local
variation in prices paid by NHS providers as a result of negotiated discounts, no data are available on these
discounts. We therefore followed the NICE convention of using NHS list prices for medications.123 Similarly,
the costs of many NHS services (e.g. outpatient consultations and routine tests) are now set in a national
tariff that is not subject to local negotiation, and so we treated these costs as deterministic. However,
there were some large drivers of costs which were subject to considerable uncertainty: notably the
duration of time spent in inpatient care and the cost of negative pressure isolation. These elements were
sampled probabilistically. For sampling purposes, when no estimate of uncertainty was available, standard
errors were set at 10% or 20% of the mean. For all elements estimated probabilistically, the distribution
applied and standard error are reported with their mean values in the tables below.
Decision scenarios
Six sets of PSA samples were taken to reflect different combinations of assumptions over the location of
molecular testing (centralised vs. localised) and over the proportion of patients being tested for TB who are
judged by clinicians to be at high risk of MDR disease. The location of testing has potential impacts on the
cost and timing of the diagnostic process. We assumed that microscopy and initial culture testing is currently
conducted locally, but that DST for culture-positive cases is conducted only at specialist TB reference
laboratories. These arrangements were assumed not to change with the introduction of molecular testing.
Under the ‘centralised’ scenario, the equipment and consumables for molecular testing would be located at
the TB reference laboratories and used efficiently, at maximum capacity. However, a cost would be incurred
for transport of the sample to the reference laboratory for molecular testing – we assumed an average cost of
£6.50 per sample. Under the ‘localised’ scenario, we assumed that molecular tests would be conducted at
TABLE 24 Example of QALY calculation: high-risk person with DS smear-positive disease (group 1_C)
Care pathway Duration (days) Utility decrement QALY loss
Active TB untreated 73 0.051 0.010
Active acute TB on treatment 27 0.206 0.015
Active postacute TB on treatment 156 0.067 0.029
Time on MDR medication 27 0.112 0.228
Total lifetime QALYs lost 0.282
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local laboratories, incurring no additional transport costs compared with current practice. However, we
assumed that they would be operating below capacity for molecular tests, losing some economies of scale.
Across England, there are 110 local TB laboratories, each processing on average 1030 tests per year.112 We
estimated that this would increase the mean cost per test by approximately £6 compared with centralisation
of molecular tests. The net effect of transport and capacity on the cost per molecular test is therefore minimal.
There is, however, a potential time delay associated with the transport of samples to a reference laboratory for
molecular testing: we assumed 1 day extra, on average.
We produced PSA samples for centralised and localised locations of testing for each of the three
populations modelled. For each population, we varied the proportion of patients with suspected TB who
clinicians would judge to be at sufficiently high risk of MDR-TB to justify presumptive treatment: 2% for
the Black African and South Asian populations and 25% for Eastern Europeans.
Test accuracy parameters
Estimates of the sensitivity and specificity of the rapid molecular tests for detecting drug sensitivity in
patients with confirmed TB disease, compared with the reference standard of culture DST, have been
presented in Chapter 3. However, many studies lacked the breakdown of diagnostic accuracy by smear
status and by test for TB or drug susceptibility. This limited which studies could be used to inform the
economic analysis.
It was important to differentiate diagnostic accuracy by patients’ smear status for the economic analysis, as
this impacted on decisions about presumptive treatment and isolation. Smear status also had an important
impact on transmission probability in the dynamic model (reported in the following chapter). Similarly, the
care pathways and transmission risks also depended on the accuracy of molecular tests for early detection
of TB disease.
The diagnostic accuracy parameters for the GeneXpert, MTBDRplus and INNO-LiPA assays are shown in
Tables 25–27. These estimates were based on studies included in the systematic review. In addition,
estimates of the sensitivity and specificity of GeneXpert assays for detection of TB (compared with culture
as the reference standard) were obtained from Drobniewski et al.124
To account for uncertainty, the diagnostic accuracy results were sampled probabilistically. For sampling of
the diagnostic accuracy, it is important to retain the correlations between the sensitivity and specificity
parameters. To do this, we first calculated the DOR from the mean estimates of the sensitivity and
specificity. The DOR is a summary measure of diagnostic accuracy, the ratio of the odds of a positive test
result if the patient has the disease over the odds of a positive test result if the patient does not have the
disease, and can be expressed as a function of the sensitivity (Se) and specificity (Sp).
DOR=
Se.Sp
(1−Se)(1−Sp)
(1)
We drew random samples for one of the accuracy parameters (sensitivity); as this is simply a proportion, it
was sampled from a beta distribution. We then rearranged the equation above and used the DOR and the
sampled sensitivity values to calculate the corresponding specificity values. This approach is likely to
underestimate the overall uncertainty (as it does not allow for uncertainty over the DOR). Simultaneous
sampling of correlated sensitivity and specificity parameters (e.g. with a Dirichlet distribution) would better
account for uncertainty. However, the reported data in the literature lacked estimates of covariance or the
absolute numbers of TP, TN, FP and FN results for each assay broken down by smear status.
For GeneXpert, we were able to obtain only one estimate of diagnostic accuracy for smear-negative
patients. This estimate had a mean of 1.00, so we were unable to resample this value and retain this mean
value in our PSA estimates. For this reason, we set the sensitivity as fixed and sampled the specificity
directly from a beta distribution.
.
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TABLE 25 Diagnostic accuracy parameters for GeneXpert
Parameter Mean (standard error) Distribution Source
For diagnosis of TB
Smear positive
DOR 4851 (2867.4) Fixed Drobniewski et al. (2013)124
Sensitivity 0.98 (0.003) Beta
Specificity 0.99 (< 0.0005) –
Smear negative
DOR 297 (175.55) Fixed Drobniewski et al. (2013)124
Sensitivity 0.75 (0.015) Beta
Specificity 0.99 (< 0.0005) –
For diagnosis of drug sensitivity in people with confirmed TB
Smear positive
DOR 810 (478) Fixed C Boehme, derived from Boehme et al. (2011)38
Sensitivity 0.964 (0.931–0.982) Beta
Specificity 0.968 (0.950–0.980) –
Smear negative
DOR 36443 Fixed C Boehme, derived from Boehme et al. (2011)38
Sensitivity 1.00 (0.871–1.00) Fixed
Specificity 0.948 (0.915–0.969) Beta
TABLE 26 Diagnostic accuracy parameters for MTBDRplus
Parameter Mean (standard error) Distribution Source
For diagnosis of TB
Smear positive
DOR 808 Fixed Crudu et al. (2012)69
Sensitivity 0.867 (0.0867) Beta
Specificity 0.992 –
Smear negative
DOR 251 Fixed Crudu et al. (2012)69
Sensitivity 0.803 (0.0803) Beta
Specificity 0.984 –
For diagnosis of drug sensitivity in people with confirmed TB
Smear positive
DOR 2766 (2031) Fixed From systematic review and meta-analysis (see
Chapter 3)
Sensitivity 0.9676 (0.0215) Beta
Specificity 0.9893 (0.0038) –
Smear negative
DOR 234 Fixed Crudu et al. (2012)69
Sensitivity 0.907 (0.0907) Beta
HEALTH-CARE COSTS AND UTILITIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Unit costs for health-care resources
All costs were considered from a NHS perspective. Some items relate to one-off events, such as the cost of
the rapid molecular test or the cost of the culture and DST. Others are time dependent, including the cost
of medication, inpatient care (including isolation) and outpatient care. Where possible, unit costs were
based on published national tariffs. Otherwise, estimates were derived from local information or from
the literature.
Table 28 shows the unit costs for diagnostic tests. Costs for culture and rapid molecular assays were
estimated, based on the costs of consumables, capital costs and overheads from the NMRL laboratory
finance department. Capital costs were discounted over a period of 10 years and apportioned to each test,
assuming that all equipment is used at full capacity. Labour costs of administering the assays were
estimated based on the person-hours per test, estimated from a time-and-motion study at the NMRL
(see Chapter 4). A transport cost of £6.50 per sample was included in the total cost of administering each
assay, including culture. All costs have been inflated to 2011–12 levels. It has been assumed that the
NMRL cost profile is indicative of the other reference laboratories in Newcastle and Birmingham. Regional
variation in cost of labour and overheads has not been explored here, because of a lack of data.
Unit costs for medications (Table 29) were sourced from the British National Formulary (BNF),128 with one
exception: costs for prothionamide are not currently listed in the BNF, and so a mean cost was taken from
three hospitals. The unit costs of other health services are listed in Table 30.
TABLE 27 Diagnostic accuracy parameters for INNO-LiPA
Parameter Mean (standard error) Distribution Source
For diagnosis of TB
Smear positive
DOR 64.87 (38.34) Fixed Drobniewski et al. (2013)124
Sensitivity 0.93 (0.005) Beta
Specificity 0.83 (0.010) –
Smear negative
DOR 44.57 (26.35) Fixed Drobniewski et al. (2013)124
Sensitivity 0.65 (0.033) Beta
Specificity 0.96 (0.008) –
For diagnosis of drug sensitivity in people with confirmed TB
Smear positive
DOR 1739 (1569) Fixed From systematic review and
meta-analysis (see Chapter 3)
Sensitivity 0.9346 (0.023) Beta
Specificity 0.9922 (0.007) –
Smear negative
DOR 653 Fixed ECDC109
Sensitivity 0.8571 (0.6732–0.9588) Beta
Specificity 0.9909 (0.9673–0.9986) –
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TABLE 28 Unit costs of diagnostic tests
Resource item
Unit:
2011–12 £
Mean, £
(standard error)
Distribution
(PSA) Source
Mantoux test Per test 1.30 – NICE108
IGRA test 56.24 – Pareek et al. (2013)125
Blood test 3.05 – NHS reference costs126
Smear test 1.56 – NHS reference costs126
Liver function test 1.03 – NICE108
Chest radiography 24.21 – Department of Health National
Tariff 2013–14127
Culture diagnosis of TB 22.29 (2.23) Gamma Local data
Culture drug sensitivity 13.64 (1.36) Gamma Local data
GeneXpert @ regional laboratory 63.15 (6.32) Gamma Local data
MTBDRplus @ regional laboratory 42.73 (4.27) Gamma Local data
INNO-LiPA @ regional laboratory 27.68 (2.77) Gamma Local data
GeneXpert @ local laboratory 68.53 (6.90) Gamma Local data
MTBDRplus @ local laboratory 45.16 (4.52) Gamma Local data
INNO-LiPA @ local laboratory 30.10 (3.01) Gamma Local data
Cost of sample transport 6.50 (0.65) Gamma Local data
IGRA, interferon-gamma release assay.
TABLE 29 Unit costs of medication
Resource item Unit: 2011–12 £ Mean (£) Source
Latent TB treatment
Isoniazid Per month 44.93 BNF128
Rifampicin Per month 24.61 BNF128
Pyridoxine (vitamin B6) 10-mg tablets Per month 0.52 BNF
128
Standard front-line regimen (I, R, P)
Rifater®, Sanofi-Aventis (50 mg isoniazid/120 mg
rifampicin/300 mg pyrazinamide)
Per day 0.37 BNF128
Rifinah®-150, Sanofi-Aventis (100 mg isoniazid/
150 mg rifampicin)
Per day 0.50 BNF128
MDR regimen (seven-drug combination)
Amikacin Per day 2.09 BNF128
Moxifloxacin Per day 2.57 BNF128
Prothionamide Per day 3.26 Average from three hospitals
Cycloserine Per day 8.31 BNF128
Ethambutol Per day 0.63 BNF128
Pyrazinamide Per day 4.32 BNF128
Pyridoxine Per day 0.02 BNF128
MDR regimen (seven drugs) Per day 21.20 BNF128
I, isoniazid; P, pyrazinamide; R, rifampicin.
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Costs for general practice consultations were taken from the Personal Social Services Research Unit (PSSRU)
estimates,129 and from the Department of Health reference costs for inpatient and outpatient care.126 The
costs of negative pressure isolation were uprated for inflation from published estimates,52 using the
hospital and community services pay and price index.129 Costs for standard isolation were estimated by the
authors from the NHS reference costs for TB requiring non-elective inpatient stay.126 The lower estimate of
an excess bed-day was taken as the cost of a non-isolated inpatient-day and the average cost of a bed-day
for pulmonary TB with complications was taken as an estimate of a day in isolation. The cost of hospital
admissions was treated probabilistically. Details of the figures and distributions sampled are available in
Table 30.
Resource utilisation
Parameters on health-care utilisation per patient were sourced from literature, local audit, and, in some
cases, expert clinical advice (Tables 31–33).
Utility and quality-adjusted life-year loss
Estimates of parameters used to estimate QALY losses attributable to TB are shown in Table 34. Patients
with TB were assumed to occupy three health states and attract a corresponding utility decrement while
in that state: active TB pretreatment, active TB on treatment as inpatient, and active TB on treatment as
an outpatient. The utility estimates applied are listed in Table 34. For each care pathway these utility
estimates were integrated over the estimated time period spent in each health state to calculate a QALY
loss attributable to TB.
TABLE 30 Unit costs of health-care use
Resource item
Unit:
2011/12 £
Mean, £
(standard error)
Distribution
(PSA) Source
Outpatient visits
GP Per visit 37 – PSSRU129
A&E Per visit 126 – NHS reference costs126
Outpatient consultant-led first attendance Per visit 179 – NHS reference costs126
Outpatient consultant follow-up appointment Per visit 134 – NHS reference costs126
TB specialist nurse: face-to-face follow-up Per visit 62 – NHS reference costs126
TB specialist nurse: telephone call Per call 26 – NHS reference costs126
Admissions
Inpatient care non-isolated Per day 282 Fixed NHS reference costs126
Incremental cost of standard isolation over normal
inpatient care
Per day 108 (110) Gamma
Standard isolation Per day 390 – NHS reference costs126
Incremental cost of negative pressure isolation
over standard isolation
Per day 735 (74) Gamma
Negative pressure isolation Per day 1126 – Drobniewski et al.
(2000)52
Adjusted to 2011/12 (£)
A&E, accident and emergency; GP, general practitioner.
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TABLE 31 Resource-use parameters: prior to referral to TB specialist
Resource item Units Mean Source
Via GP % 65 Expert opinion
Via A&E % 30 Expert opinion
Via inpatient referral % 5 Expert opinion
A&E visits n 1 Expert opinion
GP visits n 2 Expert opinion
Chest radiographs n 1 Expert opinion
Blood tests n 1 Expert opinion
A&E, accident and emergency.
TABLE 32 Resource-use parameters: for contact tracing and treatment of contacts with latent infection
Resource item Units Mean Source
Contact tracing (per contact screened)
Specialist nurse face-to-face contacts n 2 Expert opinion
Specialist nurse phone call n 1 Expert opinion
Mantoux screening tests n 1 Expert opinion
IGRA screening tests n 0.5 Expert opinion
Contacts tested for active TB (per index case) n 4.7 Expert opinion
Treatment of LTBI in contacts
Contacts treated for LTBI per index case n 1.1 Expert opinion
Prophylaxis % completing treatment % 0.85 Expert opinion
Duration of treatment (completers) Months 3 Expert opinion
Duration of treatment (non-completers) Months 1 Expert opinion
Outpatient clinic visits per case treated n 3 Expert opinion
TB nurse consultations per case treated n 2 Expert opinion
Duration of isoniazid treatment n 3 Expert opinion
Duration of rifampicin treatment n 3 Expert opinion
Duration of vitamin B6 (pyridoxine) treatment n 3 Expert opinion
IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection.
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TABLE 33 Resource-use parameters: treatment
Resource item Units
Mean
(standard
error)
Distribution
(PSA) Source
Delay from first symptom to start of
diagnostic process
Days 73 (7.3) Gamma
(rounded)
Saldana et al. (2013)130
Treatment duration
DS TB (completers) Days 183 Fixed NICE108
Multiplier for MDR-TB treatment duration
as a function of DS TB treatment duration
Ratio 0.3 (0.03) Beta
MDR-TB (completers) Days 610 Estimated as
(1/0.3)a DS
treatment
duration
WHO114
Multiplier for non-completers treatment
duration as a function of completers
Ratio 0.5 (0.05) Beta
MDR-TB (non-completers) Days 305 Estimated
as 0.5 of
Completers
Assumption
DS TB (non-completers) Days 92 Assumption
Inpatient length of stay
MDR-TB smear negativea Days 46 (12) Gamma Marc Lipman, audit data,
Royal Free Hospital 2014
MDR-TB smear positivea Days 89 (21) Gamma
DS TB smear negative Days 0 Assumption
DS TB smear positive Days 14 (2.8) Gamma Assumption
Outpatient consultations
Standard regimen: consultant # per
month
1 – Expert opinion
MDR regimen: consultant # per
month
1 – Expert opinion
MDR regimen: TB specialist nurse # per
month
1 – Expert opinion
a Average length of inpatient stay for MDR patients was estimated from data provided from an audit of patients with
MDR-TB and XDR-TB patients at the Royal Free Hospital, London, UK, 2014.
TABLE 34 Parameter estimates for QALY losses attributable to TB
Health state Units
Mean
(standard
error) PSA Source
Baseline utility
Age weighted mean without TB 0–1 0.880 – Health Survey for England122
Utility loss due to TB
Active TB pretreatment 0–1 0.051 (0.083) Beta Kruijshaar et al. (2010)116
Active TB on treatment, inpatient 0–1 0.210 (0.045) Beta Kruijshaar et al. (2010)116
Active TB on treatment, outpatient 0–1 0.067 (0.038) Beta Kruijshaar et al. (2010)116
QALY loss attributable to TB case fatality
Mean QALY loss per fatality QALYs 19.96 – Estimated by authors
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Parameter estimates used to estimate QALY loss attributable to MDR treatment are listed in Table 35.
Based on available data we were able to estimate the serious adverse event rate for MDR treatment only at
an average of 4 months on treatment, with 42% experiencing ototoxicity.118 On any pathway for which a
patient is on MDR treatment for < 4 months, the adverse event rate was adjusted pro rata, based on their
time on treatment. On pathways for which a patient is on treatment for > 4 months, it was assumed that
they would attract this maximum risk of adverse effects.
Following Veenstra et al.,120 we assumed that, of those patients who experienced a MDR treatment-related
hearing impairment, 50% would have a ‘mild’ impairment not requiring any treatment, 25% would have a
‘moderate’ impairment requiring a hearing aid and 25% would have a ‘severe’ impairment that would
be appropriate for cochlear implantation. Utility losses attributable to moderate and severe levels of
impairment were sourced from the literature. There is good evidence for the validity and responsiveness of
the Health Utilities Index Mark 3 (HUI3) as a measure of health-related quality of life in people with hearing
TABLE 35 Parameter estimates for QALY losses attributable to adverse effects of MDR treatment
Parameter Units
Mean
(standard
error) PSA Source
Incidence of hearing impairment and utility loss
% ototoxicity % 42 (4.2) Beta Törün et al. (2005)118
Mild hearing loss
% with mild hearing loss not requiring implant
or aid
% 50
Utility loss 0–1 0.05 Author estimate
Moderate hearing loss
% requiring hearing aid % 25 Veenstra et al. (2007)120
Utility loss with aid 0–1 0.166 (0.01) Beta Barton et al. (2004)131
Severe hearing loss
% requiring cochlear implant % 25 Veenstra et al. (2007)120
Utility loss with implant 0–1 0.18 (0.04) Beta UK Cochlear Implant Study
Group132
QALY loss attributable to adverse events of MDR treatment
Mean utility loss per patient experiencing
hearing loss
0–1 0.11
Average life expectancy Years 42
Discounted QALY loss per person treated with MDR
medications for 4 months
QALYs 1.03
Costs (£) attributable to adverse effects of MDR treatment
Lifetime cost of hearing aid (discounted) 477 Department of Health National
Tariff 127
Lifetime cost of implant (discounted) 8934 Bond et al. (2009)133
For adult (age 50 years) with
unilateral cochlear implant
Mean cost (£) per person treated with MDR medication
Lifetime cost (discounted) 983
Equivalent annual cost (discounted) 45
HEALTH-CARE COSTS AND UTILITIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
impairment.134 HUI3 utility estimates were obtained from a sample of 609 hearing-impaired adults assessed
at four UK audiology clinics between April 2000 and October 2002,131 and for 311 ‘postlingually deafened’
adults before and after they received a cochlear implant.132 To estimate the utility loss associated with
hearing impairment per se, we subtracted the reported HUI3 scores (with treatment) from a population
norm, based on a large general population sample (n= 4048) in the USA.135 We assumed a utility loss
owing to mild (untreated) hearing impairment of 0.05, in the absence of an empirical estimate. Lifetime
discounted QALY loss attributable to hearing loss was then estimated, based on a mean life expectancy for
individuals at TB diagnosis.
Lifetime discounted costs of treatment for treatment-related hearing loss were also estimated. Costs
for hearing aids included costs for assessment, purchase of devices, fitting, follow-up, replacement
(assumed once per 5 years), and maintenance (one repair per year). Audiology costs were taken from the
Department of Health National Tariff.127 Lifetime costs for patients receiving a cochlear implant were
based on an estimate for adults receiving a unilateral implant taken from a published Health Technology
Assessment report,133 and uprated for inflation.129 This estimate included the cost of the implant,
assessment, the procedure, treatment for complications, replacement and maintenance.
Summary of results
Mean estimates of the costs by pathway are shown in Table 36 for the culture-based diagnostic strategy
and in Table 37 with the addition of a rapid molecular test (at reference laboratories). It can be seen that,
with culture, the total estimated cost ranges from £2252 per patient for pathway 28_C (smear-negative
patient correctly identified as free from TB) to £130,214 for pathway 18_C (smear-positive patients with
MDR-TB not identified as high risk, and therefore not treated presumptively). The range is similarly wide
with molecular testing: from a minimum of £2334 for pathways 14_R and 28_R (correctly diagnosed
smear-negative patients without TB) to a maximum of £131,771 for 2_R (smear-positive patients with
MDR-TB, who are thought to be at high risk and who have an inaccurate molecular test result indicating
DS disease). It should be noted that the incidence of the very-high-cost pathways is likely to be low
(as both MDR-TB and misdiagnoses are rare). The expected cost for a patient with smear-positive DS
disease, deemed low risk of MDR-TB, correctly diagnosed by molecular test, and treated appropriately, is
£9392. The cost for a similar patient, correctly diagnosed and treated under the culture strategy is slightly
lower, at £8670.
Similarly, estimated mean QALY losses by pathway are shown in Tables 38 and 39 for the culture and
molecular testing strategies. These range from 0 (for patients without TB who are correctly diagnosed
and treated) to about 1.205 QALYs lost (for patients with smear-positive MDR-TB with delayed diagnosis and
who are not treated presumptively). A large proportion of the estimated QALY loss is attributable to adverse
events related to MDR treatment.
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TABLE 38 Mean QALY loss by pathway: culture only
ID
Active TB untreated Active TB inpatient Active TB outpatient Adverse events
Days
Utility
loss
QALY
loss Days
Utility
loss
QALY
loss Days
Utility
loss
QALY
loss
Utility
loss
QALY
loss
Total
QALY
loss
7_C 0 0.051 0.000 13 0.206 0.007 0 0.067 0.000 0.112 0.110 0.117
21_C 0 0.051 0.000 13 0.206 0.007 0 0.067 0.000 0.112 0.000 0.007
14_C 0 0.051 0.000 13 0.206 0.007 0 0.067 0.000 0.112 0.000 0.007
28_C 0 0.051 0.000 0 0.206 0.000 0 0.067 0.000 0.112 0.000 0.000
1_C 73 0.051 0.010 27 0.206 0.015 156 0.067 0.029 0.112 0.228 0.282
15_C 73 0.051 0.010 14 0.206 0.008 169 0.067 0.031 0.112 0.000 0.049
8_C 87 0.051 0.012 27 0.206 0.015 156 0.067 0.029 0.112 0.118 0.174
22_C 87 0.051 0.012 0 0.206 0.000 183 0.067 0.034 0.112 0.000 0.046
4_C 73 0.051 0.010 89 0.206 0.050 521 0.067 0.096 0.112 1.030 1.187
18_C 73 0.051 0.010 116 0.206 0.065 521 0.067 0.096 0.112 1.030 1.202
11_C 87 0.051 0.012 46 0.206 0.026 564 0.067 0.104 0.112 1.030 1.172
25_C 101 0.051 0.014 46 0.206 0.026 578 0.067 0.107 0.112 1.030 1.177
TABLE 39 Mean QALY loss by pathway: culture and molecular testing
ID
Active TB untreated Active TB inpatient Active TB outpatient Adverse events
Days
Utility
loss
QALY
loss Days
Utility
loss
QALY
loss Days
Utility
loss
QALY
loss
Utility
loss
QALY
loss
Total
QALY
loss
7_R 0 0.051 0.000 2 0.206 0.001 0 0.067 0.000 0.112 0.000 0.001
33_R 0 0.051 0.000 13 0.206 0.007 0 0.067 0.000 0.112 0.000 0.007
34_R 0 0.051 0.000 13 0.206 0.007 0 0.067 0.000 0.112 0.093 0.100
21_R 0 0.051 0.000 2 0.206 0.001 0 0.067 0.000 0.112 0.000 0.001
35_R 0 0.051 0.000 13 0.206 0.007 0 0.067 0.000 0.112 0.000 0.007
36_R 0 0.051 0.000 13 0.206 0.007 0 0.067 0.000 0.112 0.093 0.100
14_R 0 0.051 0.000 0 0.206 0.000 0 0.067 0.000 0.112 0.000 0.000
29_R 0 0.051 0.000 0 0.206 0.000 11 0.067 0.002 0.112 0.000 0.002
30_R 0 0.051 0.000 11 0.206 0.006 0 0.067 0.000 0.112 0.093 0.099
28_R 0 0.051 0.000 0 0.206 0.000 0 0.067 0.000 0.112 0.000 0.000
31_R 0 0.051 0.000 0 0.206 0.000 11 0.067 0.002 0.112 0.000 0.002
32_R 0 0.051 0.000 11 0.206 0.006 0 0.067 0.000 0.112 0.093 0.099
1_R 76 0.051 0.011 16 0.206 0.009 167 0.067 0.031 0.112 0.000 0.050
3_R 76 0.051 0.011 27 0.206 0.015 156 0.067 0.029 0.112 0.211 0.266
15_R 76 0.051 0.011 16 0.206 0.009 167 0.067 0.031 0.112 0.000 0.050
17_R 76 0.051 0.011 27 0.206 0.015 156 0.067 0.029 0.112 0.211 0.266
8_R 76 0.051 0.011 0 0.206 0.000 183 0.067 0.034 0.112 0.000 0.044
continued
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TABLE 39 Mean QALY loss by pathway: culture and molecular testing (continued )
ID
Active TB untreated Active TB inpatient Active TB outpatient Adverse events
Days
Utility
loss
QALY
loss Days
Utility
loss
QALY
loss Days
Utility
loss
QALY
loss
Utility
loss
QALY
loss
Total
QALY
loss
10_R 76 0.051 0.011 25 0.206 0.014 158 0.067 0.029 0.112 0.211 0.265
12_R 87 0.051 0.012 14 0.206 0.008 169 0.067 0.031 0.112 0.118 0.169
22_R 76 0.051 0.011 0 0.206 0.000 183 0.067 0.034 0.112 0.000 0.044
24_R 76 0.051 0.011 25 0.206 0.014 158 0.067 0.029 0.112 0.211 0.265
26_R 87 0.051 0.012 0 0.206 0.000 183 0.067 0.034 0.112 0.000 0.046
2_R 101 0.051 0.014 116 0.206 0.065 519 0.067 0.096 0.112 1.030 1.205
4_R 76 0.051 0.011 91 0.206 0.051 519 0.067 0.096 0.112 1.030 1.188
16_R 101 0.051 0.014 116 0.206 0.065 519 0.067 0.096 0.112 1.030 1.205
18_R 76 0.051 0.011 91 0.206 0.051 519 0.067 0.096 0.112 1.030 1.188
9_R 101 0.051 0.014 46 0.206 0.026 589 0.067 0.109 0.112 1.030 1.179
11_R 76 0.051 0.011 46 0.206 0.026 564 0.067 0.104 0.112 1.030 1.171
13_R 87 0.051 0.012 46 0.206 0.026 564 0.067 0.104 0.112 1.030 1.172
23_R 101 0.051 0.014 46 0.206 0.026 589 0.067 0.109 0.112 1.030 1.179
25_R 76 0.051 0.011 46 0.206 0.026 564 0.067 0.104 0.112 1.030 1.171
27_R 101 0.051 0.014 46 0.206 0.026 578 0.067 0.107 0.112 1.030 1.177
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Chapter 6 Dynamic transmission model
Overview
An integrated transmission-dynamic and economic model was used to evaluate the cost-effectiveness of
introducing rapid molecular testing for TB infection and DST in England and Wales, including accounting
for effects of faster diagnosis and treatment in averting transmission of infection. Three population groups
are considered: South Asians, Black Africans and Eastern Europeans. The first two groups represent a large
proportion (61%) of the TB cases in England and Wales and the available data allow us to estimate rates
of transmission in England and Wales, which allows us to estimate numbers of transmission events
expected to be averted by faster diagnosis and treatment of TB and MDR-TB. The Eastern European group
is of interest because of its high proportion of TB cases that are MDR (≈27%), which means that faster
DST results offered by molecular testing are potentially a key benefit. However, the available data do not
allow us to estimate rates of transmission from this group.
Population
The evaluation considers ethnic groups in England and Wales, that is Black African, South Asian and
Eastern European. Each ethnic group is modelled separately. Within each group, the model distinguishes
those who are UK born and those who were born overseas, with these subgroups assumed to
mix homogeneously.
We assume that UK-born and non-UK-born individuals from the same ethnic population mix homogeneously,
with equal chance of acquiring and passing on TB infection. We also assume that they can all potentially
benefit from the intervention and that within the population group there is equal access to services. The
model population is also assumed to remain constant in size over time in the current practice scenario. Rates
of population turnover (i.e. birth rate, immigration rate and death rate owing to non-TB causes) are assumed
to be constant over time. A reduction in TB deaths would result in an increase in population size. The rate of
patients presenting to care is assumed not to change over time. The rates of entry and exit for the different
ethnic populations were estimated from the Office for National Statistics (ONS) data on new arrivals into the
country and birth rates were calculated from the number of children between 0 and 4 years of age per
ethnic group. The data sources are cited in the parameter table (Table 40).
Transmission-dynamic model structure and assumptions
The model used is a compartmental (state transition) model of the type described by Anderson and May,136
which is a well-established modelling method that has been applied successfully to TB, as well as many
other infectious diseases. This approach divides the population up according to infection status (i.e. naive,
latent infection, active disease, on treatment, recovered, etc.), each contained in a separate compartment.
There are flows between compartments as individuals become infected, progress to disease, are diagnosed
and placed on treatment, etc. The rates of flow depend upon per-capita rates and the number of
individuals in the relevant compartment at the particular point in time. The compartmental structure is
based on that of Salomon et al.,137 which was built on the work of Vynnycky and Fine138 and Dye et al.,139
with the modification of inserting a preclinical disease stage between latent infection and active disease.
Radiological abnormalities often precede clinical signs and symptoms, so these individuals’ disease is
detectable by radiography but is not yet clinically detectable (or infectious). Individuals in the active disease
compartment are detectable – with variable sensitivity and specificity – by different diagnostic methods
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including radiography, sputum smear microscopy, molecular testing and laboratory-based culture
confirmation of TB infection and determination of drug susceptibility.
The compartmental model is used to describe the infection and treatment dynamics for both non-MDR
and MDR-TB strains. Those who acquire TB infection develop latent infection, which is either slow
progressing or fast progressing. Slow progressors are at risk of exogenous reinfection, which causes
fast-progressing latent infection. Progression from latent infection leads to preclinical disease (detectable
by radiography but without clinically detectable signs or symptoms), followed by active disease. Active
disease may be smear negative or smear positive, with the latter being much more infectious.
In the absence of molecular testing – the ‘current practice’ scenario – those with smear-positive active
disease, who access health care, are diagnosed rapidly (based on sputum smear microscopy) and rapidly
placed on non-MDR-TB treatment. Meanwhile, samples are sent for culture confirmation of TB and DST.
The result of the DST is used to correct the treatment regimen if MDR-TB is identified. Those with
smear-negative active disease, who access health care, wait for culture confirmation of TB before being
placed on treatment.
Molecular testing offers faster confirmation of TB infection and MDR status. We assume that molecular
testing is used in addition to culture confirmation and DST. In the molecular testing scenarios, case-finding
and treatment remain unchanged, and a rapid molecular test is used for TB confirmation and DST. This
reduces the delay between sample collection and obtaining TB confirmation and the DST result back, but
culture-based confirmation and DST are still performed as the gold standard. Three different molecular
tests are considered: (1) GeneXpert only, (2) GeneXpert combined with INNO-LiPA line-probe assay, and
(3) MTBDRplus, in two locations: either local to the hospital or in a regional laboratory. Locally based
testing is quicker and has a very marginally lower cost per test than regionally based testing. Reductions in
delays in TB diagnosis may reduce transmission of TB and/or reduce costs of precautionary isolation.
A proportion of those starting treatment are destined to complete treatment successfully and the remainder are
destined to fail treatment. In the model, those undergoing successful treatment are non-infectious and, upon
completion, they enter the recovered compartment and have reduced susceptibility to subsequent infection.
Those who are destined to fail treatment as a result of poor adherence to treatment return to the compartment
from which they commenced treatment after failure and resume infectiousness. MDR-TB-infected individuals
placed on non-MDR-TB treatment remain infectious throughout the duration of this treatment. Those with
untreated and treated active disease are subject to additional TB-associated mortality.
TABLE 40 Population characteristicsa
Ethnicity Region of birth Population size
Birth rate in England and
Wales) per year
Immigration
rate per year
South Asian (i.e. Indian,
Pakistani, Bangladeshi)
UK 1,469,558 0.038 p.a. –
Foreign 1,515,112 – 0.07 p.a.
Black African UK 323,276 0.067 p.a. –
Foreign 666,352 – 0.04–0.07 p.a.
Eastern European UK Not available Not available –
Foreign 1,114,368 – 0.11 p.a.
p.a., per annum.
a All parameters were derived from the ONS 2011 Census tables available on www.nomisweb.co.uk/census/2011. Data
were selected based on ethnicity (South Asian, Black African and Eastern European) and country of birth. Birth rate was
calculated from the number of 0- to 4-year-olds per ethnic group in 2011. The number of new arrivals in the UK linking
the country of origin to the ethnic group was used to estimate the immigration rate.
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Model flow diagrams
For clarity, mortality and entry into (and exit from) the population are omitted from the flow diagram
(Figure 17). Infectious compartments are shown in green. There are multiple compartments for people
who are on treatment, so that if treatment fails the person they can be returned to the compartment from
where they started treatment. People who will fail treatment are placed in separate compartments
from those who will complete treatment because the time to failure is usually quite short, whereas the
time to successful completion is much longer.
Data sources
Epidemiological parameter estimates and data sources are summarised in Tables 40 and 41. Where
UK-specific data were not available, parameter estimates from the literature were used. The ethnic group
population sizes, rates of birth and immigration were estimated from the ONS 2011 data.140 Baseline TB
incidence and proportion of MDR-TB cases were obtained from Enhanced Tuberculosis Surveillance (ETS)
data (2009–11).141 Economic parameters are reported in Chapter 5.
Transmission model parameter values
Analysis
All analysis of the model was done for all three ethnic groups considered in this report. Time and resource
constraints meant that not all possible sensitivity analyses could be performed.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was performed to evaluate the impact on cost-effectiveness of diagnostic
and treatment time delays, diagnosis costs and treatment costs, and associated QALYs. We ran the model
simulation with 10,000 parameter sets and report the resulting incremental costs and incremental QALYs.
Deterministic sensitivity analysis
Parameters relating to diagnostic test performance were subject to deterministic sensitivity analysis, in
which each parameter was varied individually across its range. Results are presented in tornado plots.
Results
Analyses are presented for South Asians, Black Africans and East Europeans, in this order.
South Asians
There is a marginal effect of introduction of molecular testing on annual numbers of diagnoses (Figure 18)
owing to a small reduction in transmission and an increase in FP results. In the INNO-LiPA and MTBDRplus
scenarios there are increases in diagnoses owing to the latter effect dominating, whereas in the GeneXpert
scenario the former dominates. Local molecular testing has a faster turnaround time than regional
molecular testing, so the annual number of diagnoses in the local testing configuration is slightly lower than
in the regional testing configuration. However, this effect is tiny, with < 1% fewer diagnoses annually.
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TABLE 41 Transmission model default parameter values and data sources
Parameter description Value Source/reference
TB natural history
Proportion of incident infections that are
slow progressing
0.86 Salomon et al. (2006)137
Per-capita rate of slow progression to
preclinical disease
1.13 × 10–4 p.a. Salomon et al. (2006)137
Per-capita rate of fast progression to
preclinical disease
0.995 p.a. Based on Salomon et al. (2006)137 (0.88 p.a.) but
adjusted for insertion of preclinical disease state
into natural history
Per-capita rate of progression from preclinical
disease to active disease
7.6 p.a. Abubakar et al. (2011)142
Proportion of new disease that is
smear positive
0.45 Salomon et al. (2006)137
Per-capita mortality rate of untreated
active disease
0.23 p.a. National Tuberculosis Institute [India]143
Per-capita rate of conversion from smear
negative to smear positive
0.015 p.a. Salomon et al. (2006)137
Per-capita rate of self-cure: natural reversion
from active disease to latent infection
0.21 p.a. National Tuberculosis Institute [India]143
Relative transmissibility of MDR-TB compared
with non-MDR-TB
Fitted –
Prevalence of TB among new migrants Fitted –
Proportion of MDR-TB among
TB-infected new migrants
Fitted –
Screening and treatment
Average duration from active TB to
seeking care
73 days Saldana et al. (2013)130
Proportion of those tested that have
laboratory-confirmed TB
0.05 Assumption
Proportion non-MDR-TB treated successfully 0.84 Health Protection Agency141
Proportion MDR-TB treated successfully 0.80 Health Protection Agency141
Mean duration of successful non-MDR
treatment
0.5 years
(6 months)
Recommended course of treatment for
non-MDR disease: NICE108
Mean duration of unsuccessful non-MDR
treatment
0.25 years
(3 months)
Assumption
Mean duration of successful MDR treatment 1.67 years
(20 months)
This study
Mean duration of unsuccessful
MDR treatment
0.83 years
(10 months)
This study
Per-capita mortality rate of unsuccessfully
treated disease
0.077 p.a. Salomon et al. (2006)137
Culture and DST turnaround time 28 days Assumption
Rapid molecular test turnaround time 3.5 days Assumption
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There is a significant incremental net benefit (INB) in the GeneXpert scenario, MTBDRplus scenario and
INNO-LiPA scenario (Table 42 and Figure 19). These molecular tests reduced net costs and increased
QALYs as more individuals were appropriately treated for TB. As the options are cost-saving, results are
presented as an INB rather than using incremental cost-effectiveness ratios (ICERs).
For all tests (GeneXpert scenario, MTBDRplus scenario and INNO-LiPA) the INB for local and regional
testing are very similar (see Table 42 and Figure 19). GeneXpert and MTBDRplus scenarios have similar
INBs, which are higher than the INNO-LiPA scenario. INNO-LiPA has a higher FP rate, leading to more
inappropriate treatment of patients, increasing costs and reducing QALYs. It also has the lowest sensitivity
for detection of smear-negative TB cases, leading to fewer TB diagnoses and treatment, further reducing
the number of QALYs gained. When comparing over a time horizon of 20 years rather than 10 years, the
INBs are greater but the overall picture is broadly similar, although MTBDRplus appears to be relatively
more cost-effective than the other two rapid assays (Figure 20 and Table 43).
TABLE 41 Transmission model default parameter values and data sources (continued )
Parameter description Value Source/reference
Transmission
Transmission parameter for smear-positives Fitted –
Relative infectivity of smear-negatives
(vs. smear-positives)
0.25 Abu-Raddad et al. (2009)144
Relative susceptibility of latent (slow) and
recovered individuals (vs. those susceptible)
0.35 Salomon et al. (2006);137 Abu-Raddad et al. (2009)144
Relative infectivity of unsuccessfully treated
(vs. untreated)
0.25 Salomon et al. (2006)137
p.a., per annum.
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FIGURE 18 Effects of introducing molecular testing on annual numbers of TB diagnoses in the South Asian
population. Annual numbers of TB diagnoses in South Asians following the introduction of different rapid
molecular tests. Three different molecular tests are considered (GeneXpert only, GeneXpert combined with
INNO-LiPA line-probe assay and MTBDRplus) in two locations: either local to the hospital or in a regional
laboratory. Note that the vertical axis does not start at zero and the magnitude of the changes is, in fact, small.
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FIGURE 19 Cost-effectiveness plane of different molecular testing interventions compared with current practice in
South Asians, over a 10-year time horizon. This figure shows the cost-effectiveness plane resulting from comparing
the effect of different rapid molecular tests for TB confirmation and DST with the current practice in South Asians.
Three different molecular tests are considered (GeneXpert only, GeneXpert combined with INNO-LiPA line-probe
assay and MTBDRplus) in two locations: either local to the hospital or in a regional laboratory. The solid diagonal
line indicates the threshold of £30,000 per QALY and the dashed line £20,000 per QALY.
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GeneXpert only
There is uncertainty in the GeneXpert scenario over the impact on both costs and, particularly, health, and
hence there is uncertainty in cost-effectiveness (Figures 21 and 22). However, in all realisations of the PSA
there is a net reduction in costs, and net increases in QALYs. When local and regional testing are
compared (Figure 23), there are increases in costs in all realisations of the PSA and increases in the QALYs
in most realisations when moving from local to regional testing.
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FIGURE 20 Cost-effectiveness plane of different molecular testing interventions compared with current practice in
South Asians, over a 20-year time horizon. This figure shows the cost-effectiveness plane resulting from comparing
the effect of different rapid molecular tests for TB confirmation and DST with the current practice in South Asians.
Three different molecular tests are considered (GeneXpert only, GeneXpert combined with INNO-LiPA line-probe
assay and MTBDRplus) in two locations: either local to the hospital or in a regional laboratory. The solid diagonal
line indicates the threshold of £30,000 per QALY and the dashed line £20,000 per QALY.
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FIGURE 21 Cost-effectiveness plane of PSA samples of local GeneXpert-based testing compared with current
practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from comparing
GeneXpert-based TB confirmation and DST in South Asians with current practice in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of GeneXpert-based TB confirmation and DST compared with current practice. Parameters were
varied in both current practice and the intervention scenario. The green line indicates the threshold of £30,000 per
QALY and the black dashed line £20,000 per QALY.
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Figure 24 shows that the most influential test performance characteristics that affect the cost-effectiveness
of the GeneXpert scenario compared with current practice are the sensitivity for detection of MDR
infection in those in whom TB is detected (as FN results lead to inappropriate treatment for DS infection),
and specificity for detection of MDR infection in those in whom TB is detected (as FP results lead to
inappropriate treatment for MDR infection, which incurs cost and harms health). Sensitivity and specificity
for detection of TB infection and time to obtain culture-based DST results are much less influential.
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FIGURE 22 Cost-effectiveness plane of PSA samples of regional GeneXpert-based testing compared with current
practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from comparing
GeneXpert-based TB confirmation and DST in South Asians with current practice in PSA. The stochastic parameters
included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of GeneXpert base TB confirmation and DST compared with current practice. Parameters were
varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000 per
QALY and the black dashed line £20,000 per QALY.
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FIGURE 23 Cost-effectiveness plane of PSA samples of regional vs. local GeneXpert-based testing compared with
current practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from
comparing regionally based GeneXpert-based TB confirmation and DST in South Asians with locally based
GeneXpert-based TB confirmation and DST in PSA. The stochastic parameters included in the samples were those
associated with TB diagnosis time delay, costs and QALYs on the cost-effectiveness of GeneXpert base TB
confirmation and DST compared with current practice. Parameters were varied in both current practice and the
intervention scenario. The green line indicates the threshold of £30,000 per QALY and the black dashed line
£20,000 per QALY. Note the very small magnitude of the differences.
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GeneXpert with INNO-LiPA test
In the INNO-LiPA scenario there is considerable uncertainty over the impact on both costs and health.
However, in all realisations of the PSA for both local and regional testing there is a reduction in costs, and
an increase in QALYs (Figure 25 and 26).
Figure 27 shows that the most influential test performance characteristics that affect the cost-effectiveness
of the GeneXpert with INNO-LiPA scenario compared with current practice are the sensitivity for detection
of MDR infection in those in whom TB is detected (as FN results lead to inappropriate treatment for
DS infection), and specificity for detection of MDR infection in those in whom TB is detected (as FP results
lead to inappropriate treatment for MDR infection, which incurs cost and harms health). Sensitivity and
specificity for detection of TB infection and time to obtain culture-based DST results are much less influential.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
Incremental net benefit (£M)
17.0 17.5 18.0 18.5 19.0 19.5 20.0 20.5 21.0 21.5 22.0
FIGURE 24 Tornado plot of the influence on INB in South Asians of GeneXpert-based testing compared with
current practice, over a 10-year time horizon. This figure shows the effects of varying different test performance
parameters on the INB of GeneXpert-based TB confirmation and DST in South Asians compared with current
practice, if a QALY is valued at £20,000. Individually, parameters are varied from their minimum (green bar) to
maximum (black bar) values.
DOI: 10.3310/hta19340 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 34
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Drobniewski et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
20
15
10
5
– 10
– 5
– 15
– 20
– 150 – 100 – 50 0
Total incremental QALYs
To
ta
l i
n
cr
em
en
ta
l c
o
st
 (
£M
)
50 100 150
0
FIGURE 25 Cost-effectiveness plane of PSA samples of local GeneXpert with INNO-LiPA-based testing compared
with current practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from
comparing GeneXpert with INNO-LiPA test-based TB confirmation and DST in South Asians with current practice in
PSA. The stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs
and QALYs on the cost-effectiveness of GeneXpert with INNO-LiPA test-based TB confirmation and DST compared
with current practice. Parameters were varied in both current practice and the intervention scenario. The green
line indicates the threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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FIGURE 26 Cost-effectiveness plane of PSA samples of regional GeneXpert with INNO-LiPA-based testing compared
with current practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from
comparing GeneXpert with INNO-LiPA test-based TB confirmation and DST in South Asians with current practice in
PSA. The stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs
and QALYs on the cost-effectiveness of GeneXpert with INNO-LiPA test-based TB confirmation and DST compared
with current practice. Parameters were varied in both current practice and the intervention scenario. The green
line indicates the threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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MTBDRplus test
In the MTBDRplus scenario (Figures 28 and 29), there is a wide range of uncertainty with regard to the
magnitude of the impact on health and costs, but in all realisations of the PSA there is a net reduction in
costs and increases in QALYs.
When local and regional testing are compared (Figure 30), there are modest increases in costs in almost all
of the realisations of the PSA, and modest increases in QALYs in most PSA samples, but with modest
decreases also occurring in some realisations.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
20
Incremental net benefit (£M)
14 15 16 17 18 19
FIGURE 27 Tornado plot of the influence on INB in South Asians of GeneXpert with INNO-LiPA-based testing
compared with current practice, over a 10-year time horizon. This figure shows the effects of varying different test
performance parameters on the INB of GeneXpert with INNO-LiPA-based TB confirmation and DST in South Asians
compared with current practice, if a QALY is valued at £20,000. Individually, parameters are varied from their
minimum (green bar) to maximum (black bar) values.
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FIGURE 28 Cost-effectiveness plane of PSA samples of local MTBDRplus-based testing compared with current
practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from comparing
MTBDRplus-based TB confirmation and DST in South Asians with current practice in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of MTBDRplus-based TB confirmation and DST compared with current practice. Parameters
were varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000
per QALY and the black dashed line £20,000 per QALY.
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FIGURE 29 Cost-effectiveness plane of PSA samples of regional MTBDRplus-based testing compared with current
practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from comparing
MTBDRplus-based TB confirmation and DST in South Asians with current practice in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of MTBDRplus-based TB confirmation and DST compared with current practice. Parameters were
varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000 per
QALY and the black dashed line £20,000 per QALY.
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Figure 31 shows that the most influential test performance characteristics that affect the cost-effectiveness
of the MTBDRplus scenario compared with current practice are the specificity for detection of TB infection
(as FP results lead to inappropriate treatment, which incurs cost and harms health), sensitivity for detection
of TB infection (as FN results delay treatment), and specificity and sensitivity for detection of MDR infection
in those infected with TB. Figure 18 shows how moving from current practice to the GeneXpert scenario
results in a reduction in annual TB diagnoses, whereas moving from current practice to the MTBDRplus
scenario results in an increase in diagnoses; the key difference is the specificity of the tests.
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FIGURE 30 Cost-effectiveness plane of PSA samples of regional vs. local MTBDRplus-based testing compared with
current practice over a 10-year time horizon in South Asians. This figure shows the ICER pairs resulting from
comparing regionally based MTBDRplus-based TB confirmation and DST in South Asians with locally based
MTBDRplus-based TB confirmation and DST in PSA. The stochastic parameters included in the samples were those
associated with TB diagnosis time delay, costs and QALYs on the cost-effectiveness of MTBDRplus-based TB
confirmation and DST compared with current practice. Parameters were varied in both current practice and the
intervention scenario. The green line indicates the threshold £30,000 per QALY and the black dashed line £20,000
per QALY. Note the very small magnitude of the differences.
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GeneXpert only compared with MTBDRplus test
Comparing the cost-effectiveness of regionally based testing in the GeneXpert and MTBDRplus scenarios
finds that there is considerable uncertainty with regard to both costs and health benefits (Figure 32). In all
realisations of the PSA there are reductions in costs, but in a large proportion of samples there are also
reductions in QALYs when moving from the MTBDRplus scenario to the GeneXpert scenario.
Black Africans
As with South Asians, there is a marginal effect of introduction of molecular testing on annual numbers of
diagnoses (Figure 33) owing to a small reduction in transmission and an increase in FP results. In the
INNO-LiPA and MTBDRplus scenarios there are increases in diagnoses as a result of the latter effect
dominating, whereas in the GeneXpert scenario the former dominates. Local molecular testing has a faster
turnaround time than regional molecular testing, so the annual number of diagnoses in the local testing
configuration is slightly lower than in the regional testing configuration. However, this effect is tiny, with
< 1% fewer diagnoses annually.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
2322
Incremental net benefit (£M)
16 17 18 19 20 21
FIGURE 31 Tornado plot of the influence on INB in South Asians of MTBDRplus-based testing compared with
current practice, over a 10-year time horizon. This figure shows the effects of varying different test performance
parameters on the INB of MTBDRplus-based TB confirmation and DST in South Asians compared with current
practice, if a QALY is valued at £20,000. Individually, parameters are varied from their minimum (green bar) to
maximum (black bar) values.
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There are significant INBs in the GeneXpert, MTBDRplus and INNO-LiPA scenarios (Table 44 and Figure 34).
These molecular tests reduce net costs and achieve an associated QALY gain as more individuals are
appropriately treated for TB. As the options are cost saving, results are presented as INB rather than
using ICERs.
For all tests (GeneXpert scenario, MTBDRplus scenario and INNO-LiPA) the INBs for local and regional
testing are very similar (see Table 44 and Figure 35). The GeneXpert scenario has the highest INB, with the
MTBDRplus and INNO-LiPA scenarios having INBs that are similar to each other.
When comparing over a time horizon of 20 years, rather than 10 years, the INBs are greater but the overall
picture is broadly similar (see Figure 35 and Table 45).
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FIGURE 32 Cost-effectiveness plane of PSA samples of regional GeneXpert vs. regional MTBDRplus molecular
testing compared with current practice over a 10-year time horizon in South Asians. This figure shows the ICER
pairs resulting from comparing regionally based GeneXpert-based TB confirmation and DST in South Asians with
regionally based MTBDRplus-based TB confirmation and DST-based TB confirmation and DST in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of GeneXpert-based TB confirmation and DST compared with current practice. Parameters were
varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000 per
QALY and the black dashed line £20,000 per QALY.
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FIGURE 33 Effects of introducing molecular testing on annual numbers of TB diagnoses in the Black African
population. Annual numbers of TB diagnoses in Black Africans following the introduction of different rapid
molecular tests. Three different molecular tests are considered (GeneXpert only, GeneXpert combined with
INNO-LiPA line-probe assay and MTBDRplus) in two locations: either local to the hospital or in a regional
laboratory. Note that the vertical axis does not start at zero and the magnitude of the changes is, in fact, small.
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TABLE 44 Analysis of the cost-effectiveness of molecular testing in Black Africans over a 10-year time horizona
Scenario
Total costs,
£M (95% CI)
Total QALYs
(95% CI)
Compared with baseline INB, £M (95% CI)
Incremental
cost, £M
(95% CI)
Incremental
QALYs
(95% CI) QALY= £20,000 QALY= £30,000
Current 24.5
(25.4 to 31.1)
7,502,098
(7,502,064 to
7,502,119)
– – – –
GeneXpert
local
11.4
(11.3 to 11.4)
7,502,255
(7,502,244.4 to
7,502,265.1)
–13.2
(–13.3 to –13.1)
179.4
(177.8 to 180.9)
16.8
(16.7 to 16.9)
18.6
(18.5 to 18.7)
GeneXpert
regional
11.5
(11.4 to 11.5)
7,502,228
(7,502,217.2 to
7,502,237.9)
–13.1
(–13.1 to –13.0)
152.2
(150.7 to 153.7)
16.1
(16.0 to 16.2)
17.6
(17.6 to 17.7)
MTBDRplus
local
11.9
(11.8 to 11.9)
7,502,118
(7,502,104.5 to
7,502,132.3)
–12.7
(–12.8 to –12.6)
43
(34.5 to 51.5)
13.6
(13.4 to 13.8)
14
(13.7 to 14.3)
MTBDRplus
regional
12
(12.0 to 12.1)
7,502,088
(7,502,074.4 to
7,502,102.4)
–12.6
(–12.6 to –12.5)
13.1
(4.5 to 21.8)
12.8
(12.6 to 13.0)
12.9
(12.7 to 13.2)
INNO-LiPA
local
12.7
(12.7 to 12.8)
7,502,143
(7,502,132.5 to
7,502,154.0)
–11.9
(–11.9 to –11.8)
67.9
(66.4 to 69.3)
13.2
(13.1 to 13.3)
13.9
(13.8 to 14.0)
INNO-LiPA
regional
12.8
(12.7 to 12.8)
7,502,117
(7,502,106.1 to
7,502,127.6)
–11.7
(–11.8 to –11.6)
41.9
(40.5 to 43.4)
12.5
(12.5 to 12.6)
13
(12.9 to 13.0)
a Under current practice, confirmatory testing for TB and DST is carried out using culture. Addition of molecular testing at
local or regional level is compared, over a time horizon of 10 years. Costs and QALYs are discounted at 3.5% per year.
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FIGURE 34 Cost-effectiveness plane of different molecular testing interventions compared with current practice in
Black Africans over a 10-year time horizon. This figure shows the cost-effectiveness plane resulting from comparing
the effect of different rapid molecular tests for TB confirmation and DST with the current practice in Black Africans.
Three different molecular tests are considered (GeneXpert only, GeneXpert combined with INNO-LiPA line-probe
assay and MTBDRplus) in two locations: either local to the hospital or in a regional laboratory. The solid diagonal
line indicates the threshold £30,000 per QALY and the dashed line £20,000 per QALY.
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TABLE 45 Analysis of the cost-effectiveness of molecular testing in Black Africans over a 20-year time horizona
Scenario
Total costs,
£M (95% CI)
Total QALYs
(95% CI)
Compared with baseline INB, £M (95% CI)
Incremental
cost, £M
(95% CI)
Incremental
QALYs
(95% CI) QALY= £20,000 QALY= £30,000
Current 41.8
(43.1 to 54.2)
12,820,477
(12,820,399 to
12,820,515)
– – – –
GeneXpert
local
19.2
(19.1 to 19.3)
12,820,912
(12,820,879.4 to
12,820,944.1)
–23
(–23.1 to –22.8)
504.4
(499.8 to 509.0)
33
(32.9 to 33.2)
38.1
(37.9 to 38.3)
GeneXpert
regional
19.4
(19.3 to 19.5)
12,820,826
(12,820,793.7 to
12,820,858.1)
–22.7
(–22.8 to –22.6)
418.6
(414.0 to 423.1)
31.1
(30.9 to 31.3)
35.3
(35.1 to 35.5)
MTBDRplus
local
20.1
(20.0 to 20.3)
12,820,482
(12,820,439.3 to
12,820,525.1)
–22
(–22.1 to –21.9)
74.8
(48.5 to 101.2)
23.5
(22.9 to 24.1)
24.2
(23.4 to 25.1)
MTBDRplus
regional
20.5
(20.3 to 20.6)
12,820,389
(12,820,346.0 to
12,820,432.3)
–21.7
(–21.8 to –21.6)
–17.8
(–44.6 to 9.0)
21.3
(20.8 to 21.9)
21.2
(20.3 to 22.0)
INNO-LiPA
local
21.5
(21.5 to 21.6)
12,820,600
(12,820,566.3 to
12,820,632.8)
–20.6
(–20.7 to –20.5)
192.2
(187.7 to 196.7)
24.4
(24.3 to 24.6)
26.4
(26.2 to 26.5)
INNO-LiPA
regional
21.7
(21.6 to 21.8)
12,820,513
(12,820,479.5 to
12,820,546.0)
–20.3
(–20.4 to –20.2)
109.7
(105.2 to 114.2)
22.5
(22.4 to 22.6)
23.6
(23.4 to 23.8)
a Under current practice, confirmatory testing for TB and DST is carried out using culture. Addition of molecular testing at
local or regional level is compared, over a time horizon of 20 years. Costs and QALYs are discounted at 3.5% per year.
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FIGURE 35 Cost-effectiveness plane of different molecular testing interventions compared with current practice in
Black Africans over a 20-year time horizon. This figure shows the cost-effectiveness plane resulting from comparing
the effect of different rapid molecular tests for TB confirmation and DST with the current practice in Black
Africans. Three different molecular tests are considered (GeneXpert only, GeneXpert combined with INNO-LiPA
line-probe assay and MTBDRplus) in two locations: either local to the hospital or in a regional laboratory. The solid
diagonal line indicates the threshold £30,000 per QALY and the dashed line £20,000 per QALY.
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GeneXpert only
As with the South Asian population, there is uncertainty in the GeneXpert scenario over the impact on
both costs and, particularly, health, and hence there is uncertainty in cost-effectiveness (Figures 36 and
37). However, in all realisations of the PSA there is a net reduction in costs, and net increases in QALYs.
When local and regional testing are compared (Figure 38), there are increases in costs and reductions in
QALYs in all realisations of the PSA, although the magnitudes are small particularly for costs.
Figure 39 shows that the most influential test performance characteristics that affect the cost-effectiveness
of the GeneXpert scenario compared with current practice are the same as for South Asians: sensitivity for
detection of MDR infection in those in whom TB is detected, and specificity of detection of MDR infection
in those in whom TB is detected.
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FIGURE 36 Cost-effectiveness plane of PSA samples of local GeneXpert-based testing compared with current
practice in Black Africans over a 10-year time horizon. This figure shows the ICER pairs resulting from comparing
GeneXpert-based TB confirmation and DST in Black Africans with current practice in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of GeneXpert base TB confirmation and DST compared with current practice. Parameters were
varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000 per
QALY and the black dashed line £20,000 per QALY.
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FIGURE 38 Cost-effectiveness plane of PSA samples of regional vs. local GeneXpert-based testing compared with
current practice over a 10-year time horizon in Black Africans. This figure shows the ICER pairs resulting from
comparing regionally based GeneXpert-based TB confirmation and DST in Black Africans with locally based
GeneXpert-based TB confirmation and DST in PSA. The stochastic parameters included in the samples were those
associated with TB diagnosis time delay, costs and QALYs on the cost-effectiveness of GeneXpert-based TB
confirmation and DST compared with current practice. Parameters were varied in both current practice and the
intervention scenario. The green line indicates the threshold £30,000 per QALY and the black dashed line £20,000
per QALY. Note the very small magnitude of the differences.
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FIGURE 37 Cost-effectiveness plane of PSA samples of regional GeneXpert-based testing compared with current
practice in Black Africans over a 10-year time horizon. This figure shows the ICER pairs resulting from comparing
GeneXpert-based TB confirmation and DST in Black Africans with current practice in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of GeneXpert-based TB confirmation and DST compared with current practice. Parameters were
varied in both current practice and the intervention scenario. The green dashed line indicates the threshold
£30,000 per QALY and the black dashed line £20,000 per QALY.
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GeneXpert with INNO-LiPA test
In the INNO-LiPA scenario there is considerable uncertainty over the impact on both costs and health.
However, in all realisations of the PSA for both local and regional testing there are reductions in costs, and
in the large majority of realisations there are increases in QALYs (Figures 40 and 41).
Figure 42 shows that the most influential test performance characteristics that affect the cost-effectiveness
of the GeneXpert scenario compared with current practice are the same as for South Asians: sensitivity
for detection of MDR infection in those in whom TB is detected, and specificity of detection of MDR
infection in those in whom TB is detected.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
17.517.0
Incremental net benefit (£M)
15.0 15.5 16.0 16.5
FIGURE 39 Tornado plot of the influence on INB in Black Africans of GeneXpert-based testing compared with
current practice, over a 10-year time horizon. This figure shows the effects of varying different test performance
parameters on the INB of GeneXpert-based TB confirmation and DST in Black Africans compared with current
practice, if a QALY is valued at £20,000. Individually, parameters are varied from their minimum (green bar) to
maximum (black bar) values.
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FIGURE 40 Cost-effectiveness plane of PSA samples of local GeneXpert with INNO-LiPA-based testing compared
with current practice in Black Africans over a 10-year time horizon. This figure shows the ICER pairs resulting from
comparing GeneXpert with INNO-LiPA test-based TB confirmation and DST in Black Africans with current practice
in PSA. The stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs
and QALYs on the cost-effectiveness of GeneXpert with INNO-LiPA test-based TB confirmation and DST compared
with current practice. Parameters were varied in both current practice and the intervention scenario. The green
line indicates the threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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FIGURE 41 Cost-effectiveness plane of PSA samples of regional GeneXpert with INNO-LiPA-based testing compared
with current practice in Black Africans over a 10-year time horizon. This figure shows the ICER pairs resulting from
comparing GeneXpert with INNO-LiPA test-based TB confirmation and DST in Black Africans with current practice
in PSA. The stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs
and QALYs on the cost-effectiveness of GeneXpert with INNO-LiPA test-based TB confirmation and DST compared
with current practice. Parameters were varied in both current practice and the intervention scenario. The green
line indicates the threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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MTBDRplus test
As with South Asians, in the MTBDRplus scenario (Figure 43 and 44), there is a wide range of uncertainty
with regard to the impact on health and costs. In all realisations of the PSA there is a net reduction in
costs, but the effect on health is uncertain, with the PSA realisations covering a large range of incremental
QALYs, both negative and positive.
When local and regional testing are compared (Figure 45), there are reductions in QALYs and increases in
costs in almost all of the realisations of the PSA when moving from local to regional testing.
Figure 46 shows that the most influential test performance characteristic that affects the cost-effectiveness
of the MTBDRplus scenario compared with current practice is the sensitivity for detection of TB infection in
smear-positive patients. Figure 33 shows how moving from current practice to the GeneXpert scenario
results in a reduction in annual TB diagnoses, whereas moving from current practice to the MTBDRplus
scenario results in an increase in diagnoses; the key difference is the specificity of the tests.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
14.513.5 14.0
Incremental net benefit (£M)
10.5 11.511.0 12.0 12.5 13.0
FIGURE 42 Tornado plot of the influence on INB in Black Africans of GeneXpert with INNO-LiPA-based testing
compared with current practice, over a 10-year time horizon. This figure shows the effects of varying different test
performance parameters on the INB of GeneXpert with INNO-LiPA-based TB confirmation and DST in Black
Africans compared with current practice, if a QALY is valued at £20,000. Individually, parameters are varied from
their minimum (green bar) to maximum (black bar) values.
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FIGURE 43 Cost-effectiveness plane of PSA samples of local MTBDRplus-based testing compared with current
practice in Black Africans over a 10-year time horizon. This figure shows the ICER pairs resulting from comparing
MTBDRplus-based TB confirmation and DST in Black Africans with current practice in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of MTBDRplus-based TB confirmation and DST compared with current practice. Parameters
were varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000
per QALY and the black dashed line £20,000 per QALY.
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FIGURE 44 Cost-effectiveness plane of PSA samples of regional MTBDRplus-based testing compared with current
practice in Black Africans over a 10-year time horizon. This figure shows the ICER pairs resulting from comparing
MTBDRplus-based TB confirmation and DST in Black Africans with current practice in PSA. The stochastic
parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs on the
cost-effectiveness of MTBDRplus-based TB confirmation and DST compared with current practice. Parameters
were varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000
per QALY and the black dashed line £20,000 per QALY.
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FIGURE 45 Cost-effectiveness plane of PSA samples of regional vs. local MTBDRplus-based testing compared with
current practice over a 10-year time horizon in Black Africans. This figure shows the ICER pairs resulting from
comparing regionally based MTBDRplus-based TB confirmation and DST in Black Africans with locally based
MTBDRplus-based TB confirmation and DST in PSA. The stochastic parameters included in the samples were those
associated with TB diagnosis time delay, costs and QALYs on the cost-effectiveness of MTBDRplus-based TB
confirmation and DST compared with current practice. Parameters were varied in both current practice and the
intervention scenario. The green line indicates the threshold £30,000 per QALY and the black dashed line £20,000
per QALY. Note the very small magnitude of the differences.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
2010 15
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FIGURE 46 Tornado plot of the influence on INB in Black Africans of molecular testing compared with current
practice, over a 10-year time horizon. This figure shows the effects of varying different test performance
parameters on the INB of MTBDRplus-based TB confirmation and DST in Black Africans compared with current
practice, if a QALY is valued at £20,000. Individually, parameters are varied from their minimum (green bar) to
maximum (black bar) values.
DYNAMIC TRANSMISSION MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
106
Eastern Europeans
As we do not have information allowing us to estimate transmission rates in the UK in this group, we
cannot account for an effect on transmission.
With a 10-year time horizon, there is a modest INB in the GeneXpert scenario, MTBDRplus scenario and
INNO-LiPA scenario of a similar magnitude (Table 46 and Figure 47). All three molecular tests may be
considered cost-effective according to usual criteria of valuing a QALY at £20,000 or £30,000.
TABLE 46 Analysis of the cost-effectiveness of molecular testing in Eastern Europeans over a 10-year time horizona
Scenario
Total costs, £M
(95% CI)
Total QALYs
(95% CI)
Compared with baseline INB, £M (95% CI)
Incremental cost,
£M (95% CI)
Incremental
QALYs (95% CI) QALY=£20,000 QALY=£30,000
Current 1.1928 (1.3 to 1.5) 8,447,788
(8,447,787 to
8,447,789)
– – – –
GeneXpert
local
0.4636
(0.4615 to 0.4656)
8,447,791.6
(8,447,791.3 to
8,447,791.9)
–0.7287
(–0.7318 to –0.7256)
3.8005
(3.7562 to 3.8449)
0.8047
(0.8015 to 0.808)
0.8427
(0.8394 to 0.8461)
GeneXpert
regional
0.4634
(0.4613 to 0.4654)
8,447,791
(8,447,790.6 to
8,447,791.2)
–0.7289
(–0.732 to –0.7258)
3.0969
(3.053 to 3.1407)
0.7909
(0.7876 to 0.7941)
0.8218
(0.8185 to 0.8252)
MTBDRplus
local
0.4583
(0.4561 to 0.4606)
8,447,789
(8,447,788.4 to
8,447,789.1)
–0.7339
(–0.7371 to –0.7307)
0.9526
(0.7683 to 1.1368)
0.753
(0.7485 to 0.7575)
0.7625
(0.7566 to 0.7685)
MTBDRplus
regional
0.459
(0.4568 to 0.4612)
8,447,788
(8,447,787.7 to
8,447,788.4)
–0.7333
(–0.7365 to –0.7301)
0.2067
(0.0207 to 0.3927)
0.7374
(0.7329 to 0.7419)
0.7395
(0.7335 to 0.7455)
INNO-LiPA
local
0.5061
(0.5038 to 0.5085)
8,447,788
(8,447,787.9 to
8,447,788.5)
–0.6861
(–0.6894 to –0.6829)
0.3936
(0.3483 to 0.4389)
0.694
(0.6905 to 0.6975)
0.6979
(0.6943 to 0.7016)
INNO-LiPA
regional
0.5046
(0.5023 to 0.5069)
8,447,788
(8,447,787.3 to
8,447,787.9)
–0.6877
(–0.691 to –0.6844)
–0.1908
(–0.2349 to –0.1467)
0.6839
(0.6805 to 0.6873)
0.682
(0.6784 to 0.6856)
a Under current practice, confirmatory testing for TB and DST is carried out using culture. Addition of molecular testing at
local or regional level is compared, over a time horizon of 10 years. Costs and QALYs are discounted at 3.5% per year.
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FIGURE 47 Cost-effectiveness plane of different molecular testing interventions compared with current practice in
Eastern Europeans over a 10-year time horizon. This figure shows the cost-effectiveness plane resulting from
comparing the effect of different rapid molecular tests for TB confirmation and DST with the current practice in
Eastern Europeans. Three different molecular tests are considered (GeneXpert only, GeneXpert combined with
INNO-LiPA line-probe assay and MTBDRplus) in two locations: either local to the hospital or in a regional
laboratory. The solid diagonal line indicates the threshold £30,000 per QALY and the dashed line £20,000
per QALY.
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The INBs for the GeneXpert, MTBDRplus and INNO-LiPA scenarios (see Table 46 and Figure 47) are, in all
cases, slightly greater in the local testing configuration than in the regional testing. The health benefit of
local testing is greater, as a result of earlier diagnoses and treatment initiation.
A similar pattern of results was found with a 20-year time horizon (Table 47 and Figure 48).
TABLE 47 Analysis of the cost-effectiveness of molecular testing in Eastern Europeans over a 20-year time horizona
Scenario
Total costs, £M
(95% CI)
Total QALYs
(95% CI)
Compared with baseline INB, £M (95% CI)
Incremental cost,
£M (95% CI)
Incremental
QALYs (95% CI) QALY=£20,000 QALY=£30,000
Current 2.0383
(2.1 to 2.6)
14,436,584
(14,436,582 to
14,436,586)
– – – –
GeneXpert
local
0.7922
(0.7886 to 0.7957)
14,436,592
(14,436,591.4 to
14,436,592.6)
–1.2454
(–1.2507 to –1.2401)
8.8709
(8.7592 to 8.9825)
1.4228
(1.417 to 1.4285)
1.5115
(1.5052 to 1.5178)
GeneXpert
regional
0.7919
(0.7883 to 0.7954)
14,436,590
(14,436,589.6 to
14,436,590.9)
–1.2457
(–1.251 to –1.2404)
7.1578
(7.0473 to 7.2683)
1.3889
(1.3831 to 1.3946)
1.4604
(1.4542 to 1.4667)
MTBDRplus
local
0.7833
(0.7795 to 0.7871)
14,436,585
(14,436,584.4 to
14,436,586)
–1.2543
(–1.2598 to –1.2488)
2.0361
(1.5819 to 2.4903)
1.295
(1.2852 to 1.3048)
1.3154
(1.3015 to 1.3292)
MTBDRplus
regional
0.7844
(0.7806 to 0.7882)
14,436,583
(14,436,582.5 to
14,436,584.1)
–1.2532
(–1.2586 to –1.2477)
0.213
(–0.2455 to 0.6715)
1.2574
(1.2475 to 1.2673)
1.2595
(1.2456 to 1.2735)
INNO–LiPA
local
0.865
(0.861 to 0.8689)
14,436,585
(14,436,584 to
14,436,585.4)
–1.1726
(–1.1782 to –1.167)
1.5698
(1.4584 to 1.6813)
1.204
(1.1979 to 1.2101)
1.2197
(1.2131 to 1.2263)
INNO–LiPA
regional
0.8623
(0.8584 to 0.8662)
14,436,583
(14,436,582.5 to
14,436,583.8)
–1.1753
(–1.1808 to –1.1697)
0.0678
(–0.0413 to 0.1769)
1.1766
(1.1706 to 1.1826)
1.1773
(1.1708 to 1.1838)
a Under current practice, confirmatory testing for TB and DST is carried out using culture. Addition of molecular testing at
local or regional level is compared, over a time horizon of 20 years. Costs and QALYs are discounted at 3.5% per year.
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FIGURE 48 Cost-effectiveness plane of different molecular testing interventions compared with current practice in
Eastern Europeans over a 20-year time horizon. This figure shows the cost-effectiveness plane resulting from
comparing the effect of different rapid molecular tests for TB confirmation and DST with the current practice in
Eastern Europeans. Three different molecular tests are considered (GeneXpert only, GeneXpert combined with
INNO-LiPA line-probe assay, and MTBDRplus) in two locations: either local to the hospital or in a regional
laboratory. The solid diagonal line indicates the threshold £30,000 per QALY and the dashed line £20,000
per QALY.
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GeneXpert only
There is uncertainty in the GeneXpert scenario over the impact on both costs and, particularly, health, and
hence there is uncertainty in cost-effectiveness (Figures 49 and 50). However, in all realisations of the PSA
there is a net reduction in costs, and net increases in QALYs.
Figure 51 shows that the most influential test performance characteristic that affects the cost-effectiveness
of the GeneXpert scenario compared with current practice is the specificity for detection of MDR infection
in those infected with TB. Time to DST (culture) result was also influential.
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FIGURE 49 Cost-effectiveness plane of PSA samples of local GeneXpert-based testing compared with current
practice in Eastern Europeans over a 10-year time horizon. This figure shows the ICER pairs resulting from
comparing GeneXpert-based TB confirmation and DST in Eastern Europeans with current practice in PSA. The
stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs
on the cost-effectiveness of GeneXpert-based TB confirmation and DST compared with current practice. Parameters
were varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000
per QALY and the black dashed line £20,000 per QALY.
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FIGURE 50 Cost-effectiveness plane of PSA samples of regional GeneXpert-based testing compared with current
practice in Eastern Europeans over a 10-year time horizon. This figure shows the ICER pairs resulting from
comparing GeneXpert-based TB confirmation and DST in Eastern Europeans with current practice in PSA. The
stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs and QALYs
on the cost-effectiveness of GeneXpert-based TB confirmation and DST compared with current practice. Parameters
were varied in both current practice and the intervention scenario. The green line indicates the threshold £30,000
per QALY and the black dashed line £20,000 per QALY.
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GeneXpert with INNO-LiPA test
In the INNO-LiPA scenario, although there is considerable uncertainty in both the impact on costs and
health, in all realisations of the PSA for both local and regional testing there is a reduction in costs.
However, there is a large variation in the effect on incremental QALYs, ranging from negative to positive
(Figures 52 and 53).
Figure 54 shows that the most influential test performance characteristic that affects the cost-effectiveness
of the GeneXpert with INNO-LiPA scenario compared with current practice is the specificity for detection of
MDR infection in those infected with TB.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
0.830.81 0.82
Incremental net benefit (£M)
0.76 0.78 0.790.77 0.80
FIGURE 51 Tornado plot of the influence on INB in Eastern Europeans of GeneXpert-based testing compared with
current practice, over a 10-year time horizon. This figure shows the effects of varying different test performance
parameters on the INB of GeneXpert-based TB confirmation and DST in Eastern Europeans compared with current
practice, if a QALY is valued at £20,000. Individually, parameters are varied from their minimum (green bar) to
maximum (black bar) values.
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FIGURE 52 Cost-effectiveness plane of PSA samples of local GeneXpert with INNO-LiPA-based testing compared
with current practice in Eastern Europeans over a 10-year time horizon. This figure shows the ICER pairs resulting
from comparing GeneXpert with INNO-LiPA test-based TB confirmation and DST in Eastern Europeans with current
practice in PSA. The stochastic parameters included in the samples were those associated with TB diagnosis time
delay, costs and QALYs on the cost-effectiveness of GeneXpert with INNO-LiPA test-based TB confirmation and DST
compared with current practice. Parameters were varied in both current practice and the intervention scenario.
The green line indicates the threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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FIGURE 53 Cost-effectiveness plane of PSA samples of regional GeneXpert with INNO-LiPA-based testing compared
with current practice in Eastern Europeans over a 10-year time horizon. This figure shows the ICER pairs resulting
from comparing GeneXpert with INNO-LiPA test-based TB confirmation and DST in Eastern Europeans with current
practice in PSA. The stochastic parameters included in the samples were those associated with TB diagnosis time
delay, costs and QALYs on the cost-effectiveness of GeneXpert with INNO-LiPA test-based TB confirmation and DST
compared with current practice. Parameters were varied in both current practice and the intervention scenario.
The green line indicates the threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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MTBDRplus test
In the MTBDRplus scenario (Figures 55 and 56), there is a wide range of uncertainty with regard to the
impact on health and, to some extent, on costs. In all realisations of the PSA there is a reduction in net
costs, but the effect on health is uncertain, with incremental QALYs ranging from negative to positive.
When local and regional testing (Figure 57) are compared, there are reductions in QALYs in 100% of
realisations of the PSA and increases in costs in the majority of realisations of the PSA when moving from
local to regional testing.
-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
0.740.720.700.66 0.68
Incremental net benefit (£M)
0.56 0.60 0.620.58 0.64
FIGURE 54 Tornado plot of the influence on INB in Eastern Europeans of GeneXpert with INNO-LiPA-based testing
compared with current practice, over a 10-year time horizon. This figure shows the effects of varying different test
performance parameters on the INB of GeneXpert with INNO-LiPA-based TB confirmation and DST in Eastern
Europeans compared with current practice, if a QALY is valued at £20,000. Individually, parameters are varied from
their minimum (green bar) to maximum (black bar) values.
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FIGURE 55 Cost-effectiveness plane of PSA samples of local MTBDRplus-based testing compared with current
practice in Eastern Europeans over a 10-year time horizon. This figure shows the ICER pairs resulting from
comparing MTBDRplus-based TB confirmation and DST in Eastern Europeans with current practice in PSA. The
stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs and
QALYs on the cost-effectiveness of MTBDRplus-based TB confirmation and DST compared with current practice.
Parameters were varied in both current practice and the intervention scenario. The green line indicates the
threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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FIGURE 56 Cost-effectiveness plane of PSA samples of regional MTBDRplus-based testing compared with current
practice in Eastern Europeans over a 10-year time horizon. This figure shows the ICER pairs resulting from
comparing MTBDRplus-based TB confirmation and DST in Eastern Europeans with current practice in PSA.
The stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs and
QALYs on the cost-effectiveness of MTBDRplus-based TB confirmation and DST compared with current practice.
Parameters were varied in both current practice and the intervention scenario. The green line indicates the
threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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Figure 58 shows that the most influential test performance characteristics that affect the cost-effectiveness
of the MTBDRplus scenario compared with current practice are the sensitivity for detection of smear-
positive TB infection and the specificity for detection of TB infection (as FP results lead to inappropriate
treatment, which incurs cost and harms health).
GeneXpert only compared with MTBDRplus test
Comparing the cost-effectiveness of regionally based testing in the GeneXpert and MTBDRplus scenarios
finds that there is considerable uncertainty with regard to health benefits (Figure 59) but little uncertainty
in costs, with the effect being very small.
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FIGURE 57 Cost-effectiveness plane of PSA samples of regional vs. local MTBDRplus-based testing compared with
current practice over a 10-year time horizon in Eastern Europeans. This figure shows the ICER pairs resulting from
comparing regionally based MTBDRplus-based TB confirmation and DST in Eastern Europeans with locally based
MTBDRplus-based TB confirmation and DST in PSA. The stochastic parameters included in the samples were those
associated with TB diagnosis time delay, costs and QALYs on the cost-effectiveness of MTBDRplus-based TB
confirmation and DST compared with current practice. Parameters were varied in both current practice and the
intervention scenario. The green line indicates the threshold £30,000 per QALY and the black dashed line £20,000
per QALY. Note the very small magnitude of the differences.
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-   Sensitivity for detection of MDR
-   Specificity for detection of MDR
-   Sensitivity for detection of MTB (smear negative)
-   Sensitivity for detection of MTB (smear positive)
-   Specificity for detection of MTB
-   Time to detect MTB (molecular test)
-   Time to perform DST (culture)
0.850.80.750.65 0.7
Incremental net benefit (£M)
0.4 0.5 0.550.45 0.6
FIGURE 58 Tornado plot of the influence on INB in Eastern Europeans of MTBDRplus-based testing compared with
current practice, over a 10-year time horizon. This figure shows the effects of varying different test performance
parameters on the INB of MTBDRplus-based TB confirmation and DST in Eastern Europeans compared with current
practice, if a QALY is valued at £20,000. Individually, parameters are varied from their minimum (green bar) to
maximum (black bar) values.
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Summary
The introduction of molecular testing was estimated to have only a very small impact on transmission,
because current practice is effective in limiting transmission from TB patients while they are undergoing
clinical examination.
There is likely to be a benefit to smear-negative patients, most of whom test positive by molecular
methods and therefore can be diagnosed and start treatment earlier than if they had to wait for
culture confirmation.
Molecular tests are likely to increase annual numbers of TB diagnoses as a result of faster TB diagnoses
and FP results, as a result of imperfect specificity. This results in inappropriate treatment of some patients,
which incurs a QALY loss as well as a financial cost.
The major benefit of molecular testing is faster diagnosis of MDR-TB, which produces cost savings when
patients with smear-positive suspected MDR-TB are kept in isolation until their MDR status is known and
then appropriate treatment commenced, this is because isolation has a high daily cost.
Overall, all molecular-testing scenarios considered were more cost-effective compared with current practice
at conventional threshold values per QALY for the UK (Table 48).
Based on our data and assumptions, the most cost-effective assay differed between the population
groups considered. In a South Asian population, MTBDRplus had the largest estimated INB based on the
conventional UK cost-effectiveness thresholds of £20,000 per QALY and £30,000 per QALY, and over both
10- and 20-year time horizons. At a time horizon of 10 years, GeneXpert had a similar INB to MTBDRplus,
whereas INNO-LiPA had a lower estimated INB. However, at a time horizon of 20 years, the estimated INB
for GeneXpert and INNO-LiPA were similar (and both lower than the estimated INB for MTBDRplus). In this
population there was a very high level of uncertainty over the relative cost-effectiveness of local scenarios
compared with regional test scenarios.
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FIGURE 59 Cost-effectiveness plane of PSA samples of regional GeneXpert vs. regional MTBDRplus molecular
testing compared with current practice over a 10-year time horizon in Eastern Europeans. This figure shows the
ICER pairs resulting from comparing regionally based GeneXpert-based TB confirmation and DST in Eastern
Europeans with regionally based MTBDRplus-based TB confirmation and DST-based TB confirmation and DST in
PSA. The stochastic parameters included in the samples were those associated with TB diagnosis time delay, costs
and QALYs on the cost-effectiveness of GeneXpert-based TB confirmation and DST compared with current practice.
Parameters were varied in both current practice and the intervention scenario. The green line indicates the
threshold £30,000 per QALY and the black dashed line £20,000 per QALY.
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In the Black African and Eastern European populations, GeneXpert was consistently the most cost-effective
rapid assay considered, with the greatest INB across 10- and 20-year time horizons, and at £20,000 and
£30,000 per QALY thresholds. Estimated INBs were similar for MTBDRplus and INNO-LiPA. In these
populations the local testing scenarios appeared more cost-effective than the regional scenarios but
absolute differences were small.
It should be emphasised that there is considerable uncertainty over the relative cost-effectiveness of the
alternative rapid assays and particularly over the comparison between regional and local testing scenarios.
This uncertainty has been quantified in the PSA results and tornado diagrams presented in this chapter.
However, there is additional uncertainty related to modelling assumptions and data that could not be
integrated in these sensitivity analyses.
TABLE 48 Summary of the INB (95% CI) for each assay, population and scenario, compared with current practice
Assay
South Asian Black African Eastern European
Local Regional Local Regional Local Regional
10-year time horizon
£20,000 per QALY
GeneXpert 20.3
(20.3 to 20.4)
20.2
(20.1 to 20.2)
16.8
(16.7 to 16.9)
16.1
(16.0 to 16.2)
0.8047
(0.8015 to 0.8080)
0.7909
(0.7876 to 0.7941)
MTBDRplus 20.5
(20.4 to 20.6)
20.3
(20.2 to 20.4)
13.6
(13.4 to 13.8)
12.8
(12.6 to 13.0)
0.753
(0.7485 to 0.7575)
0.7374
(0.7329 to 0.7419)
INNO-LiPA 17.5
(17.4 to 17.6)
17.4
(17.3 to 17.5)
13.2
(13.1 to 13.3)
12.5
(12.5 to 12.6)
0.694
(0.6905 to 0.6975)
0.6839
(0.6805 to 0.6873)
£30,000 per QALY
GeneXpert 21.8
(21.7 to 21.9)
21.7
(21.6 to 21.8)
18.6
(18.5 to 18.7)
17.6
(17.6 to 17.7)
0.8427
(0.8394 to 0.8461)
0.8218
(0.8185 to 0.8252)
MTBDRplus 22.6
(22.5 to 22.7)
22.3
(22.2 to 22.4)
14
(13.7 to 14.3)
12.9
(12.7 to 13.2)
0.7625
(0.7566 to 0.7685)
0.7395
(0.7335 to 0.7455)
INNO-LiPA 18.7
(18.6 to 18.7)
18.6
(18.5 to 18.7)
13.9
(13.8 to 14.0)
13
(12.9 to 13.0)
0.6979
(0.6943 to 0.7016)
0.682
(0.6784 to 0.6856)
20-year time horizon
£20,000 per QALY
GeneXpert 35.4
(35.3 to 35.6)
36.3
(36.2. 36.5)
33
(32.9 to 33.2)
31.1
(30.9 to 31.3)
1.4228
(1.4170 to 1.4285)
1.3889
(1.3831 to 1.3946)
MTBDRplus 44.2
(43.7 to 44.8)
45
(44.5 to 45.6)
23.5
(22.9 to 24.1)
21.3
(20.8 to 21.9)
1.295
(1.2852 to 1.3048)
1.2574
(1.2475 to 1.2673)
INNO-LiPA 34.5
(34.3 to 34.6)
35.5
(35.3 to 35.7)
24.4
(24.3 to 24.6)
22.5
(22.4 to 22.6)
1.204
(1.1979 to 1.2101)
1.1766
(1.1706 to 1.1826)
£30,000 per QALY
GeneXpert 38.3
(38.1 to 38.4)
39.8
(39.7 to 40.0)
38.1
(37.9 to 38.3)
35.3
(35.1 to 35.5)
1.5115
(1.5052 to 1.5178)
1.4604
(1.4542 to 1.4667)
MTBDRplus 52.3
(51.5 to 53.2)
53.8
(53.0 to 54.6)
24.2
(23.4 to 25.1)
21.2
(20.3 to 22.0)
1.3154
(1.3015 to 1.3292)
1.2595
(1.2456 to 1.2735)
INNO-LiPA 38.8
(38.6 to 38.9)
40.5
(40.4 to 40.7)
26.4
(26.2 to 26.5)
23.6
(23.4 to 23.8)
1.2197
(1.2131 to 1.2263)
1.1773
(1.708 to 1.1838)
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Chapter 7 Discussion
The increasing prevalence of drug-resistance threatens TB control programmes worldwide. Conventionalculture-based DST is a slow process, which can take several weeks to be completed; however, it
remains the ‘gold standard’ for MTB diagnosis. Rapid diagnosis of drug resistance (or its exclusion),
allowing early implementation of an appropriate treatment regimen, both decreases patient morbidity
and, by rendering the individual non-infectious, reduces disease transmission. Such tests are useful in
determining the type and degree of isolation needed, which can be a significant part of the overall
treatment costs. Similarly, the length of treatment for drug-susceptible TB (6 months) compared with the
almost 2 years needed for MDR-TB therapy requires accurate and reliable tests. The impact of diagnostic
delay on patient care can be severe (see Appendix 8). Molecular tests for the diagnosis of drug resistance,
particularly rifampicin and isoniazid, are widely available and have moved from the status of in-house tests
to commercial products; however, the health-economic impact of their adoption into the diagnostic
pathway has remained incompletely explored.
In this study, we addressed key questions regarding the performance [specificity, sensitivity, positive
predictive value (PPV), negative predictive value (NPV)] of the main commercial systems available and
endorsed globally. We assessed the likely clinical impact and cost-effectiveness of different assays
identifying genetic markers associated with MDR- and XDR-TB in patients with TB across the UK. First, this
entailed a systematic review of the literature to establish the diagnostic accuracy parameters of the most
popular molecular tests compared with conventional culture-based DST. Second, a decision-analytic
health-economic model of various screening strategies and transmission-dynamic model was developed to
determine the implications of secondary transmission. The study focused on the two main commercial
LPAs for detection of MDR-TB, INNO-LiPA and MTBDRplus, and the automated real-time PCR-based
assay, GeneXpert.
Systematic review
Principal findings
The findings of this review suggest that all three commercial tests, INNO-LiPA, GeneXpert and MTBDRplus,
demonstrate promising levels of diagnostic discrimination when compared with standard culture-based
methods. The findings of the current study are consistent with previous estimates that have indicated that
these rapid diagnostic tests can demonstrate high levels of sensitivity and specificity when detecting
rifampicin and isoniazid susceptibility in clinical samples.27,47,145
It is reassuring that despite different selection criteria and the exclusion of studies using cultured samples,
the pooled estimates of sensitivity (83.4%, 95% CI 66.3% to 100.0%) and specificity (99.6%, 95% CI
99.0% to 100.0%) for detecting isoniazid resistance by MTBDRplus are similar to those of Ling et al.,27
who estimated a sensitivity of 84.3% (95% CI 75.5% to 89.9%) and specificity of 99.5% (95% CI 97.5%
to 99.9%).
This is also apparent when comparing the pooled specificity for detecting rifampicin resistance. The current
study estimated a pooled specificity of 98.2% (95% CI 97.2% to 99.3%) similar to the pooled estimates
of both Ling et al.27 (99.5%, 95% CI 97.5% to 99.9%) and Arentz et al.145 (98.0%, 95% CI 95.1% to
99.2%). However, the sensitivity of MTBDRplus was slightly lower than reported by Ling et al.27 and Arentz
et al.,145 at 94.6% (95% CI 91.6% to 97.6%) as opposed to 98.1% (95% CI 95.9% to 99.1%) and
95.9% (95% CI 94.5% to 97.0%), respectively. These previous reviews did not include studies published
after January 2012, analysed fewer studies overall in their meta-analyses, and included tests performed on
cultured samples, which may account for this disparity.
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The pooled estimates of sensitivity for INNO-LiPA (95.4%, 95% CI 92.2% to 98.3%) and specificity
(99.7%, 95% CI 99.5% to 100.0%) suggested good levels of diagnostic accuracy when used to detect
rifampicin resistance in clinical samples. These results were similar to those reported by Arentz et al.,145
who reported pooled estimates from four studies of 94.1% (95% CI 86.5% to 97.6%) for sensitivity and
98.8% (95% CI 93.8% to 99.8%) for specificity.
Equally, the pooled estimates of sensitivity (96.8%, 95% CI 94.2% to 99.4%) and specificity (98.4%,
95% CI 97.8% to 99.0%) for the detection of rifampicin resistance by GeneXpert are also similar to those
published by a previous review,45 where the pooled sensitivity was estimated at 94% (95% CI 87% to
97%) and the specificity 98% (95% CI 97% to 99%).
The quality of each study deemed eligible, either through bias or concerns regarding applicability, was
assessed using the QUADAS-2.146 In the ‘Flow and timing’ domain, used to assess possible biases
introduced by the use of patient samples, there was often a marked lack of clarity surrounding the timing
and thresholds of the index test and reference test, and the exclusion of samples from the assay. When
compared with the studies included in the INNO-LiPA and GeneXpert analysis, there appeared to be a
marked reduction in the quality of methodological reporting with studies using MTBDRplus. The lack of
detail regarding timing, thresholds, patient selection and blinding resulted in the majority of studies
classified as either high bias or unclear bias in the four key QUADAS domains. This is particularly marked in
the ‘Flow and timing’ domain, in which all studies performed poorly.
Strengths and weaknesses
Although a certain amount of heterogeneity may be present in any meta-analyses,47,102,146 the level of
heterogeneity observed in each commercial test category suggests that the predicted and pooled estimates
of diagnostic accuracy should be interpreted with caution. A key limitation of this work is the absence of
subcategory analyses to explore potential sources of heterogeneity between the studies. This heterogeneity
may be statistical heterogeneity (e.g. caused by methodological differences) or clinical heterogeneity
(e.g. differences in the HIV status of the study population recruited by studies).102,146 There was often insufficient
methodological and recruitment detail reported in the papers to record these differences systematically, as
demonstrated by the small number of studies that reported details on study blinding and study design.
In addition to this, the small sample sizes used to evaluate diagnostic drug susceptibility tests have resulted
in the exclusion of studies that would otherwise supplement the data set and allow subcategory analysis to
be performed. The minimum number of samples criteria specified in the protocol resulted in a discrepancy
between the number of studies included in this review and those published in other published systematic
reviews evaluating GeneXpert and MTBDRplus.27,45 In this review some large cross-sectional studies were
excluded due to sample size alone, as a direct consequence of the low incidence of MDR-TB in the area in
which the study was conducted. In these studies a large number of samples may be initially screened but
the number of MDR cases are so few that there are insufficient samples to calculate sensitivity and
specificity of a rapid test confidently compared with a culture-based method. It can be argued that there is
value in excluding studies of diagnostic accuracy which use a small number of samples if these studies are
considered on an individual basis. Small sample sizes may be an indicator of study quality and can lead to
imprecise estimates of diagnostic accuracy with large CIs.103 This may be particularly relevant when the
study in question is not blinded, a small subset of unrepresentative samples may be preferentially selected,
and, subsequently, adds bias to estimates of diagnostic accuracy. Yet by excluding these studies we are
conversely prevented from investigating heterogeneity owing to variation in study quality by subcategory
analysis, and thus the sample size restriction included in the protocol may be considered a limitation.
One of the key strengths of this work was the broad set of inclusion criteria used to systematically select
the relevant studies. All of the diagnostic studies that compared a molecular test with a gold standard test
were considered in this review. No restrictions on study setting were applied and studies from all countries
and in all languages were eligible for inclusion. By adopting a protocol that specified that all languages
were included, this review avoided potential bias that could lead to potentially misleading estimates of
diagnostic accuracy.104
DISCUSSION
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Future work and research recommendations
In future it would be valuable to investigate to what extent freezing and decontaminating samples affects
the apparent specificity and sensitivity of these rapid diagnostic methods. It has been noted that, although
DNA may survive both freezing and decontamination, the organism may not be cultured successfully.147
In diagnostic accuracy studies this could lead to apparent FPs when using a rapid diagnostic test.
Retrospective studies, where stored samples were used, may conceivably find different assessments of
diagnostic accuracy than those studies that used fresh samples.
This review supports the findings of Bachmann et al.,103 who demonstrated a disturbing lack of formal
sample size calculations in published literature of diagnostic accuracy studies. The studies included in this
review did not publish or refer to formal sample size estimates to calculate adequately the diagnostic
accuracy for any of the rapid diagnostic tests evaluated. As discussed previously, small sample sizes may
lead to imprecise estimations of diagnostic accuracy and it is imperative that future planned evaluations of
rapid diagnostic tests are encouraged to calculate adequate sample sizes for their study.
Time-and-motion analysis of drug susceptibility testing
In the UK and other developed countries, the salary costs for personnel conducting the assay constitute a
significant portion of the overall assay cost. Typically, the only available estimates of working time come
from the kit manufacturers themselves and are probably representative of only the quickest possible
scenarios. In order to determine the ‘hands-on’ time for each of the molecular tests compared with culture
tests accurately, we conducted a time-and-motion study at the NMRL, where all of these tests are
used routinely.
Samples were usually processed in batches, with the number in each batch dependent on day-to-day
variation. The theoretical time taken to process a single specimen was calculated. However, it was noted
that the time taken per batch did not have a linear relationship to the number of samples processed.
Thus, the working times determined at the NMRL may be substantially different from those at other
laboratories with different levels of specimen throughput.
The calculated time taken to conduct each assay for a single respiratory specimen was remarkably similar
for all tests, ranging from 41 to 50 minutes. However, in addition to the batch size dependency, it is
also notable that the susceptibility information obtained from each test was not the same, ranging from
one drug (GeneXpert and INNO-LiPA) to 10 drugs (BACTEC MGIT 960 DSTs).
Health-economic modelling of screening strategies
Principal findings
As rapid molecular tests are less accurate than culture, current ECDC guidance recommends that, although
they may have a role alongside culture, they should not replace culture.109 This means that the cost of the
molecular test cannot be offset by savings from reduced need for culture, and there is a trade-off between
the increased costs and negative health impacts. Tests cannot be evaluated in isolation but have to be
considered within a pathway of care, specifying how patients are treated while waiting for test results,
what treatments they are offered when the results arrive, how and when diagnostic errors (FPs and FNs)
are detected and then what corrective action is taken.
Forty-four unique care pathways were defined: 12 in which culture only was utilised and 32 including the
rapid molecular assay. The care pathways differed by true clinical status, smear status and MDR risk status.
Costs were determined for each of these pathways, with all elements priced from a NHS perspective. It was
found that, with culture, the total estimated cost ranged from £2252 per patient (smear-negative patient
correctly identified as free from TB) to £130,214 (smear-positive patients with MDR-TB not identified as
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high risk, and therefore not treated presumptively). The range was similarly wide with molecular testing:
from a minimum of £2334 (correctly diagnosed smear-negative patients without TB) to a maximum of
£131,771 (smear-positive patients with MDR-TB thought to be at high risk and with an inaccurate
molecular test result indicating DS disease). It should be noted that the incidence of the very-high-cost
pathways is likely to be low (as both MDR-TB and misdiagnoses are rare). The expected cost for a patient
with smear-positive DS disease, deemed to be at low risk of MDR-TB, correctly diagnosed by molecular test
and treated appropriately is £9392. The cost for a similar patient, correctly diagnosed and treated under the
culture strategy is slightly lower, at £8670. Estimated mean QALY losses ranged from 0 (for patients without
TB who are correctly diagnosed and treated) to about 1.205 QALYs lost (for patients with smear-positive
MDR-TB with delayed diagnosis and who are not treated presumptively). A large proportion of the
estimated QALY loss was attributable to adverse events related to MDR treatment.
For infectious diseases, the calculated value of a diagnostic test should also account for impacts related to
transmission, including QALY loss and costs for secondary cases. A transmission-dynamic model was
integrated with the economic model to evaluate the cost-effectiveness of introducing rapid molecular
testing for TB infection in averting transmission of infection. Three population groups were considered:
South Asians and Black Africans who constitute a large proportion (61%) of the TB cases in England and
Wales, and Eastern Europeans who have a high proportion of TB cases that are MDR (≈27%).
The introduction of molecular testing had only a very small impact on transmission, because current
practice is effective in limiting transmission from TB patients while they are undergoing clinical
examination. There is a benefit to smear-negative patients, most of whom test positive by molecular
methods and therefore can be diagnosed and start treatment earlier than if they have to wait for culture
confirmation. However, the major benefit of molecular testing is in faster diagnosis of MDR-TB, which
produces cost savings when patients with smear-positive suspected MDR-TB are kept in isolation until their
MDR status is known and then appropriate treatment commenced, this is because isolation has a high
daily cost. Molecular tests were estimated to increase the annual numbers of TB diagnoses resulting from
FP results, caused by imperfect specificity. This resulted in inappropriate treatment of some patients, which
incurred a QALY loss as well as a financial cost.
The results of the transmission modelling suggest that all assays are cost saving and achieve an increase in
QALYs compared with current practice. Across the Black African and Eastern European populations, the
GeneXpert scenario was the most cost-effective of the rapid assays considered, at both 10- and 20-year
time horizons, and £20,000 or £30,000 willingness-to-pay threshold per QALY. For the South Asian
population, using a 10-year time horizon, the MDRTBplus scenario was the most cost-effective assay,
with the highest estimated INB compared with current practice, although the difference with GeneXpert
was very small. At a 20-year time horizon, for the same population the MTBDRplus scenario was the
most cost-effective; GeneXpert and INNO-LiPA achieved a similar INB in this case.
In light of the rapid development of technology, decision-makers may prefer to give more weight to the
10-year time horizon than the 20-year time horizon, even though the potentially long duration of TB
infection means that the impact of the interventions is long term. There is considerable uncertainty around
these results, particularly regarding the relative cost-effectiveness of the different assays, and of regional
compared with local testing, given the uncertainty over input parameters and the underlying assumptions.
Limitations
The results of the economic evaluation and transmission modelling are subject to uncertainty relating to
parameter estimates and also as a result of various simplifying assumptions. We have attempted to reflect
parametric uncertainty through the PSA. However, the PSA does not capture uncertainty associated with
structural assumptions. For example, a key assumption throughout this report has been that culture-based
diagnosis of MTB and DST is perfectly accurate and provides the reference standard for evaluation of the
rapid molecular tests. Another important simplification required for the economic evaluation and dynamic
transmission modelling was that we did not distinguish between different patterns of drug resistance.
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This entails the assumption that the rapid tests evaluated would be similarly accurate at detecting MDR-TB,
and that the cost and QALY implications of alternative patterns of resistance would be similar.
To cost the various care pathways, we also had to make a series of assumptions about clinical
decision-making. An important driver for decisions about presumptive treatment, admission and isolation is
the clinician’s prior suspicion about the likelihood that an individual has drug-resistant TB. In the absence
of clear normative criteria about which patients should be treated presumptively, or empirical evidence
about how clinicians make these judgements, we assumed that a fixed proportion of patients would be
identified as being at ‘high risk’ for MDR-TB. For our analysis we assumed that this proportion would equal
the true proportion of MDR cases out of all TB cases in the population of interest – assuming that clinicians
are ‘well calibrated’ in their judgements. For the economic evaluation, we also assumed that culture-based
diagnosis and DST would always be conducted alongside rapid molecular tests, and that clinicians would
treat the culture results as definitive. This is important for assumptions about when and how clinicians
‘step-down’ presumptive treatment. Thus, we assumed that any patients with negative culture results
would then be treated as TNs, and that any treatment or public health action would be halted. In practice,
clinicians do sometimes continue treatment in such situations if they have a high index of suspicion.
Clinical practice is also likely to vary geographically, in response to local practice and practicalities. The high
estimated costs for patients with (or suspected of having) MDR-TB were largely driven by long inpatient
stays and expensive negative pressure isolation. These estimates were based on local audit data and might
not reflect practice around the country. Another assumption required for the economic evaluation was
that patients who fail to complete a course of treatment would, on average, default half way through
the course.
A series of assumptions was also required to estimate the QALY loss associated with adverse effects of
MDR-TB treatment, the frequency of hearing loss, and the duration and utility loss associated with that
loss. The transmission model introduced some further structural assumptions, which add further to
uncertainty. For example, the model assumed homogeneous mixing of UK- and overseas-born people with
the ethnic subgroups. Rates of population turnover were also assumed to be constant over time.
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Chapter 8 Conclusions
Rapid molecular tests, such as the manual LPAs and automated GeneXpert, are able to identifyrifampicin resistance (and isoniazid resistance for some LPAs) with promising levels of specificity and
are almost as sensitive as microbiological culture but produce results more quickly (in 1 day from the
taking of a patient sample). The PPV for resistance is dependent on the prevalence of drug resistance,
which is low in the UK; a proportion of rifampicin resistance results will be FPs if used in a general screen,
as the PPV will be > 90% only when the underlying prevalence is > 15%. The corresponding NPV of
course will be high. This occurs within populations in some countries and in some migrant groups to the
UK from those countries, for example the Baltic States, Russia and Ukraine, where MDR-TB prevalence is
generally much higher and from which active migration occurs. Other populations in countries may
similarly have a high prevalence of MDR-TB, for example China and South Africa. This low PPV associated
with low prevalence is linked to the current WHO advice to perform a confirmatory test (e.g. other
molecular or culture based).
l The results of the transmission modelling suggest that all assays are cost saving and achieved an
increase in QALYs compared with current practice. For the Black African and Eastern European
populations, GeneXpert was likely to be the most cost-effective approach compared with current
practice. For the South Asian population, the MTBDRplus assay was most favourable achieving the
highest INB compared with current practice. ‘Real-life’ and ‘real clinical use’ evaluation studies, both
retrospective and prospective studies within the UK, and comparable environments are needed to
determine if the trial performance of these tests is maintained in real NHS use.
l This is a rapidly moving field and should be reflected in the updating of professional
(including NICE) guidelines.
l Further research should investigate whether or not the likely benefits of use in populations with a high
MDR-TB does translate into improved outcome, lower personal and NHS costs.
l Further analysis of transmission patterns is required to enable models to be produced which more
accurately reflect those patterns; this is necessary to improve the estimates of numbers of infections
averted by interventions.
l The real-world value/necessity of a ‘two-assay’ approach to specimens showing rifampicin resistance
initially (i.e. FP issue) should be assessed.
l The diagnostic value and cost-effectiveness of whole genomic sequencing for drug resistance should be
evaluated as the technology develops for analysis of patient specimens.
The performance of these tests is less clear-cut for non-pulmonary material and other ‘low-bacillary’
specimens, for example from children and from HIV-positive patients. There were few studies available
for analysis.
l Further studies of the performance of these tests are needed for non-pulmonary specimens, and in
children, and, to some extent, in HIV-positive populations.
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Underlying data for costings, patient stays and cost-effectiveness determinations were often difficult to
find, not available or relied on published work/literature that was published a long time ago. Costings for
service provision outside a health environment or the movement of specimens and analysis from outside a
health environment into the NHS was difficult to obtain and relied heavily on expert estimates. This
analysis produced detailed independent diagnostic assay costs for the first time and actual bed-stay
durations in pilot sites.
l There is a need to improve costings for bed-stays and treatment routes, which should include detailed
and wide-ranging assessment of bed-stays in different institutions and regions.
l There is a need to create pilots that can provide detailed information for real test performance and
associated cost–benefits when rapid tests are delivered as a near ‘POC’ test within and outside a
traditional hospital environment (e.g. in a clinic within a hospital, a mobile unit, a prison, a homeless
shelter, migrant accommodation, etc.).
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Appendix 1 Example of search strategy
Number Search terms
#7 Search #5 OR #6
#8 Search #5 OR #6 Filters: Publication date from 2000/01/01 to 2011/05/15
#6 Search #2 AND #4
#5 Search #2 AND #3
#4 Search INNO-LiPA[tw] OR INNOLiPA[tw] OR ‘Hain LifeScience’[tw] OR MTBDR*[tw] OR Cepheid[tw] OR
‘Gene Xpert’[tw]
#3 Search molecular[tw] OR gyr*[tw] OR genotyp*[tw] OR mutation*[tw] OR hybrid*[tw] OR array*[tw] OR
microarray*[tw] OR macroarray*[tw] OR probe*[tw] OR chip*[tw] OR biprobe*[tw] OR microchip*[tw] OR lipa
[tw] OR ‘molecular beacon’[tw] OR ‘real-time PCR’[tw]
#2 Search (tuberculosis[MESH] OR tuberculosis[tw] OR Mtb OR Mycobacterium tuberculosis OR M. tuberculosis)
AND (rifamp*[tw] OR isoniazid[tw] OR fluoroquinolone*[tw] OR levofloxacin[tw] OR ofloxacin[tw] OR
moxifloxacin[tw]) AND (resistan*[tw] OR susceptib*[tw] OR test*[tw] OR assay*[tw] OR method*[tw])
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Study
Microscopy Index test details
Microscopy?
Type of
microscopy
Number of
samples per
participant
tested
Type of
smear
Test
category
Rapid test
type (other)
Ajbani (2012)76 No
microscopy
Yes,
Ziehl–Neelsen
One specimen
per patient
Concentrated
(processed)
MTBDRsl MTBDRsl
Albert (2010)73 No
microscopy
Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Not stated MTBDRplus
Anek-Vorapong
(2010)72
No
microscopy
Not stated Not stated Not stated MTBDRplus
Antonova (2008)81 Not stated Not stated Not stated Not stated TB
biochip/
microchip
Biological microchip
assay
Asencios (2012)71 Not stated Not stated Not stated Concentrated
(processed)
MTBDRplus GenoType
MTBDRplus
Barnard (2008)70 No
microscopy
Yes-FM 99 Not stated Concentrated
(processed)
MTBDRplus
Barnard (2012)71 No
microscopy
Not stated Not stated Direct MTBDRsl GenoType MDRsl LPA
Boehme (2010)29 No
microscopy
Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Concentrated
(processed)
GeneXpert
Boehme (2011)38 No
microscopy
Not stated Multiple
specimens
per patient
Concentrated
(processed)
GeneXpert
Calderón-Espinoza
(2006)82
No
microscopy
Not stated Not stated Concentrated
(processed)
PCR/
in-house
assays
PCR-UHG-RIF
Cauwelaert (2011)67 Ziehl–Neelsen Not stated Not stated Concentrated
(processed)
MTBDRplus
Cho (2009)83 Not stated Not stated Not stated Not stated PCR/in-
house
assays
Sequencing
Choi (2010)84 No
microscopy
Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Not stated PCR/
in-house
assays
Direct DNA
sequencing analysis
of katG, rpoB, embB
and pncA
Costeira (2007)51 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated INNO-LiPA
Crudu (2012)69 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated MTBDRplus MTBDRplus
Dorman (2012)68 No Not stated One specimen
per patient
Not stated MTBDRplus
Drobniewski
(2000)52
No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated INNO-LiPA DNA hybridisation
(Accuprobe,
Gen-Probe,
San Diego, CA, USA)
Eliseev (2013)66 No
microscopy
Not stated Multiple
specimens
per patient
Not stated MTBDRplus MTBDRplus
Farooqi (2012)65 No
microscopy
Not stated Not stated Concentrated
(processed)
MTBDRplus
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Reference test details
Reference
test
category
Reference
test type
(solid)
Reference
test type
(liquid)
Indeterminate
results
reported?
Reference
test (other)
Number of
contaminated
cultures
(Reference)
Number
of cultures
performed
Pretreatment
of sample?
Liquid
culture
BACTEC
MGIT 960a
No 1 170 NALC-NaOH
Liquid
culture
BACTEC
MGIT 960a
Yes 92 118 NALC-NaOH
Liquid
culture
BACTEC
MGIT 960a
Yes 164 NALC-NaOH
Solid
culture
LJ Not stated 78 78
Solid and
liquid
culture
LJ No 100 NALC-NaOH
Solid and
liquid
culture
7H11 Yes 536 NALC-NaOH
Liquid
culture
Other
(specify)
No MGIT 1 657 NALC-NaOH
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes 1462 NALC-NaOH
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
No 1 1266 NALC-NaOH
Solid
culture
Not stated Not stated DST,
proportion
method
1 200 NALC-NaOH
Solid
culture
LJ No NALC-NaOH
Solid
culture
LJ Not stated 1 46 NaOH (Petroff)
Solid
culture
LJ Not stated 113 Not stated
Liquid
culture
BACTEC
MGIT 960a
No 1 113 Not stated
Solid
culture
7H11 156 NALC-NaOH
Liquid
culture
BACTEC
MGIT 960a
Yes 1 529 NALC-NaOH
Liquid
culture
BACTEC
460 TBa
NALC-NaOH
Liquid
culture
BACTEC
MGIT 960a
Yes 211 Not stated
Solid
culture
LJ No 1 108 NALC-NaOH
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Study
Microscopy Index test details
Microscopy?
Type of
microscopy
Number of
samples per
participant
tested
Type of
smear
Test
category
Rapid test
type (other)
García-Sierra
(2011)85
No
microscopy
Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Not stated PCR/
in-house
assays
Pyrosequencing
Gryadunov (2005)86 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Concentrated
(processed)
TB
biochip/
microchip
Biochip assay
Guo (2009)87 Not stated Not stated Not stated Not stated TB
biochip/
microchip
In-house biochip
system
Higuchi (2004)53 Not stated Not stated Not stated Concentrated
(processed)
INNO-LiPA Finnos LiPA/Rif TB
(Nipro, Osaka, Japan)
Also, AMPLICOR MTB
(Roche Diagnostics,
Tokyo, Japan)
Hillemann (2006)64 Not stated Not stated Not stated Concentrated
(processed)
MTBDRplus
Hillemann (2009)78 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Concentrated
(processed)
MTBDRsl MTBDRsl assay
Johansen (2003)54 Not stated Not stated Not stated Not stated INNO-LiPA
Kim (2001)89 Not stated Not stated Not stated PCR/
in-house
assays
Nested PCR-linked
single-strand
conformation
Kim (2012)58 No
microscopy
Not stated Not stated Concentrated
(processed)
GeneXpert
Kontsevaya (2013)37 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated MTBDRsl GenoType
MTBDRplus
Kurbatov (2013)59 No
microscopy
Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Concentrated
(processed)
GeneXpert Also TB biochip
(Biochip-IMB
Ltd, Russia)
Lacoma (2008)75 No
microscopy
Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Concentrated
(processed)
MTBDRplus MTBDRplus
Lacoma (2012)77 Ziehl–Neelsen Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Concentrated
(processed)
MTBDRsl MTBDRsl
Lu (2012)90 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated TB
biochip/
Microchip
Biochip MDR assay
Lyu (2013)63 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated MTBDRplus MTBDRplus
Macedo (2009)98 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Concentrated
(processed)
MTBDRplus MTBDRplus
Maschmann
(2013)100
Not stated Not stated Not stated Not stated MTBDRplus
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Reference test details
Reference
test
category
Reference
test type
(solid)
Reference
test type
(liquid)
Indeterminate
results
reported?
Reference
test (other)
Number of
contaminated
cultures
(Reference)
Number
of cultures
performed
Pretreatment
of sample?
Liquid
culture
BACTEC
460 TBa
Not stated 48 Not stated
Solid
culture
LJ No 113 NALC-NaOH
Solid
culture
LJ NaOH (Petroff)
Liquid
culture
BACTEC
MGIT 960a
No 1 42 NALC-NaOH
Solid
culture
LJ 42 NALC-NaOH
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes 1 64 NALC-NaOH
Liquid
culture
BACTEC
460 TBa
Yes 1 60 Not stated
Solid
culture
Not stated Yes 1 56 Not stated
Solid
culture
LJ No 1 62 NALC-NaOH
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes 1 90 Not stated
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes 1 62 NALC-NaOH
Liquid
culture
BACTEC
460 TBa
No 51 NALC-NaOH
Liquid
culture
BACTEC
460 TBa
Yes 1 54 NALC-NaOH
Solid
culture
LJ No 690 NALC-NaOH
Liquid
culture
BACTEC
MGIT 960a
No 428 Not stated
Liquid
culture
BACTEC
460 TBa
Not stated 68
Solid
culture
LJ No 1 68 NaOH (Petroff)
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Study
Microscopy Index test details
Microscopy?
Type of
microscopy
Number of
samples per
participant
tested
Type of
smear
Test
category
Rapid test
type (other)
Mikhailovich
(2001)91
Not stated Not stated Not stated Concentrated
(processed)
TB
biochip/
microchip
Hybridisation –
TB-MAGIChip
Miotto (2012)79 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Concentrated
(processed)
MTBDRsl MTBDRsl
Mironova (2012)34 Not stated Not stated Not stated Not stated MTBDRplus MTBDRplus
Mokrousov (2003)92 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated PCR/
in-house
assays
NAS-PCR assay
Naidoo (2010)60 Not stated Not stated Not stated Not stated GeneXpert
Nikolayevskyy
(2009)99
No
microscopy
Yes,
Ziehl–Neelsen
One specimen
per patient
Concentrated
(processed)
MTBDRplus
Nosova (2013)93 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Concentrated
(processed)
TB
biochip/
Microchip
TB biochip
O’Grady (2012)61 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated GeneXpert
Ogwang (2009)55 No
microscopy
Not stated Unknown
number of
specimens
per patient
Concentrated
(processed)
INNO-LiPA
Pang (2013)88 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Concentrated
(processed)
TB
biochip/
Microchip
Genechip
Sam (2006)56 No
microscopy
Yes,
Ziehl–Neelsen
Multiple
specimens
per patient
Not stated INNO-LiPA
Seoudi (2012)35 No
microscopy
Yes-FM 99 One specimen
per patient
Concentrated
(processed)
INNO-LiPA
Sheen (2009)94 No
microscopy
Yes-FM 99 Unknown
number of
specimens
per patient
Concentrated
(processed)
PCR/
in-house
assays
PCR-SSCP test
Siu (2011)95 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Not stated PCR/
in-house
assays
MAS-PCR
Skenders (2005)57 No
microscopy
Yes,
Ziehl–Neelsen
Unknown
number of
specimens
per patient
Not stated INNO-LiPA
Somoskovi (2006)74 No
microscopy
Yes,
Ziehl–Neelsen
One specimen
per patient
Concentrated
(processed)
MTBDRplus
Tukvadze (2012)62 No
microscopy
Yes,
Ziehl–Neelsen
Not stated Concentrated
(processed)
MTBDRplus MTBDR plus
Vadwai (2012)96 No
microscopy
Yes,
Ziehl–Neelsen
One specimen
per patient
Not stated PCR/
in-house
assays
MAS PCR
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Reference test details
Reference
test
category
Reference
test type
(solid)
Reference
test type
(liquid)
Indeterminate
results
reported?
Reference
test (other)
Number of
contaminated
cultures
(Reference)
Number
of cultures
performed
Pretreatment
of sample?
Solid
culture
LJ No 1 31 NALC-NaOH
Liquid
culture
BACTEC
MGIT 960a
Yes 1 59 NALC-NaOH
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes 689 NALC-NaOH
Not stated Yes 1 114 Not stated
Liquid
culture
BACTEC
MGIT 960a
Not stated 801 801 Not stated
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Not stated 149 165 NALC-NaOH
Liquid
culture
BACTEC
MGIT 960a
No 38 38 None
Liquid
culture
BACTEC
MGIT 960
No 99 111 NALC-NaOH
Liquid
culture
BACTEC
460 TBa
Not stated 203 NaOH (Petroff)
Solid
culture
LJ No 1814 NALC-NaOH
Solid
culture
LJ Yes 657 NALC-NaOH
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes NALC-NaOH
Liquid
culture
BACTEC
460 TBa
Not stated 1 52 Other, specify
Solid
culture
7H10 Yes 198 Other, specify
Liquid
culture
BACTEC
460 TBa
Yes 1 89 Other, specify
Liquid
culture
BACTEC
460 TBa
Yes 1 143 NaOH (Petroff)
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes 1 500 NALC-NaOH
Solid and
liquid
culture
LJ BACTEC
MGIT 960a
Yes MGIT SIRE 289 NALC-NaOH
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Study
Microscopy Index test details
Microscopy?
Type of
microscopy
Number of
samples per
participant
tested
Type of
smear
Test
category
Rapid test
type (other)
Viveiros (2005)33 No
microscopy
Yes,
Ziehl–Neelsen
Unknown
number of
specimens
per patient
Not stated INNO-LiPA
Zhang (2012)97 One specimen
per patient
PCR/
in-house
assays
CapitalBio DNA
microarray (CapitalBio
Corp, Beijing, China)
MAS-PCR, multiplex allele-specific PCR; NAS-PCR, nested allele-specific; NALC-NaOH, N-acetyl-L-cysteine-sodium hydroxide
PCR; SSCP, single-strand conformation polymorphism test; UHG, universal heteroduplex generator.
a Becton Dickinson Diagnostic Instrument Systems, Towson, MD, USA.
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Reference test details
Reference
test
category
Reference
test type
(solid)
Reference
test type
(liquid)
Indeterminate
results
reported?
Reference
test (other)
Number of
contaminated
cultures
(Reference)
Number
of cultures
performed
Pretreatment
of sample?
Liquid
culture
BACTEC
MGIT 960a
No 342 NALC-NaOH
Liquid
culture
LJ BACTEC
MGIT 960a
Yes 1 93 NALC-NaOH
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Appendix 6 Participant information and drug
resistance investigated
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Study (first
author
and year)
Participant information
Drug resistance
investigated
Recruitment
Age
category
HIV
status
Previous
history
of TB?
Previous
history
of TB (n)
Previous
history of TB
(denominator)
Outcomes
evaluated?
Isoniazid
study?
Rifampicin
study?
Ajbani
(2012)76
Consecutive Not
stated
Not
stated
Not
stated
No N N
Albert (2010)73 Consecutive Not
stated
Not
stated
118 118 No Y Y
Anek-
Vorapong
(2010)72
Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Antonova
(2008)81
Not stated Not
stated
Not
stated
Not
stated
Not stated N N
Asencios
(2012)71
Random Not
stated
Not
stated
Not
stated
Not stated Y Y
Barnard
(2008)70
Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Barnard
(2012)80
Consecutive Not
stated
Not
stated
Not
stated
Not stated N N
Boehme
(2010)29
Consecutive Adults
(≥16
years)
HIV–/
HIV+
671 1447 Yes N Y
Boehme
(2011)38
Consecutive Adults
(≥16
years)
HIV–/
HIV+
Not
stated
Not stated N Y
Calderón-
Espinoza
(2006)82
Not stated Not
stated
Not
stated
153 200 Not stated N Y
Cauwelaert
(2011)67
Convenience Not
stated
Not
stated
Not
stated
Not stated Y Y
Cho (2009)83 Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Choi (2010)84 Other
(specify)
Adults
and
children
Not
stated
111 111 Yes Y Y
Costeira
(2007)51
Not stated Not
stated
Not
stated
Not
stated
Not stated N Y
Crudu (2012)69 Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Dorman
(2012)68
Consecutive Adults
(≥ 16
years)
HIV–/
HIV+
699 2516 Not stated Y Y
Drobniewski
(2000)52
Consecutive Not
stated
HIV–/
HIV+
No N Y
Eliseev
(2013)66
Consecutive Adults
and
children
HIV–/
HIV+
144 812 No Y Y
Farooqi
(2012)65
Random Not
stated
Not
stated
Not
stated
Not stated Y Y
García-Sierra
(2011)85
Consecutive Not
stated
Not
stated
Not
stated
Not stated Y Y
Gryadunov
(2005)86
Not stated Not
stated
Not
stated
113 147 No Y Y
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Amikacin
study
Quinolones
study?
Moxifloxacin
study?
Ofloxacin
study?
Capreomycin
study?
Other
study?
Ethambutol
study?
Kanamycin
study?
Other study
(specify)
N N N N N Y Y Y FQ
N N N N N N N N
N N N N N Y N N Streptomycin
and ethambutol
N N N Y N N N N
N N N N N Y N N MDR
N N N N N N N N
Y N N Y N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N MDR, streptomycin
N N N N N N N N
N N N N N N N N
N N N N N Y Y N Pyrazinamide
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
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Study (first
author
and year)
Participant information
Drug resistance
investigated
Recruitment
Age
category
HIV
status
Previous
history
of TB?
Previous
history
of TB (n)
Previous
history of TB
(denominator)
Outcomes
evaluated?
Isoniazid
study?
Rifampicin
study?
Guo (2009)87 Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Higuchi
(2004)53
Consecutive Not
stated
Not
stated
Not
stated
Not stated N Y
Hillemann
(2006)64
Not stated Not
stated
Not
stated
Not
stated
Y Y
Hillemann
(2009)78
Consecutive Not
stated
Not
stated
Not
stated
Not stated N N
Johansen
(2003)54
Not stated Not
stated
Not
stated
Not
stated
Not stated N Y
Kim (2001)89 Not stated Not
stated
Not
stated
Not
stated
Not stated N Y
Kim (2012)58 Consecutive Not
stated
HIV– 53 71 Yes N Y
Kontsevaya
(2013)37
Not stated Adults
(≥16
years)
HIV + Not
stated
38 90 No N N
Kurbatov
(2013)59
Consecutive Adults
(≥16
years)
Not
stated
Not stated N Y
Lacoma
(2008)75
Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Lacoma
(2012)77
Not stated Not
stated
Not
stated
Not
stated
Not stated N N
Lu (2012)90 Consecutive Not
stated
Not
stated
241 907 No Y Y
Lyu (2013)63 Consecutive Not
stated
Not
stated
Not
stated
105 428 No Y Y
Macedo
(2009)98
Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Maschmann
(2013)100
Consecutive Adults
(≥16
years)
Not
stated
Not
stated
Not stated Y Y
Mikhailovich
(2001)91
Not stated Not
stated
Not
stated
Not
stated
Not stated N Y
Miotto
(2012)79
Not stated Not
stated
Not
stated
59 59 No N N
Mironova
(2012)34
Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Mokrousov
(2003)92
Convenience Not
stated
Not
stated
Not stated N Y
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Amikacin
study
Quinolones
study?
Moxifloxacin
study?
Ofloxacin
study?
Capreomycin
study?
Other
study?
Ethambutol
study?
Kanamycin
study?
Other study
(specify)
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N Y N N Y N Amikacin and
capreomycin tested
together as
AM-CM
N N N N N N N N
N N N N N N N N
N N N N N N N N
Y N N N Y Y Y Y FQ
N N N N N N N N
N N N N N Y N N MDR
N Y N N Y N Y Y Kanamycin and
capreomycin are
tested together as
KM/CM
N N N N N Y N N MDR
N N N N N N N N
N N N N N N N N
N N N N N Y N N MDR
N N N N N N N N
N N N N N N Y N Second-line
injectable drugs
tested together
N N N N N N N N
N N N N N N N N
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Study (first
author
and year)
Participant information
Drug resistance
investigated
Recruitment
Age
category
HIV
status
Previous
history
of TB?
Previous
history
of TB (n)
Previous
history of TB
(denominator)
Outcomes
evaluated?
Isoniazid
study?
Rifampicin
study?
Naidoo
(2010)60
Not stated Not
stated
Not
stated
Not
stated
Not stated N Y
Nikolayevskyy
(2009)99
Consecutive Not
stated
Not
stated
89 168 Not stated Y Y
Nosova
(2013)93
Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
O’Grady
(2012)61
Not stated Adults
(≥16
years)
HIV–/
HIV+
Not
stated
Not stated N Y
Ogwang
(2009)55
Consecutive Adults
(≥16
years)
Not
stated
Not stated N Y
Pang (2013)88 Not stated Not
stated
Not
stated
Not
stated
Not stated Y Y
Sam (2006)56 Consecutive Not
stated
Not
stated
Not
stated
Not stated N Y
Seoudi
(2012)35
Consecutive Not
stated
Not
stated
Not
stated
Not stated N Y
Sheen (2009)94 Not stated Not
stated
HIV–/
HIV+
Not
stated
Not stated N N
Siu (2011)95 Consecutive Not
stated
Not
stated
Not
stated
Not stated Y N
Skenders
(2005)57
Consecutive Not
stated
Not
stated
Not stated N Y
Somoskovi
(2006)74
Consecutive Not
stated
Not
stated
Not
stated
Not stated Y Y
Tukvadze
(2012)62
Consecutive Not
stated
Not
stated
121 500 Not stated Y Y
Vadwai
(2012)96
Consecutive Not
stated
Not
stated
Not
stated
No Y Y
Viveiros
(2005)33
Consecutive Adults
and
children
HIV–/
HIV+
189 Not stated N Y
Zhang (2012)97 Consecutive Adults
and
children
HIV– 35 153 No Y Y
N, no; Y, yes.
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Amikacin
study
Quinolones
study?
Moxifloxacin
study?
Ofloxacin
study?
Capreomycin
study?
Other
study?
Ethambutol
study?
Kanamycin
study?
Other study
(specify)
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N Y N N Pyrazinamide
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N N N N
N N N N N Y N N Fluoroquinolone
N N N N N N N N
N N N N N N N N
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Appendix 7 Timed tasks in the time-and-motion
study
Timed steps in each stage of the Xpert MTB/RIF assay
Stage Step
Preparation/set-up Paperwork
Label tubes
Transfer specimens
Spin down CSF specimens (if > 2ml)
Decontamination Set up for decontamination
Add alkaline solution to respiratory specimens
Stand for 30 minutes, vortexing every 10 minutes
Add buffer to neutralise
Centrifuge for 30 minutes
Add buffer to pellet
Specimen pretreatment Centrifuge to concentrate
Sample preparation and loading machine Add Cepheid reagent to decontaminated sputum pellet
Stand for 15 minutes
Transfer 2ml into cartridge and load on to GeneXpert
Run instrument
Recording results Record results
Transfer results to relevant desk
Record on MOLIS
MOLIS, Modular Open Laboratory Information System.
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Timed steps in each stage of the line probe assays
Procedure Stage Step
INNO-LiPA and MTBDRplus
(day 1)
Preparation/set-up Paperwork
Label tubes
Prepare extraction reagents
Transfer 1-ml specimen to microcentrifuge tube
Sample
decontamination
Put in centrifuge
Aliquot extraction reagents
Prepare wax block samples
Remove tissue tubes from centrifuge
Discard supernatant
Resuspend pellet in 1ml water
Put in centrifuge
Add buffer to wax blocks
Discard supernatant
Resuspend pellet in 250 µl or 50 µl of buffer
Lysing of cells Put wax samples on heat block
Remove tubes and flick to resuspend
Put tubes in a 95 °C hot block or water bath for 20 minutes
Allow tubes to cool for 5 minutes
Add chloroform to wax samples
Put tubes in sonic bath
Vortex samples
Centrifuge tubes for 5 minutes
First-round PCR Clean area in clean laboratory
Remove buffer and primers from fridge to thaw
Prepare PCR tubes
Prepare PCR mastermix in centrifuge tube
Centrifuge briefly
Distribute aliquots into PCR tubes
Close lids, clean up and transfer to CL2 laboratory
Vortex
Preparation
Place PCR tubes in PCR rack
Put in centrifuge
Prepare tubes
Add DNA extract to labelled PCR tubes
Add inhibition control to inhibition control tubes
Clean area
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
Procedure Stage Step
INNO-LiPA (day 2) Second-round PCR Remove buffer and primers from fridge to thaw
Set up
Prepare PCR master mix
Distribute aliquots into PCR tubes
Close lids, clean up and transfer to PCR product laboratory
Remove tubes from thermocycler and place in rack
Centrifuge tubes on picofuge
Assemble equipment in cabinet
Add 1 µl of first-round reaction to second-round tubes
Spin tubes on picofuge
Load tubes into thermocycler and start programme
Clean up
Gel electrophoresis Make up agarose, pour into gel trays and leave to set
Remove combs and tape and place gels in tanks with buffer
Spot loading dye on to parafilm
Mix samples with dye and load on to gel, add markers
Set up tanks for running
Take gels from tanks, photograph on UV transilluminator and print
Labelling printout image
LiPA assay Label PCR tubes
Remove reagents from box and set-up
Mix denaturing solution and pipette some into each tray
Pipette of 10 µl PCR product into each tray
Take out test strips, label with pencil and place in tray
Pipette of 1ml hybridisation solution into each tray
Tip out hybridisation solution and add 1ml stringent wash
Agitate on shaker for 1 minute
Repeat wash step
Remove hybridisation solution and add stringent wash
Make up rinse solution and conjugate solution
Remove stringent wash and add rinse solution, shake for 1 minute
Repeat wash step
Remove all rinse solution and add conjugate solution, shake
Wash strips twice in rinse solution (1 minute each)
Rinse strips in substrate buffer for 1 minute
Add dilute substrate to each test and agitate until readable
Wash strips with dH2O twice and agitate for 1 minute each
Remove strips from tray, dry and stick on form
Recording results Record results
Get results to relevant desk
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Procedure Stage Step
MTBDRplus (day 2) Setting up BeeBlot Set BeeBlot machine to clean itself
Swap buffers in BeeBlot machine
MTBDRplus assay Add denaturation solution into wells
Mark strips with pencil
Add amplified samples into wells
Incubate for 5 minutes
Add hybridisation buffer to each well
Place each membrane in tray and set to run
Remove strips from the machine and set machine to wash itself
Sticking strips to form and fill in form
Interpreting results
Recording results Record results
Get results to relevant desk
dH2O, distilled water.
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Timed steps in each procedure of primary specimen culture
Procedure Stage Step
Inoculation Paperwork/set-up Paperwork and labelling tubes
Transfer specimens to falcon tubes
Add sputasol to CF samples, incubate 15 minutes
Load CF samples into centrifuge
Unload centrifuge
Decontamination Add 6ml of NaOH-NALC to samples (or oxalic acid/
sulphuric acid if CF sputum), mix by vortexing
Incubate for 30 minutes, mixing every 10 minutes
Add 40ml of BD BBL Mycoprep PB and mix
Load into centrifuge
Unload centrifuge, discard supernatant and resuspend in
1.5ml of sterile PB
Preparing LJ and MGITs and inoculating
with sample
Rack up and label MGIT and LJ tubes
Mix PANTA with growth supplement and add to MGITs
Inoculate MGIT and LJ slopes with resuspended sample
Loading samples into incubator and
BACTEC MGIT 960
Load LJ slopes into incubator
Load MGITs into BACTEC MGIT 960
Reading and
reporting results
Preparing positive MGIT samples for
smear microscopy and blood plates
Unload positives from BACTEC MGIT 960
Print report
Set up (label universal tubes, slides, blood plates, etc.)
Transfer MGIT cultures to universals, make slides and
inoculate blood plates
Set up (finding forms)
Enter information into computer and print labels
Label positives worksheet
Load universals and blood plates into incubator
Staining slides and performing
smear microscopy
Remove slides from hot plate and arrange over sink, add
paper over slides and add dye
Leave dye on slides for a few minutes
Rinse slides and add phenol solution
Leave slides for a few minutes
Rinse slides and add second phenol solution
Leave slides for a few minutes
Rinse slides and add stain
Add slides to hot block to dry
Check blood plates for contamination
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Procedure Stage Step
Remove slides from hot plate
Set up microscope, etc.
View slides under microscope and record status of slides
Clean up
Reporting MGIT culture results and
retreating contaminated samples
Fill in positives worksheet
Fill in the contamination information
Retreat the three contaminated samples and load
into centrifuge
Report results on MOLIS
Make fresh samples from the retreated contaminated
samples (for reculture)
Paperwork and labelling the MTB-positive samples to be
sent to the reference laboratory
Reading LJ slopes (weekly) Set up and read cultures
Clean up
BD, BD Diagnostic Systems; CF, cystic fibrosis; MOLIS, Modular Open Laboratory Information System; PANTA, Polymyxin B -
Amphotericin B - Nalidixic acid - Trimethoprim -Azlocillin; PB, phosphate buffer.
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Timed steps in each procedure for drug susceptibility testing
on solid media
Procedure Stage Step
Preparation of LJ slopes Preparing the LJ medium Collect eggs
Sterilise eggs with acetone
Set up (get out glycerol, blender, drugs, etc.)
Break eggs into blender, blend and pour into flask
Clean up
Add penicillin
Add glycerol mineral salts
Add green dye
Paperwork
Set up
Pour LJ into flasks
Add different amounts of drug to each flask
Make up the final dilutions
Clean up
Aliquotting the LJ medium into
bijou bottles
Aliquot LJ into bijou bottles
Put bijou bottles in oven to solidify
Filling trays with DST LJ slopes Arrange DST LJ slopes in trays ready for inoculation
Inoculation LJ slopes Set up Print labels
Sort samples
Set up (label bijou, archive and inoculum tubes)
Inoculating slopes Transfer cultures to bijou tubes
Inoculate LJ slopes (20 slopes per sample)
Put slopes in walk-in incubator
Reading LJ DST
results (weekly)
Set up Paperwork/set-up
Collecting cultures from hot room
Checking controls Checking controls
Reading and reporting cultures Reading and reporting the susceptibility status of
cultured samples
Clearing away read cultures
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Timed steps in each procedure for drug susceptibility testing
using BACTEC MGIT 960
Procedure Stage Step
MGIT inoculation Paperwork/set-up Collect cultures
Quality control of BACTEC MGIT 960
Paperwork
Preparing tubes
for inoculation
Prepare tray of tubes for DST inoculation
Add enrichment supplement and PANTA to MGITs
Add drugs to MGITs
Enter DST information into computer and add labels
to MGITs
Adding sample to tubes Add subculture to drug-containing MGITs
Machine loading and
clean-up
Paperwork
Load DST tubes into BACTEC MGIT 960
Clean up
Reading MGIT DST
results (daily)
Reading and
recording results
Check reports on computer system and print results
Remove the tubes from the BACTEC MGIT 960
Check the tubes visually
Enter test status into the computer system
Report results
Paperwork
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Appendix 8 Diagnostic delays: a patient’s story
X is a former patient who had drug-susceptible pulmonary tuberculosis (TB) in both lungs. She wassymptomatic from 2004 and received two courses of treatment, including surgery, in 2005 and
2006–7. She remained under close follow-up until discharged from outpatient care in 2010.
X was symptomatic for 9 months in 2004 before she was referred from primary care to a London hospital
for an initial chest X-ray that showed persistent inflammation and partial lung collapse. As a result of
administrative delays, it was another 3 months before X was referred internally to the local chest clinic for
diagnosis and subsequent treatment of her TB. Therapy did not start for a further 4 weeks, during which
time X received support from the TB specialist nursing team. Further examination showed collapse of the
left lung and severe weight loss. X received 2 weeks of inpatient treatment. She took 9 months of TB
treatment with standard drugs and also required other medication including weight gain supplements.
Prior to TB patients being exempt from paying for NHS prescriptions in 2007, people were required to
pay for the full cost of TB treatment. In order to reduce the burden, X applied for a pre-paid certificate.
X returned to university to begin the new academic year, while also bearing the cost of travel from outside
London to attend clinic appointments. X received a student loan and had no other form of income.
In December 2005, X completed the course of TB treatment but remained under follow-up care. In January
2006, she was referred to a dietitian for assessment and treatment; however, in mid-2006, X was
admitted to the London hospital and placed in a side room with presumed relapse of her TB. Infection
control measures were put in place, with health-care staff and visitors who entered the side room being
required to wear a mask. X commenced treatment for TB and was discharged after one and a half weeks.
Tests on cultured samples confirmed that the TB was fully drug susceptible. X was also diagnosed and
treated for Pseudomonas lung infection – indicating the presence of chronic lung damage. X was
diagnosed with bronchiectasis and referred back to the care of physiotherapists for additional,
ongoing treatment.
During this time, X interrupted her studies as an intermittent student, which led to serious funding
implications. X was no longer eligible to receive a student loan while not in attendance at university and,
owing to student status, did not qualify for social security entitlements. X received no additional financial
support, and as a result, relied on credit and a student account overdraft to support living costs and
treatment. X had no previous history of debt or financial difficulties.
As well as treatment side effects in the form of nausea and joint pains, X suffered from hair loss during the
first 2 months of starting treatment on both occasions, was referred to a dermatologist for investigation
and was diagnosed with folate deficiency.
In early 2007, X’s treatment had been reduced but further examinations showed a reservoir of infection
that had caused the TB to infiltrate the previously healthy right lung. X eventually had a pneumonectomy
to improve quality of life and increase the chance of a full cure. X continued on TB treatment for the right
lung until November 2007.
Upon returning to university after 18 months, X became liable to the Student Loans Company for part of
the loan awarded during the previous academic year. X plunged into debt and owed the university a full
term’s rent instalment. The university was now in a position to refuse registration, which would prevent X
from continuing her studies. X received advice and representation from the Students’ Union, including
information about additional sources of income, and eventually was able to continue studying at the
university. It took X 5 years to complete undergraduate studies and the university withheld the degree
certificate until the debt was repaid in full.
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Two years after completing TB treatment, X was diagnosed with anxiety and depression, which X’s GP
believes is a result of the severity and prolonged nature of the illness. X had no previous history of
depression or anxiety.
X was treated using a combination of antidepressants for 6 months, along with counselling and therapy
from the university and the NHS for a period of 18 months.
The estimated cost of travel to London for clinic appointments, TB treatment/additional drugs, loss of
income/productivity and the burden of debt ran into thousands of pounds.
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